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Estrogens have many beneficial effects in the brain. Previous studies have evaluated effects of 
estrogens on specific neurotransmitter systems including dopaminergic, serotoninergic, 
noradrenergic as well as glutamatergic pathways. However, a comprehensive profile of the 
collection of neurochemical changes that occur following menopause and estrogen treatments 
within specific regions of the brain has not been available. Therefore, it is necessary to directly 
and systematically compare the effect of estrogens on these multiple interacting brain 
neurotransmitter (NT) pathways between the two clinically relevant menopauses: surgical 
menopause (OVX) and transitional menopause (VCD). 
In the first part of my thesis research, I comprehensively characterized and compared the 
neurochemical changes associated with surgical and transitional menopausal rat models in three 
regions of the brain at two time points. Naturally cycling rats sacrificed on proestrus (high estrogen 
level) and diestrus (low estrogen level) phases were also added to the investigation. Results showed 
that while many of the effects of surgical vs. transitional menopause were the same, there also 
were some important differences that varied by brain region and by time following the menopause. 
In the second part of this thesis, I further investigated and compared the effects of chronic 
treatments of estradiol (E2) and selective estrogen receptor (ER) agonists (PPT, DPN, G-1) on 
brain NT pathways between surgical and transitional menopause at two time points. The results 
demonstrated significant differences in the effects of ER agonist treatments on neurochemical 





dependent. These results were the first to systematically and simultaneously evaluate the effects 
of ER agonist treatments on multiple neurochemical endpoints in multiple regions of the brain in 
two models of menopause. The fact that agonist treatments had lesser effects in VCD-treated rats 
than in OVX rats may help to explain reports of lesser effects of estrogen replacement on cognitive 
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1.0  CHAPTER 1: INTRODUCTION 
1.1 EFFECTS OF ESTROGEN ON BRAIN FUNCTIONS 
Ovarian hormones play critical roles in women's health throughout the lifespan. Thanks to the 
great improvement seen in the healthcare, life expectancy has increased significantly. Menopause 
in women occurs when all of the ovarian follicles have been lost due to ovulation or atresia. The 
average age of menopause is around 51 years, ranging from 45 to 55 years [4]. Since the age to 
menopause has not changed over the years, women are spending a longer time of their lives in the 
post-menopausal years. Menopause results in irregular fluctuations in ovarian hormones during 
the transition period, and culminates in a substantial decline in ovarian production of estrogens 
and progesterone [5]. This leads to the release of LH and FSH from the pituitary due to the loss of 
negative feedback regulation at the level of the hypothalamus. A large body of work has shown 
loss of estrogen associated with menopause is associated with an increased risk for many 
neurological conditions such as the development of Alzheimer's disease, cognitive dysfunction, 
depression [6-10]. For example, previous studies have demonstrated that declining ovarian 
function increases the risk of dementia and mild cognitive impairments in menopausal women[11]. 
Estrogens have many beneficial effects on the brain including neuroprotection from cardiac 
arrest and stroke [12], increasing neuronal connectivity [13], improving cognitive performance 
[14], and preventing or slowing age-related cognitive decline [15, 16]. A large amount of work has 
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been done to focus on estrogen’s neuroprotective effects. For example, studies have shown that 
short-term estrogen replacement can improve measures of verbal learning and memory in 
perimenopausal women [17]. In addition, compared with hormone replacement therapy initiated 
in older women years after menopause, treatment started during perimenopause conferred greater 
cognitive benefit such as lowering the risk of dementia [18, 19]. Thus, the investigation of using 
transitional menopausal as a “Window of Opportunity” for estrogen treatment should be 
emphasized and studied in detail. 
 
1.2 ESTROGEN RECEPTORS AND AGONISTS 
1.2.1  ER α and ER β 
Estrogens bind to two nuclear receptors, ERα and ERβ, which act largely as DNA transcription 
regulators [3, 20]. The classical estrogen receptor ERα was discovered in 1958 by Elwood Jensen 
and cloned in 1986 [21]. ERβ was then was then discovered and cloned in 1996 [22]. These 
receptors belong to a large superfamily of nuclear receptors that regulate gene transcription, but 
also have the abilities to interact with specific membrane compartments and activate second 
messenger signaling pathways such as MAPK, CamKII, and CREB [23].  Both receptors are 
expressed in a variety of isoforms, e.g. ERα1-3 and ERβ 1-5 [24, 25] and in different tissues, e.g. 
ERα expressed in uterus, testis, ovary and  kidney while ERβ is expressed in prostate, ovary, lung 
and bladder [26]. They also have differential presence in the brain. In the brain, ER is highly 
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expressed in areas of the hypothalamus that are responsible for reproduction, as well as in areas 
involved in learning, memory, emotionality, attention and motor functions such as the 
hippocampus and cortex. ERβ is widely distributed throughout the brain including hippocampus 
and cortex [27-29].  In addition to its role in reproduction, it has been demonstrated that ERα plays 
a significant role in certain learning and memory tasks [30], in the neuroprotective effects of 
estradiol in a model of ischemic injury [31], and is responsible for estrogen-mediated decreases in 
GABA release at CA1 synapses [32, 33]. On the other hand, ERβ has been implicated in certain 
learning and memory tasks, particularly those involving stress or anxiety [34-36], and recently has 
been shown to mediate estrogen effects on glutamate release at CA1 synapses [37] and on long 
term potentiation via a mechanism involving actin polymerization in postsynaptic cells [38]. 
The two receptors can be activated by estradiol as well as by selective agonists. 4,4’,4’’-(4-
propyl-{1H}(-pyrazole-1,3,5-triyl))trisphenol (PPT) is an ERα-selective agonist that is 
approximately 410-fold more selective for ERα than ERβ [39, 40]. Diarylpropionitrile (DPN) is 
an ERβ-selective agonist with 70-fold higher binding affinity and 170-fold higher potency for ERβ 
than ERα [41].  
1.2.2 GPR30 
Recently, a membrane bound G protein-coupled receptor, GPR30, also has been identified. 
GPR30 is a novel membrane-associated estrogen receptor (ER) which is completely unrelated to 
ER and ERβ [3, 42, 43]. It is localized in  both intracellular and plasma membranes [44], and has 
been shown to promote rapid estrogen signaling in a variety of cell lines [45]. Previous 
immunohistochemical studies have confirmed the presence of GPR30 in brain, with significant 
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GPR30 expression in regions of the forebrain including hippocampus and hypothalamus [46]. The 
role that GPR30 plays in mediating estrogen effects in brain remains largely unknown. GPR30 can 
be activated by (1-[4-(6-bromobenzo[1,3] dioxol 5yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c] 
quinolin-8-yl]-ethanone (G-1), which is a non-steroidal, high-affinity selective GPR30 agonist, 
with no binding to the classic ERα or ERβ [47]. Study showed that G-1 has similar effect of E2 in 
reducing 5-HT1A receptor signaling in the hypothalamus [48].  Also, G-1 treatment demonstrated 
E2-like effect in reducing freezing behavior in a mouse model of depression [49].  In non-human 
primates, GPR30 has been shown to play an important role in estrogen-mediated regulation of 
GnRH neurons [50].  Recent studies also show that activation of GPR30 with G-1 promotes 
neuronal survival following global ischemia in the brain [51], and have implicated GPR30 in the 
protective effects of E2 against glutamate-induced injury [52]. 
Previously our lab has shown intense GPR30 immunostaining in basal forebrain cholinergic 
neurons located in the multiple brain regions such as septum, diagonal band of Broca and striatum, 
as well as in the frontal cortex and hippocampus [53]. Additionally, our lab has also demonstrated  
that G-1 enhances potassium-stimulated acetylcholine release in the hippocampus, and enhances 
acquisition of a delayed matching-to-position T-maze task by ovariectomized (OVX) rats, 
analogous to E2 [54]. Contrast to GPR30 activation, receptor inhibition by G-15 impaired 




1.3 NEUROTRANSMITTER PATHWAYS 
The effects of E2 on neurotransmitter systems innervating the hippocampus, cortex and 
striatum have been widely studied during the past decades. The most studied NT pathways include 
cholinergic [55, 56], dopaminergic [57-59], and serotoninergic [60] pathways, as well as glutamate 
[37, 61, 62] and GABA signaling [33, 63-65].  
1.3.1 Dopaminergic Pathway 
Dopamine (DA) is a neurotransmitter that has two different pathways in the brain. The first 
pathway, which begins in the substantia nigra and projects to the basal ganglia, is implicated in 
movement. The other pathway originates at the ventral tegmental area and projects to other areas 
in the brain. It is commonly known as the reward or reinforcement pathway. 
Previous study has reported that level of DA in HPC remained unchanged following OVX in 
mice [66]. In contrast to that, another study has showed a significant decrease in DA level  in HPC 
at 20 days following OVX in mice [67]. Additionally, results reported by Bitar et al. [68] have 
shown markedly elevated concentrations of HVA in male and female rats following gonadectomy 
in STR. They also detected elevated DA and DOPAC levels following OVX [68]. Furthermore,  a 
separate study using microdialysis approach has found that female rats had significantly higher 
extracellular striatal DA concentrations at proestrus than after OVX [69]. 
E2 and selective ER agonist treatments may have significant impacts on multiple endpoints in 
dopaminergic pathway. Previously, Inagaki et.al [70] reported that a single s.c. injection of E2 in 
OVX rats significantly increased levels of DA but had no effect on DOPAC in STR. Additionally, 
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levels of DA in HPC of OVX mice [66] and rats [71] were shown not to be affected by 4-6 weeks 
of chronic E2 treatment. Another study demonstrated that 4 days s.c. treatment of E2 did not alter 
levels of DA in the STR of OVX rats [72]. Jacome et al. [73] reported no effects on monoaminergic 
endpoints in OVX rat STR 2 days after a single s.c. injection of DPN. 
1.3.2 Serotoninergic Pathway 
Serotonin (5-HT) is another monoamine neurotransmitter in the brain, which is involved in the 
regulation of mood, perception of pain and gastrointestinal functions. The most important group 
of serotonergic neurons are present in the substantia nigra and raphe nuclei and project to the rest 
of the brain. 
Previous studies have showed that decreased levels of 5-HIAA [66] in HPC were detected 
following OVX in mice. On the other hand, study by Bitar et al. [68] has showed that the levels of 
5-HT and 5-HIAA remained unaltered in STR of the male and female rats following gonadectomy. 
Furthermore, reduced 5-HIAA/5-HT ratio in HPC was reported at 2 weeks but not 4 weeks after 
OVX in rats [74]. It has also been shown that levels of 5-HT in HPC remained unchanged 
following estrogen deprivation in mice [66].   
E2 and selective ER agonist treatments also may have significant impacts on multiple 
endpoints in serotoninergic pathway. Study by Lubbers et al. [72] reported that increased levels of 
5-HIAA were detected in the STR of OVX rats after 4 days s.c. treatment with E2 but not PPT. In 
addition, 4-6 weeks of chronic E2 treatment was reported to decrease levels of 5-HT in HPC of 
OVX mice [66] and in HPC and FCX of OVX rats [71]. Notably, Pestana-Olivera et al. [75] 
recently evaluated the effects of estrogen therapy on serotonin in VCD-treated rats and reported  
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that 3 weeks of E2 treatment significantly increased 5-HT levels in dorsal HPC of VCD-treated 
rats. In contract, no treatment effects were detected in several studies. For example, previous 
research found no change in 5-HIAA level in HPC following 4-6 weeks of chronic E2 treatment 
in OVX mice [66] and rats [71]. Inagaki et.al [70] reported that a single s.c. injection of E2 in 
OVX rats had no effect on 5-HIAA level in STR. Another study demonstrated that 4 days s.c. 
treatment of E2 did not alter levels of 5-HT in the STR of OVX rats [72]. 
1.3.3 Noradrenergic Pathway 
Norepinephrine (NE) is a neurotransmitter involved in the sympathetic nervous system. 
Together with epinephrine (EPI), NE is involved in the “flight-or-flight” response that our body 
makes under stressed or dangerous situations. It is also involved in our sexual behavior and control 
of appetite. These cells originate in the locus coeruleus and project their axons through the rest of 
the brain. 
Previous study has shown that decreased levels of NE were detected following OVX in mice 
[66, 67]. E2 and selective ER agonist treatments also may have significant impacts on multiple 
endpoints in noradrenergic pathway. It has also been reported that E2 and PPT treatments increased 
NE levels in the FCX of OVX rats[72]. On the other hand, a few previous studies indicated 
otherwise. For example, one study found no change in NE level in HPC following 4-6 weeks of 
chronic E2 treatment in OVX mice [66] and in HPC and FCX of OVX rats [71]. Another study by 
Inagaki et.al [70] reported that no effect on NE level in STR was detected after a single s.c. 




1.4 MENOPAUSAL RAT MODEL 
 
1.4.1  Ovariectomy (OVX) model 
Ovariectomy is to surgically remove all ovarian tissues. The OVX model is characterized by a 
sudden and complete loss of ovarian hormones, and most closely models the condition of surgical 
menopause. In the past decades, most of the preclinical studies have used ovariectomy followed 
by hormone treatment to study the effects of estrogens on the brain [76].  
However, due to lack of a perimenopause phase, this surgically-induced menopausal rodent 
model fails to adequately recapitulate the phase of menopause transition. In addition, it should be 
noted that ovariectomy also removes all of the other ovarian hormones as well as androgen 
produced by residual ovarian tissues [77], which may also affect the brain. 
 
1.4.2  VCD-induced model 
The ova-toxin, industrial 4-Vinylcyclohexene dioxide (VCD), is a diepoxide metabolite of 4-
vinylcyclohexene (VCH). Formation of the bioactive form (VCD) can occur in the liver through 
cytochrome P450. The ovary itself also expresses the relevant enzymes and is capable of this 
conversion[1]. The development of ovarian follicles in the ovary consists of several steps. Simply, 
the mammalian ovary has a finite number of follicles since birth. These follicles contain an oocyte 
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that is surrounded by somatic cells and are not regenerable or replaceable. The development of the 
follicles has several stages: starting from the most immature form termed primordial follicles 
which are surrounded by a single layer of squamous granulosa cells to primary follicles with a 
layer of cuboidal granulosa cells, then to primary follicles with theca interna cell and finally to 
preovulatory follicles responsible for 17β-estradiol production. After ovulation, the rest of the cells 
differentiate into corpus luteum, which produces progesterone. VCD specifically targets and 
destroys primordial and primary follicles, causing premature ovarian failure in rats, possibly due 
to accelerated atresia via apoptosis[1, 78].  No significant toxicity or inflammation are caused by 
VCD in other tissues when administered using recommended regimen. 
The VCD-induced transitional menopausal rat model was first established and then further 
developed by Dr. Patricia Hoyer et.al at University of Arizona. The cellular effects of VCD-
induced ovary toxicity have been well characterized. Repeated daily doses of VCD (80 mg/kg, 
i.p.) for 15 days leads to 50% of primordial and primary follicles being destroyed in the ovaries of 
immature rats [79, 80] Similar pattern of damage was seen in adult rats when the exposure of VCD 
was extended to 30 days [80]. 
In contrast to surgical menopause, natural menopause is characterized by a gradual loss of 
ovarian follicles in middle-age, a corresponding reduction in estrogen production but with 
continued production of androgens by the remaining ovarian cells. Therefore, unlike surgical 
menopause, natural menopause is associated with a shift in the ratio of estrogens to androgens.  
Recent study by Acosta et al. [81] showed that these differences are functionally important and 
result in differences in the effects of estrogen treatment on behavioral endpoints.  
VCD-induced model replicates estrous acyclicity and low levels of estrogen observed in 
human perimenopause and postmenopause, thus successfully serves as a transitional menopausal 
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model. Another advantage of the model is that transitional menopause could be achieved in young 
adult animals via VCD-induced accelerated ovarian failure, thus allows for the dissociation of the 
effects of hormone levels from the effects of aging. 
It should be noted that all of the previous studies investigating impact of estrogen deprivation 
and treatments on brain neurotransmitter endpoints have all used OVX surgical menopausal model. 
The first study of estrogen effects on brain neurotransmitter pathway was conducted by Pestana-
Olivera et al. [75] using VCD-induced model. Level of 5-HT was the only neurotransmitter they 
measured in the brain following continuous administration of E2. Despite that study, the effects of 
estrogen deprivation and treatments on the neurochemical endpoints in multiple interacting NT 
pathways remained largely unknown in VCD-induced transitional menopause. Studies on how 











1.5 OVERVIEW OF THE THESIS 
 
 
Both basic and clinical studies suggest that the loss of estrogens following menopause has been 
associated with increased risk for a variety of neuropsychiatric and neurodegenerative diseases as 
well as age-related cognitive decline and dementia. Estrogen treatment has been shown to improve 
cognitive performance and slow age-related cognitive decline for menopausal women. However, 
studies are beginning to show that the differences between the surgical and transitional 
menopauses are functionally important and may result in differences in the effects of estrogen 
treatment on behavioral endpoints.  
Our goal of the research is to understand mechanisms by which estrogens affect the brain. We 
hypothesize that many of the beneficial effects of estrogens on the brain are due in large part to 
effects on multiple interacting neurotransmitter (NT) pathways that occur within specific brain 
regions. In particular, we hypothesize that loss of ovarian function results in multiple and 
simultaneous alterations in specific monoaminergic pathways and amino acid levels in the brain, 
and that selective agonists acting at specific estrogen receptors can modify these deficits in NT 
levels, thus offering corresponding effects on cognitive performance. Also, we hypothesize that 
significant differences exist in terms of NT levels in specific region of the brain following 
estrogens deprivation and selective estrogen receptor agonist treatments between the models of 
surgical menopause and transitional menopause, contributing in part to the differences in the 
effects of estrogen treatments for these two types of menopause in the clinical settings. 
In this thesis, we have directly and systematically conducted a metabolomics analysis of 
monoamines, precursors, metabolites and amino acids in three brain regions (hippocampus, frontal 
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cortex and striatum) at two time points, in two clinically relevant models of menopause 
with/without estrogen receptor agonists treatments. Two major specific aims are: Aim 1 is to 
investigate and compare the effects of two models of menopause on NT pathways of interest. Aim 
2 is to investigate (a) whether specific estrogen receptor agonists produce distinct and simultaneous 
changes in NT pathways within specific regions of the brain; and (b) whether effects differ across 




















2.0  CHAPTER 2: COMPARISON OF TRANSITIONAL VS SURGICAL MENOPAUSE ON 
MONOAMINE AND AMINO ACID LEVELS IN THE RAT BRAIN 
 
2.1  ABSTRACT 
 
 Loss of ovarian function has important effects on neurotransmitter production and release with 
corresponding effects on cognitive performance. To date, there has been little direct comparison 
of the effects of surgical and transitional menopause on neurotransmitter pathways in the brain. In 
this study, effects on monoamines, monoamine metabolites, and the amino acids tryptophan (TRP) 
and tyrosine (TYR) were evaluated in adult ovariectomized (OVX) rats and in rats that underwent 
selective and gradual ovarian follicle depletion by daily injection of 4-vinylcyclohexene-diepoxide 
(VCD). Tissues from the hippocampus (HPC), frontal cortex (FCX), and striatum (STR) were 
dissected and analyzed at 1- and 6-weeks following OVX or VCD treatments. Tissues from 
gonadally intact rats were collected at proestrus and diestrus to represent neurochemical levels 
during natural states of high and low estrogens. In gonadally intact rats, higher levels of serotonin 
(5-HT) were detected at proestrus than at diestrus in the FCX. In addition, the ratio of 5-
hydroxyindoleacetic acid (5-HIAA)/5HT in the FCX and HPC was lower at proestrus than at 
diestrus, suggesting an effect on 5-HT turnover in these regions.  No other significant differences 
14 
 
between proestrus and diestrus were observed. In OVX- and VCD-treated rats, changes were 
observed which were both brain region- and time point-dependent. In the HPC levels of 
norepinephrine, 5-HIAA, TRP and TYR were significantly reduced at 1 week, but not 6 weeks, in 
both OVX and VCD-treated rats relative to proestrus and diestrus. In the FCX, dopamine levels 
were elevated at 6 weeks after OVX relative to diestrus.  A similar trend was observed at 1 week 
(but not 6 weeks) following VCD treatment.  In the STR, norepinephrine levels were elevated at 
1 week following OVX, and HVA levels were elevated at 1 week, but not 6 weeks, following VCD 
treatment, relative to proestrus and diestrus. Collectively, these data provide the first 
comprehensive analysis comparing the effects of two models of menopause on multiple 
neuroendocrine endpoints in the brain. These effects likely contribute to effects of surgical and 
transitional menopause on brain function and cognitive performance that have been reported.  
 















Estrogens have widespread effects in the brain, both during development and in adulthood. 
These include effects on neuronal organization and function, synaptic plasticity, and neuronal 
survival, with corresponding effects on cognitive function, neurodegenerative disease, and age-
related cognitive decline. Studies also show that, in women, loss of estrogens following 
oophorectomy or menopause can contribute significantly to risk for neurodegenerative diseases 
like Alzheimer’s disease and Parkinson's disease, as well as late-life mood disorders and age-
related cognitive decline [76, 82, 83]. A few studies have documented effects on neurotransmitter 
systems that are known to play a role in mood and cognitive changes. These include effects on 
monoaminergic pathways [84, 85], as well as cholinergic [56], glutamatergic [37, 61, 62], and 
GABAergic [86, 87] transmission. Most studies have used ovariectomy models to study the effects 
of rapid hormone depletion followed by estrogen replacement to study effects on one or two 
neurotransmitter systems in a specific region of the brain. Few studies have focused specifically 
on the effects of menopause, and in particular on comparing effects associated with surgical vs. 
transitional menopause.  
In primates, natural or transitional menopause is characterized by an accelerated loss of 
ovarian follicles, resulting in irregular fluctuations in ovarian hormones during the transition 
period, and culminating in a substantial decline in ovarian production of estrogens and 
progesterone [88]. As a consequence, the release of LH and FSH from the pituitary rises 
significantly due to the loss of negative feedback regulation.  In addition, ovarian stromal cells 
continue to produce androgens post-menopause, resulting in a substantial increase in the ratio of 
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androgens:estrogens in the systemic circulation. In contrast, ovariectomy produces a surgical 
menopause characterized by a rapid and complete loss of all ovarian hormones. In the United 
States, most women (>80%) experience a transitional menopause. Far fewer women (~13%) 
experience a surgical menopause, and many of these surgeries are conducted in younger women 
(<40 years of age) to prevent ovarian and breast cancer associated with BRCA1 and BRCA2 
mutations [89].   
Unlike primates, rodents do not experience follicular atresia resulting in a natural menopause. 
Rodents enter a condition of reproductive senescence, characterized by long periods of elevated 
levels of circulating estradiol during middle-age, and followed by persistent diestrus in old age 
[90]. This change is related to a dysfunction of the hypothalamic-pituitary-gonadal (HPG) axis that 
occurs as a result of normal aging [91]. Thus, until recently, rodents have not served as a good 
model of natural menopause in humans.   
Notably, a rodent model of progressive ovarian failure has recently been characterized [78, 
92-94]. This model involves daily injection of 4-vinylcyclohexene diepoxide (VCD), a chemical 
that selectively and over time destroys the majority of primordial and primary ovarian follicles 
[95]. Rodents treated with appropriate daily doses of VCD experience a progressive loss of ovarian 
follicles. Stromal cells remain intact and continue to produce androgens, thus mirroring conditions 
that occur in natural menopause. Using this model, studies have shown that transitional and 
surgical menopause produce differing effects on measures of brain function and cognitive 
performance [81]. The most recent evidence suggests that some of these differences may be due 
to elevated levels of androstenedione following transitional vs. surgical menopause, and the local 
conversion of androstenedione to estrone in the brain [96, 97].   
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To date, there has been little direct comparison of the effects of surgical vs. transitional 
menopause on neurotransmitter pathways in the brain. We hypothesize that surgical and 
transitional menopause produce different effects on cognitive functioning due to differential 
effects on multiple interacting neurotransmitter pathways. In this study, we utilized a high-pressure 
liquid chromatography-coulometric multi-electrode array system (HPLC-CMEAS) method to 
characterize neurochemical changes associated with surgical vs. VCD-induced transitional 
menopause in three regions of the rat brain. Results show that while many of the effects of surgical 
vs. transitional menopause are the same, there also are some important differences that vary by 

















Female Sprague–Dawley rats (~11 weeks of age) were purchased from Hilltop Laboratories, 
Inc. Young adults were selected as opposed to middle-aged rats based on several considerations. 
Rodents do not experience a natural menopause. Instead, they experience what is known as 
reproductive senescence associated with dysregulation of the HPG axis. Characteristics of 
reproductive senescence include irregular cycles, a period of constant estrous where levels of 
circulating estradiol are chronically elevated, followed eventually by constant diestrus. The timing 
of these events varies by strain and typically begin in middle-age [98]. Humans do not experience 
reproductive senescence, but instead experience accelerated follicular atresia resulting in a natural 
menopause [99]. We therefore chose to use young adults as opposed to middle-aged rats in order 
to study the effects of chemically-induced follicular atresia in the absence of confounding factors 
associated with the process of reproductive senescence. Another reason to use young adult rats is 
that, with respect to surgical menopause, the majority of women who experience surgical 
menopause are young adults (e.g., early 30s) whose ovaries are removed to prevent ovarian and 
breast cancers associated with BRCA1 and BRCA2 mutations [89]. Hence, we concluded that 
young adult rats would be more appropriate for comparing models of surgical vs. natural 
menopause with respect to neurochemical endpoints.  
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All rats were individually-housed and maintained on a 12/12 h light–dark cycle (lights on at 
7:00 a.m.) with free access to food and water and were allowed to acclimate to the housing 
environment for two weeks prior to use. All experiments were conducted in accordance with the 
NIH Guide for Care and Use of Animals and were approved by the Institutional Animal Care and 
Use Committee of the University of Pittsburgh. 
 
2.3.2 Gonadally intact controls 
Tissues were collected from rats at proestrus, and at diestrus, to represent neurochemical levels 
during natural states of high and low estrogen over the course of the estrous cycle.  Daily vaginal 
smears were collected from these rats to determine stage of the estrous cycle. Cycle stage was 
characterized by vaginal cytology and the presence/appearance of three cell types, leukocytes, 
nucleated epithelial cells, and cornified epithelial cells [100]. See Figure 1. After collecting at least 
2 weeks of cycle data, rats were killed either on proestrus or diestrus and serum as well as brain 






2.3.3 Menopausal models 
Rats were randomly assigned to either the VCD or OVX group. Rats in the VCD group 
received 4-vinylcyclohexene diepoxide (VCD; Sigma Chemicals; St Louis, MO) at a dose of 80 
mg/kg i.p. daily for a period of 30 days as previously described [101]. During this time, rats in the 
OVX group received daily injections of sesame oil (1ml/kg i.p.). At the end of 30 days, rats that 
Figure 1. Photomicrographs (x20) of stained vaginal secretion from rats at (A) Proestrus:   
predominantly consisting of nucleated epithelial cells; (B) Estrus: consisting of anucleated 
cornified cells; (C) Metestrus: consisting of the three types of cell: leukocytes, cornified, and 
nucleated epithelial cells; and (D) Diestrus: consisting predominantly of leucocytes. 
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had received sesame oil underwent bilateral ovariectomy, and rats that received VCD received 
sham surgery. Rats were anesthetized with ketamine (100 mg/kg) and xylazine (7 mg/kg) (0.1 
cc/100 g.b.w.). Ovariectomy was performed using a lateral approach. The apical tips of the uterus 
were ligated and the ovaries removed. The peritoneal muscle was closed with 6.0 suture silk, and 
the overlying skin was closed with metal wound clips. Sham surgery, consisted of skin and muscle 
incisions and wound closure only. Antibiotic cream was applied to the wound to reduce the chance 
of infection. Rats received Ketofen (3 mg/kg, i.p.）every day for 3 days to reduce post-surgical 
pain.  
 
2.3.4 Tissue collection 
At 1 week or 6 weeks following surgery, rats were anesthetized with an overdose of ketamine 
(3 mg) and xylazine (0.6 mg) and euthanized by decapitation. These time points were chosen to 
evaluate early and late effects of the two menopausal models and to evaluate changes in effects as 
Figure 2. Rat body weight during period of VCD/Oil treatment. Neither of VCD or oil 
chronic treatment negatively affected rat body weight.   
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a function of time. Trunk blood was collected for determination of serum levels of estradiol, 
testosterone, and androstenedione.  Dissections were performed according to plate designations in 
Paxinos and Watson (1998) [102] and were as follows: hippocampus (plates 21-41), frontal cortex 
(plates 11-21), and striatum (plates 11-21). An example of the brain matrix is shown in Figure 3. 
These brain regions were selected based on known monoaminergic innovation, their roles in 
learning, memory and attentional functions, and evidence that neuronal organization and 
functioning in these regions can be affected by gonadal hormones.  Tissues were stored at -80 °C 





2.3.5 Brain sample preparation 
500 µl 10 mM sodium acetate buffer (pH 6.5) were added to 50 mg tissue in a 1.5 ml microfuge 
tube. Tissue was sonicated until completely dissolved. After sonication, tissues were spun at 
Figure 3. Brain matrix for dissection. 
Horizontal lines delineate where the brain 
is cut. Spacing between lines is 1 mm. 
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14,000 g for 10 min at 4˚C. Supernatant was collected and placed at 4 ˚C. This step was repeated 
three times and the three supernatants were combined. The cell free supernatants were spun at 
15,000g for an additional 40 minutes. A 200 µl aliquot was taken for the determination of protein 
concentration using the Bradford method [103]. The remaining volume of each supernatant were 
filtered through a disposable membrane (0.22μm pore size) micropartition device (Millipore 
Ultrafree-MC) under centrifugation at 14,000g for 30 min at 4 °C to remove any compounds above 
10,000 nominal molecular weight limit. 
 
2.3.6 Protein assay 
Protein levels were determined by Bio-rad protein assay (Bio-Rad Laboratories, Inc.). Seven 
dilutions of a protein standard were prepared to make a standard curve each time the assay was 
performed: 0.2,0.4,0.6,0.8,1.0,1.2,1.4mg/ml. 5 μl of standard and diluted the brain homogenate 
was pipetted into a clean dry microplate. To prepare the working reagent, 20 μl of reagent S was 
added to each ml of reagent A needed for the run. Then, 25 μl of reagent A was added into each 
well.  The multichannel pipette was used to add 200 μl of reagent B into each well. The palate was 
then gently agitated to mix the reagent. After 15 minutes, absorbance was read at 650 nm. Each 




Figure 4. Schematic diagram showing the timeline of the experimental protocol 1. 
 
 
2.3.7 Hormone assays 
2.3.7.1 E2 assay 
Serum levels of E2 were quantified as recently described [104, 105]. Briefly, samples were 
spiked with internal standard 25µl 2,4,16,16,17-d5-17 beta-estradiol (1 ng/ml in methanol). 3-4 ml 
n-Butyl chloride was added and samples were vortexed for 1 min. Samples were then centrifuged 
at 4,770 x g at room temperature for 10 min, and the organic layer was transferred to salinized 
culture tubes and dried under a steam of nitrogen at 37ºC for 20 min. Residues were derivatized in 
0.1 ml buffered dansyl chloride solution (a 1:1 mix of acetonitrile: water, pH 10.5) and heated to 
60ºC for 3 min. The reconstituted sample was then transferred into glass vials for LC-MS/MS 
analysis.  E2 was eluted using a Waters Acquity UPLC BEH C18, 1.7 µm, 2.1 X 150 mm reversed-
phase column, with an acetonitrile: water (0.1% formic acid) gradient.  MS detection and 
quantification were achieved in the positive mode with a Thermo Fisher TSQ Quantum Ultra mass 
spectrometer interfaced via an electrospray ionization (ESI) probe with the Waters UPLC Acquity 
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solvent delivery system.  Transitions used for analysis were 506 → 171 for E2, and 511 →171 for 
the deuterated internal standard. Area under the peak was quantified and used to determine 
absolute levels of E2/ml of sample by comparison with a series of standards. The limit of 
detectability for this assay is 2.5 pg/ml. Intra-assay statistics show relative standard errors below 
8.1% and relative standard deviations below 10.4%. Inter-assay statistics show relative standard 
errors below 5.0% with relative standard deviations below 7.4%. The E2 serum concentration was 
calculated as pg/ml. 
  
2.3.7.2 Testosterone and androstenedione assay 
Testosterone (T) and Androstenedione (AD) levels in serum were quantified by a modification 
of the method described by Cawood [106] and using methods similar to the E2 detection method 
described above. Briefly, samples were spiked with 0.25 ng/ml D3-testosterone or D7-
androstenedione as the internal standard and then extracted with 3 ml n-butyl chloride. After 
centrifugation and evaporation, the residue was reconstituted in methanol and water (80 μl: 20 μl), 
and was transferred into glass vials for UPLC-MS/MS analysis. T and AD was eluted from the 
same column as E2, with a methanol: water (0.1% formic acid and 2 mM ammonium acetate) 
gradient from 50 to 85% methanol. Transitions used for T analysis were 289 →97 for T and 292 
→97 for the deuterated T; transitions used for AD analysis were 287→100 for AD and 294→ 100 




2.3.8 Monoamine analysis by HPLC-CMEAS 
Monoamines and metabolites were measured with a modified version of a HPLC-ECD method 
described by Yao et al [107]. High-performance liquid chromatography (HPLC) with 
electrochemical detection was used to detect and quantify levels of amino acids, monoamines and 
metabolites, including tryptophan (TRP) and tyrosine (TYR); dopamine (DA) and its metabolites, 
3-4-dihydroxyphenylalanine (DOPAC) and homovanillic acid (HVA); norepinephrine (NE) and 
epinephrine (EPI) and serotonin (5-HT) and its metabolite 5-hydroxyindole acetic acid (5-HIAA). 
These neurochemical endpoints were selected not only because they are known to be involved in 
a variety of cognitive functions but also are reported to be regulated by estrogens. Within each 
sample, 100 μl was injected into an ESA CoulArray Model 5600 HPLC system, consisting of two 
Model 582 pumps, one dynamic gradient mixer, two PEEK pulse dampers, a Model 542 
refrigerated autosampler injector, a CoulArray organizer module, and a serial array of 16 
coulometric electrodes. The system was controlled, and chromatograms were analyzed using the 
ESA CoulArray for Windows-32 software program.  Each sample was run on a single column 
(ESA Meta-250, 5 μm ODS, 250 x 4.6 mm ID) under a 68-minute gradient elution that ranged 
from 0% to 100% Mobile Phase B. Mobile Phase A consisted of 1.1% (w/v) of 1-pentane-sulfonic 
acid (Specrum, Inc.) pH was adjusted to 3.0 using acetic acid (Sigma-Aldrich, Inc.). Mobile Phase 
B consisted of 0.1 M lithium acetate (Sigma-Aldrich, Inc.) in a solvent mixture of methanol 
(Avantor Performance Materials, Inc.), acetonitrile (Honeywell, Inc.) and isopropanol 
(Mallinckrodt Baker, Inc.) at the ratio of 80/10/10 (v/v/v). pH was adjusted to 6.5 using acetic acid 
(Sigma-Aldrich, Inc.). The mobile phase was filtered through a 0.2 μm nylon filter (Sartorius 
Stedim Biotech,Inc.), and delivered at a fixed flow rate of 0.6 ml/min. The temperature of both 
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cells and the column was set at 25 ºC. The retention time and area of the peaks in tissue 
homogenates were measured and compared to an external calibrating standard solution containing 
TYR, TRP, DA, DOPAC, HVA, NE, EPI, 5-HT, and 5-HIAA (Sigma, St. Louis, MO, USA). 
Concentrations of these substances in the samples were calculated and expressed as ng/mg protein. 




Figure 5. Separation of a standard mixture of redox-active compounds by HPLC-CMEAS 




	 Standards Peak ID 
3-Amino-tyrosine 3-AT 
Dopamine DA 






Epinephrine  EPI 
Glutathione  GSH 
Oxidized glutathione GSSG 
5-Hydroxyindole-3-
acetic acid 5-HIAA 
Serotonin 5-HT 











2.4  STATISTICAL ANALYSIS 
 
Results are presented as mean ± standard error of the mean (SEM). A p-value of less than 0.05 
was considered statistically significant. Statistical analysis was performed by three steps. First, 
comparisons of proestrus with diestrus were performed using Student’s t-test. Second, all 6 groups 
were compared by one-way analysis of variance (ANOVA) followed by Tukey’s test if overall p 
< 0.05.  Third, a two-way analysis of variance (ANOVA) followed by Tukey’s test was performed 
with ovarian status (OVX or VCD) as one factor and Time (1 week or 6 weeks) as a second factor 
to investigate to investigate interactions between menopausal model and time.  
 
2.5  PRESENTATION OF THE DATA 
 
Hormone levels by treatment group are shown in Figure 6. For each of the brain region, data 
for DA, 5-HT and NE are shown in Figure 7-9. Data for additional monoamines, metabolites, and 
metabolite/monoamine ratios also are included for those endpoints that were statistically 
significant. Table 1-4 summarize all of the data for monoamines and metabolites. Regional profile 







2.6.1  Serum levels of hormones 
Levels of E2, T, and AD in each of the treatment groups are summarized in Figure 6. 
Significantly higher levels of E2, T, and AD were detected on proestrus than on diestrus, (t 
(14)=3.0, p<0.01 for AD; t (12)=3.1, p<0.01 for T; t (14)=4.5, p<0.001 for E2).  In proestrus rats, 
mean serum levels of circulating E2, AD and T were 46.8 ± 7.0 pg/ml, 196.5 ± 42.9 pg/ml and 
210.5 ± 41.8 pg/ml. In diestrus rats, levels of E2, AD and T were 13.6 ± 2.4 pg/ml, 66.5 ± 6.3 
pg/ml and 81.4 ± 6.0 pg/ml.  None of these hormones were detectable in OVX rats.  In rats treated 
with VCD, levels of E2, T, and AD were significantly lower than levels detected in proestrus rats 
(p<0.05 in all cases) and did not differ significantly from levels detected in diestrus rats. This was 
the case at both 1 week and at 6 weeks following the completion of VCD treatments.  
 
2.6.2 Monoamines, monoamine metabolites, and amino acids levels 
2.6.2.1 Comparison of proestrus vs. diestrus 
Few differences were detected between brain tissues collected from gonadally intact cycling 
rats.  In the frontal cortex, higher levels of 5-HT were detected at proestrus than at diestrus (t (14) 
= 2.2, p<0.05), and the ratio of 5-HIAA/5-HT was significantly lower at proestrus than at diestrus 
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(t (14) = 2.4, p<0.05).  Likewise, in the hippocampus, the ratio of 5-HIAA/5-HT was significantly 
lower at proestrus than at diestrus (t (11) = 2.7, p<0.05).  In the striatum, higher levels of TYR 
were detected at proestrus than at diestrus (t (13) = 2.2, p<0.05). No other significant differences 
were detected. There was, however, a trend for reduction in the ratio of 5-HIAA at proestrus vs. 
diestrus (t (11) = 1.8, p=0.1) in the HPC, and a strong trend for an increase in HVA (t (14) = 2.1, 
p=0.06) levels at proestrous vs. diestrous in STR.  
 
2.6.2.2 Effects of OVX and VCD treatments 
Significant effects of OVX and VCD treatments on monoamines, monoamine metabolites, and 
amino acid levels were detected.   
 
HPC 
One-way ANOVAs consistently revealed significant effects of OVX and VCD treatments on 
levels of NE (F[5,35]=8.6, p<0.0001), 5-HIAA (F[5,35]=20.6, p<0.0001), TYR and TRP 
(p<0.0001 in each case).  Effects were observed primarily at 1 week following OVX and VCD 
treatment (Fig 7).  Specifically, 1 week following OVX, levels of 5-HIAA were reduced relative 
to both diestrus (p<0.0001) and proestrus (p<0.001). There was a trend for reduction in 5-HIAA 
levels at proestrus vs. diestrus (p=0.07). Levels of NE (p<0.05) likewise were reduced relative to 
diestrus, with a trend towards reduced levels relative to proestrus (p=0.08).  Similar effects were 
observed following VCD treatments.  At 1 week following VCD treatments levels of both 5-HIAA 
and NE were reduced relative to both diestrus and proestrus (p<0.0001 for 5-HIAA; p<0.01 for 
NE in each case). These effects were not observed 6 weeks after OVX or 6 weeks following the 
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completion of VCD treatments.  Levels of the amino acids (TYR and TRP) also were significantly 
reduced (up to 80%) at 1 week following OVX and VCD treatments relative to both proestrus and 
diestrus in gonadally intact controls (Figure 7; p<0.0001 in each case).  By 6 weeks the levels of 
the amino acids had returned to levels comparable to normal cycling rats. Notably, the levels of 
DA and 5-HT were not affected.  Levels of DOPAC, HVA and EPI were undetectable.   
Significant effects on the ratios of DA/TYR (F[5,35]=10.6, p<0.0001) and 5-HIAA/5-HT 
(F[5,35]=7.4, p<0.0001) also were detected. The ratios of DA/TYR at 1 week following OVX or 
VCD treatments were significantly higher than the ratios detected at proestrus and diestrus (p<0.05 
following OVX; p<0.01 following VCD). The ratios of 5-HT/TRP at 1 week following OVX or 
VCD treatments were significantly higher than the ratios detected at proestrus and diestrus 
(p<0.001 in each case). The ratio of 5-HIAA/5-HT was significantly lower at 1 week after OVX 
or VCD treatment relative to diestrus (p<0.05 in each case), but did not differ significantly from 
proestrus.  
In no case did one-way or two-way ANOVAs reveal significant differences between the two 
menopausal models on any of the endpoints measured in the hippocampus. Results of the two-way 
ANOVAs on each of the measures revealed a significant overall effect (F[3,24]>8.0, p<0.001), a 
significant effect of time-point (p<0.0001 in each case), no main effect of model, and no interaction 
between model x time-point.  
 
FCX 
One-way ANOVA revealed significant effects on the levels of DA (F[5,40]=3.8, p<0.01).  
Elevated levels of DA were detected at 6 weeks following OVX relative to diestrus (p<0.01), as 
well as relative to VCD-treated rats at the 6-week time-point (p<0.01). Levels of DA at 1 week 
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following VCD treatments also were significantly higher than levels detected at 6 weeks following 
VCD treatments (p<0.05), with a trend towards being higher relative to diestrus (p=0.07) (Figure 
8).  One-way ANOVA also revealed a significant effect on the ratio of NE/DA (F(5,40)=3.14, 
p<0.05).  This ratio was significantly lower 6 weeks following OVX than at 1 week following 
OVX. A trend for reduction in the ratio of NE/DA was detected at 6 weeks following OVX vs. 
VCD treatments (p=0.07). In no case did the ratio of NE/DA in OVX or VCD-treated rats differ 
significantly from the ratio detected in normal cycling rats.    
Two-way ANOVA of DA levels revealed a significant overall effect (F[3,26]=3.9, p<0.05), no 
main effects of model or time-point, but a significant interaction between model x time-point 
(p<0.01) with the levels of DA higher at 6 weeks following OVX than at 6 weeks following VCD 
treatments (p<0.05).  Likewise, two-way ANOVA of NE/DA ratio revealed a significant overall 
effect (F[3,26]=4.6, p<0.01), no main effects of model or time-point, but a significant interaction 
between model x time-point (p<0.01) with the ratio of NE/DA lower at 6 weeks following OVX 
than at 6 weeks following VCD treatments (p<0.05).   
 
STR 
One-way ANOVA revealed significant effects on the levels of NE (F[5,40]=3.9, p<0.01) and 
HVA (F[5,40]=5.4, p<0.001) in the STR. Elevated levels of NE were detected at 1 week following 
OVX relative to proesturs (p<0.05), diestrus (p<0.01), and at 1 week following VCD treatment 
(p<0.01). Elevated levels of HVA were detected at 1 week following OVX and VCD treatment 
relative to diestrus, and at 1 week following VCD treatment relative to proestrus (p<0.05 in each 
case) (Figure 9). No significant effects on the levels of TYR or TRP were detected in the STR. 
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Two-way ANOVA of NE levels revealed a significant overall effect (F[3,26]=3.6, p<0.05), a 
main effect of model (p<0.05), no main effect of time-point, and a significant interaction between 
model x time-point (p<0.05) with the levels of NE higher 1 week following OVX than 1 week 
following VCD treatments (p<0.05).  Two-way ANOVA of HVA levels revealed no significant 





















Table 1. Neurochemical Endpoints in HPC of Female Rats Killed at Proestrus or Diestrus in 
Comparison with Rats that were Ovariectomized or Treated with VCD. 























































































































































































































































































































































































































































































































































































































































Table 2. Neurochemical Endpoints in FCX of Female Rats Killed at Proestrus or Diestrus in 
Comparison with Rats that were Ovariectomized or Treated with VCD. 



































































































































































































































































































































































































































































































































































































Table 3. Neurochemical Endpoints in STR of Female Rats Killed at Proestrus or Diestrus in 
Comparison with Rats that were Ovariectomized or Treated with VCD.    

















































































































































































































































































































































































































































































































































































































Table 4. Neurochemical Endpoints in STR of Female Rats Killed at Proestrus or Diestrus in 
Comparison with Rats that were Ovariectomized or Treated with VCD (Cont’d).   












































































































































































































































































































































































































































































































































































































Figure 6. Serum (A) E2 (17β-estradiol), (B) T (testosterone) and (C) AD (androstenedione) 
levels by treatment groups. Rats at P (proestrous) and D (diestrous) are used as controls. Bars 
indicate Mean±SEM. One-way ANOVA: *p<0.05, **p<0.01, ***p<0.001, relative to P; #p<0.05 
relative to VCD-1w; §p<0.05 relative to VCD-6w. T-test: $$p<0.01, $$$p<0.001, relative to P. None 

























Figure 7. Monoamine, metabolite, amino acid levels and metabolite/monoamine ratio by 
treatment groups in HPC.  Rats at P (proestrous) and D (diestrous) are used as controls. Bars 
indicate Mean ± SEM. One-way ANOVA: **p<0.01, ***p<0.001 relative to VCD/OVX-1w; 
##p<0.01, ###p<0.001 relative to P; §p<0.05, §§p<0.01, §§§p<0.001 relative to D; ‡ 0.05<p<0.1, 









Figure 8. Monoamine levels by treatment groups in FCX. Rats at P (proestrous) and D 
(diestrous) are used as controls. Bars indicate Mean ± SEM. One-way ANOVA:  **p<0.01 relative 












Figure 9. Monoamines and metabolite levels by treatment groups in STR. Rats at P 
(proestrous) and D (diestrous) are used as controls.  Bars indicate Mean ± SEM. One-way 
ANOVA:  **p<0.01 relative to VCD-1w; #p<0.05 relative to P; §p<0.05, §§p<0.01, §§§p<0.001 












Figure 10. Profile of monoamines, metabolite and precursor levels by brain region. (A) Rats 
at P/D ;(B) Rats at 1W; (C) Rats at 6W. Since not many model differences on these endpoints were 
detected, data from OVX and VCD were combined. As expected, high levels of DA were detected 
in STR compared with HPC and FCX. Levels of EPI, DOPAC and HVA were not detectable in 















2.7.1 Serum hormone measurements 
Our goal was to characterize neurochemical changes in the brain associated with two models 
of menopause, surgical vs. transitional, and to compare effects with changes observed at two stages 
of the estrous cycle, proestrus and diestrus. Circulating levels of E2, T and AD confirm that 
representation of each of these conditions was successfully accomplished.  Consistent with 
previous study using GC-MS/MS for hormone measurement [108],  levels of E2, T and AD levels 
were significantly lower at diestrous than at proestrous. In addition, E2, T and AD were not 
detected 1 week and 6 weeks after OVX, as expected with complete removal of the ovaries. Unlike 
OVX, VCD treatments eliminate only the ovarian follicles, while the androgen-producing 
interstitial cells remain intact [77]. Consequently, in VCD-treated rats E2 levels were reduced, 
whereas androgens continued to be detected at levels comparable to diestrus. These findings are 
consistent with previous characterizations of this model [81]. In addition to AD levels, our study 
provides new information regarding T levels in two distinct estrous stages in comparison to VCD 
and OVX treatment. 
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2.7.2 Fluctuations in neurochemical endpoints detected in gonadally intact rats 
Results show that significant effects are detected in the HPC and FCX associated with cycle 
stage and are limited primarily to the serotonin pathway. Specifically, levels of 5-HT in the FCX 
were significantly higher at proestrus than at diestrus, and the ratio of 5-HIAA/5-HT was 
significantly lower in the HPC and FCX in rats euthanized at proestrus vs. diestrus. Similar results 
were reported by Shimizu, where the ratio of 5-HIAA/5-HT was significantly reduced during 
proestrous in nucleus accumbens [109]. The increase in 5-HT coupled with a decrease in the ratio 
of 5-HIAA/5-HT in the FCX suggests a decrease in 5-HT release, resulting in elevated 5-HT and 
less 5-HIAA production. A similar reduction in 5-HT turnover may be occurring in the HPC, 
although levels of 5-HT were not elevated at proestrus in this region.  There also was a trend for a 
reduction in the ratio of 5-HT/TRP in the HPC at proestrus vs. diestrus, though this did not reach 
statistical significance. This may reflect greater susceptibility of the HPC to effects on amino acid 
levels with corresponding effects on neurotransmitter endpoints. These effects appear minimal and 
difficult to detect in normal cycling rats, but were exacerbated in the two models of menopause 
(see below).     
Some of our results differ from published studies.  For example, we detected no significant 
differences in neurochemical endpoints as a function of cycle in the striatum. In contrast, Xiao et 
al. [69] reported that in female rats extracellular DA concentrations in the STR were significantly 
higher at proestrus than at diestrus. In contrast to the elevation in 5HT we detected in the FCX, 
Desan et al.[110] reported no significant differences in 5-HT levels in anterior cerebral cortex, 
hippocampus or cerebellum across the estrous cycle. Differences may be due in part to 
methodologies and to the absence of verification of hormone levels.  Advantages of the current 
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study include the measurement of hormone levels, as well as multiple neurochemical endpoints, 
thus giving a more comprehensive characterization of the neurochemical signatures.  
 
2.7.3 Effects of OVX and VCD treatments on neurochemical endpoints  
A strength of the metabolomics approach is the ability to provide a comprehensive analysis of 
multiple endpoints for a variety of brain structures, all from the same set of tissues.  Multiple 
effects were detected and most effects were both region-specific and time-dependent. One of the 
key findings of our analysis is the relatively few differences in the effects of the two models on 
neurochemical endpoints, despite the fact that the hormonal profiles, particularly androgen levels, 
were quite different. This suggests that surgical and transitional menopause produce similar effects 
on these endpoints, at least during the early weeks following menopause. This, in turn, suggests 
that any differences in cognitive performance between OVX and VCD-treated rats are not due to 
differential effects on monoaminergic pathways.   
As we dissect the regional effects, we find that the greatest number of effects were detected in 
the HPC, suggesting that this region of the brain is particularly sensitive to loss of ovarian function. 
The hippocampus plays a critical role in memory consolidation as well as age-related cognitive 
decline and many studies have demonstrated significant effects of estrogens on synaptic plasticity 
and neuronal function in this region [111].  In the current study, effects of both surgical and VCD-
induced loss of ovarian function in the HPC were detected at 1 week, but not at 6 weeks, suggesting 
that these are temporary effects. The results are in agreement with previous reports showing 
decreased levels of NE [66, 67] and 5-HIAA [66] following ovariectomy in mice. Furthermore, 
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our finding of reduced 5-HIAA/5-HT ratio observed at 1 week and not 6 weeks following OVX 
or VCD treatments agrees with previous results in rats where the ratio was reduced at 2 weeks, but 
not 4 weeks, after OVX [74]. The substantial reduction in TRP as well as elevated ratios of 5-
HT/TRP and 5-HIAA/TRP suggest that at an early time-point following either OVX or VCD 
treatments serotonin turnover is significantly reduced, possibly due to reductions in the amino acid 
TRP. The fact that levels of DA and 5-HT in HPC remained unchanged following estrogen 
deprivation also concurs with earlier findings reported in mice [66].   
The fact that 5-HIAA was reduced without a reduction in 5-HT suggests that less 5-HT was 
released, perhaps in response to a reduction in 5-HT, resulting from a reduction in TRP.  A similar 
effect may be occurring in the DA and NE pathways.  Levels of NE were reduced, possibly in 
response to a reduction in TYR.  Since levels of DOPAC and HVA were not detectable in this 
region we were unable to evaluate potential effects on DA turnover; however, it may be that 
temporary reductions in TYR resulted in reduced DA release (thereby preserving DA levels) along 
with reduced metabolism of DA to NE.   
Some of our findings were surprising and not entirely consistent with previous reports. For 
example, in contrast with the HPC, relatively few effects of OVX and VCD treatments were 
detected in the FCX.  The FCX plays a critical role in attention as well as executive functions and 
significant effects of estrogen treatment on monoaminergic innervation of the FCX have been 
reported [112].  Nevertheless, in the present study none of the sizable decreases in 5-HIAA, NE 
and amino acids that were detected in the HPC at 1 week following OVX or VCD treatments were 
detected in the FCX.  This was unexpected given the significantly higher levels of 5HT and the 
lower ratio of 5-HIAA/5-HT detected in the FCX at proestrus relative to diestrus. Hence, we 
anticipated lower levels of 5-HT in the FCX following OVX and VCD treatments compared with 
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proestrus in association with the lower levels of gonadal hormones. The unexpected result suggests 
that levels of 5-HT cease to fluctuate and are restored in non-cycling animals, even in a state of 
chronically low estrogen levels.  
The significant increase in DA in the FCX of OVX-6W rats also was surprising, and contrasts 
with previous results  showing a decrease in DA at 20 days following OVX treatment in mice [67]. 
This could reflect a species difference, or possibly differences associated with the time points when 
neurotransmitter levels were evaluated. In contrast to OVX rats, higher DA levels were detected 
in the FCX at 1 week relative to 6 weeks following VCD treatments. This was one of the few 
instances where effects of the two models differed. These increases in DA in OVX and VCD-
treated rats may reflect compensatory changes in the expression or activity of metabolic enzymes 
involved in the production and degradation of the monoamines (see below). 
In contrast with effects in the HPC and FCX, OVX and VCD treatments significantly affected 
the noradrenergic pathway in the STR.  The striatum is part of the extrapyramidal motor system.  
Not only is it critically involved in extrapyramidal motor control but also plays a significant role 
in motor learning [113]. Notably, elevated estrogens have been shown to favor the use of 
hippocampal learning strategies whereas low estrogens have been shown to favor the use of striatal 
learning strategies [114].   
Our data show an increase in NE in the STR at 1 week following OVX, but not following 
VCD-treatment.  This again is one of the few model differences that were detected and may 
contribute to short-term differences in striatal function and motor learning following loss of 
ovarian function. We also detected increases in HVA at 1 week following OVX or VCD treatment. 
This agrees with results reported by Bitar et al. which showed markedly elevated concentrations 
of HVA in male and female rats following gonadectomy, whereas the level of 5-HT and 5-HIAA 
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remained unaltered in STR [68]. However, they also reported detected elevated DA and DOPAC 
levels after OVX whereas we did not. Using a microdialysis approach, a separate study found that 
female rats had significantly higher extracellular striatal dopamine concentrations at proestrus than 
after ovariectomy [69]. The reasons for these inconsistencies are unknown. Differences in 
analytical methodologies and in the length of time between ovariectomy and day of sacrifice could 
potentially account for differences.  
In the present study, increases in NE and HVA following OVX suggests an increase in NE 
production and DA release at the 1-week time point in the surgical model.  The increases in HVA 
detected in the OVX-1W and VCD-1W groups may indicate an increase in DA release at the early 
time-point in response to the loss of ovarian function. It was unexpected that elevated HVA levels 
were accompanied by unaltered DOPAC level in this brain structure. One possible explanation is 
that DA metabolism was shifted toward the DA-3MT (3- methoxytyramine)-HVA pathway (15% 
of DA turnover in normal condition), however additional study is required to elucidate the 
underlying mechanisms. 
 
2.7.4 Potential mechanisms – anabolic and catabolic enzymes 
Possible mechanism for some of the effects observed on the neurochemical endpoints could be 
alterations in synthetic and catabolic enzymes involved in monoamine regulation. Tyrosine 
hydroxylase (TH) and tryptophan hydroxylase (TPH) are the rate limiting enzymes responsible for 
the conversion of tyrosine and tryptophan to dopamine and serotonin.  Both of these enzymes are 
potently regulated by phosphorylation and are negatively regulated by monoamines [115, 116]. 
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Numerous reports show that these enzymes also can be regulated by estrogens.  Some reports are 
contradictory. For example,  Beattie et al. [117] reported that ovariectomy caused a 2-3 fold 
increase in hypothalamic TH activity in the rat, whereas Krieger et al. [118] reported no significant 
increase in TH activity in the hypothalamus or medial preoptic area following ovariectomy. 
Ivanova and Beyer [119] reported that local estrogen production increases TH mRNA and protein 
expression in the ventral midbrain of mice during late prenatal and early postnatal development.  
Sabban et al. [120] reported differing effects of estradiol on TH expression in the nucleus of the 
solitary tract and in the locus coeruleus that differed depending on mode of delivery. Kritzer et 
al.[121] reported that the density of TH immunoreactive fibers decreased in the dorsolateral 
prefrontal cortex of rhesus monkeys following ovariectomy, which was reversed by combined 
treatment with estrogen + progesterone. These findings demonstrate the potential for TH 
expression to be regulated by estradiol in a region-specific way.  
TPH expression also has been shown to be regulated by estrogen signaling.  Smith et al. [122]  
reported that 1 month of estradiol treatment increased TPH mRNA in the dorsal raphe of rhesus 
monkeys.  These same treatments also decreased expression of the serotonin transporter and 
decreased expression of monoamine oxidase (MAO)-A mRNAs.  Hiroi et al. [123] showed similar 
increases in TPH-2 mRNA in the rat raphe in response to estradiol. More recently, Hiroi et al. 
[124] reported that treating with estradiol or with conjugated equine estrogens increased TPH-2 
mRNA in the raphe with some differences in subregion-specific effects depending on which 
estrogens were administered. Collectively, these findings are consistent with estrogen 
enhancement of serotonin signaling.  
Other enzymes that may contribute to the effects of menopause on neurochemical endpoints 
are dopamine beta hydroxylase (DBH), a key enzyme in NE synthesis, as well as MAO and 
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catechol-O-methyl transferase (COMT), key enzymes responsible for the inactivation of 
monoamines.  Zhang et al. [125] reported a reduction in DBH in the locus coeruleus following 
OVX which was associated with a reduction NE levels, and Sabban et al. [120] reported that 
estradiol potently increased activation of the DBH promoter in PC12 cells.  Studies also have 
reported significant increases in MAO activity in the hypothalamus [126] and COMT activity in 
the prefrontal cortex [127] following ovariectomy in rats.  Hence, estrogen regulation of these 
enzymes is brain region specific and may differ as a function of menopause and length of time in 
a hypoestrogenic state. Further clarification of how these enzymes contribute to the effects of 
surgical and transitional menopause on neurochemical endpoints will require a detailed analysis 
of the anabolic and catabolic enzymes associated with the regulation of monoamines in each of the 
affected brain structures. 
 
2.7.5 Effects on TRP and TYR levels  
This study is also the first to analyze levels of TRP and TYR following loss of ovarian function 
in the same tissues in which multiple monoaminergic endpoints were measured. Most striking was 
the reduction in the levels of TRP and TYR detected in the HPC, but not in the FCX or STR, at 1 
week following OVX or VCD treatments, which suggests loss of ovarian function has substantial 
acute effects on amino acid homeostasis in this region of the brain. This effect was only observed 
in the HPC, was not observed in normal cycling rats, and levels returned to normal within 6 weeks. 
To our knowledge this is the first report of a substantial reduction in amino acid levels detected in 
the HPC following the loss of ovarian function. 
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At present, the mechanisms responsible for the reductions in TRP and TYR at the 1-week time-
point are unknown. TYR and TRP are large, neutral, aromatic amino acids. Their brain levels are 
controlled in part by their plasma concentrations, but are even more dependent on plasma 
concentrations of other large neutral amino acid (LNAA) and Branched Chain Amino Acids 
(BCAA). Previous research has demonstrated that certain LNAA (e.g. Phenlyalanine,PHE) as well 
as BCAAS (leucine,LEU; isoleucine ,ILE and valine ,VAL) [128] compete with TYR and TRP 
for shared transportation through the BBB by System L (e.g. LAT1), which is located on both 
luminal and abluminal sides of the BBB. In addition, it is known that LAT1 in brain capillary 
endothelial cells is typically saturated by amino acids in plasma under normal conditions because 
its Km value is smaller than the plasma concentrations of substrate amino acids. Therefore, an 
elevation in the plasma concentration of either LNAA or BCAA will influence transport activity 
of LAT1 and could reduce brain uptake of TRP and TYR. One study showed that OVX caused an 
array of metabolic changes in amino acid metabolism. Plasma levels of PHE, LEU, ILE and VAL, 
for example, all significantly increased in OVX treated rats compared with controls [129]. Another 
study reported similar effects (i.e. increases in PHE and decreases in ALA, GLN, TRP) in rat serum 
following OVX [130]. It is possible, therefore, that in our study OVX and VCD treatments resulted 
in increased levels of competing amino acids in plasma, which contributed to a reduction in TYR, 
TRP transportation through the BBB.  This, however, would not account for the selective reduction 
of TRP and TYR in the HPC and not in other brain regions.  
Other possibilities include effects on amino acid metabolism, and the rate of protein synthesis, 
all of which have been reported to be affected by estrogen deficiency. Estrogen plays an important 
role of sustaining glucose as the primary fuel source in the brain. One study previously showed 
OVX caused substantial reductions in plasma glucose levels compared with controls [129]. This 
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appears at first to be contrary to clinical observations that the prevalence of the metabolic 
syndrome such as hyperglycemia increases with menopause [131]. However, it should be noted 
that in rats hyperglycemia was observed at 13 weeks after OVX [132] while hypoglycemia was 
observed at 10 days after OVX [129], which is similar to the current study. Therefore, it is likely 
that estrogen deficiency leads to hypoglycemia at early time-points. Glucose transporter (GLUT-
1) mediates glucose transport across the blood brain barrier (BBB) and is highly sensitive to 
changes in plasma glucose levels. Under normal conditions, GLUT-1 expression is closely 
regulated by glucose availability and is upregulated in the BBB during hypoglycemia [133]. 
However, it is found that OVX may induce a significant decline in expression of GLUT-1 in the 
hippocampus. Furthermore, the protein expression and activity of hexokinase, which irreversibly 
phosphorylates glucose to glucose-6-phosphate in the glycolysis process, also was significantly 
reduced following OVX [134]. Therefore, it is possible that by compromising these two rate-
limiting steps, ovarian hormone loss further exacerbates decreased glucose availability and 
utilization in this brain structure. Previous research has reported that increased amino acid 
metabolism took place in rat neuron-enriched aggregate cultures when exposed to hypoglycaemic 
conditions [135]. Although not used primarily for cerebral energy production due to their low ATP 
production efficiency, glycogenic and ketogenic TYR and TRP might be degraded as alternative 
energy sources to form ketone bodies and TCA cycle intermediates (e.g. acetoacetate, fumarate 






Collectively, the results of our analysis describe significant changes in local levels of 
serotoninergic, dopaminergic, and noradrenergic endpoints in association with validated models 
of surgical and transitional menopause.  Most notably, effects were brain-region specific and time-
dependent. These changes are likely relevant to changes in neural function and cognitive 
performance associated with early and late time periods following menopause. However, 
interpretation of these findings needs to be carried out with caution, since the levels of these 
neurochemical endpoints do not necessarily represent a dynamic measure of neuronal activities. 
Similar studies that focus on the anabolic and catabolic enzymes involved in monoamine 
regulation will further add to our understanding of how monoaminergic regulation is affected by 













3.0  CHAPTER 3: COMPARISON OF TRANSITIONAL VS SURGICAL MENOPAUSE ON 




Estrogens play an important role in the central nervous systems in females. In our previous 
study, we compared the effects of two models of menopause on multiple monoaminergic and two 
aromatic amino acid endpoints in the brain. Emerging evidence suggests that inhibitory and 
excitatory amino acids may be involved in sex hormone effects on neuronal functions. In this 
study, we furthered our investigation by evaluating the impact of estrogen loss on levels of six 
nonessential amino acids (including excitatory and inhibitory amino acids) in the rat brain using a 
similar experimental design but with a different analytical method. Our results show that similar 
to the effects seen in the aromatic amino acids, significant reduction of each amino acid level was 
detected only in the HPC region and only at the 1-week time point following estrogen deprivation 
in both of the menopausal models. Such effects may potentially contribute to the changes in neural 
function and related cognitive performance after menopause. 
 





Estrogens play a fundamental role in the physiology of the reproductive and central nervous 
systems in females. In Chapter 2, we conducted the first comprehensive analysis comparing the 
effects of two models of menopause on neuroendocrine endpoints in the brain, which included 
multiple monoamine and metabolite endpoints as well as two aromatic amino acids TYR and TRP. 
One of the most interesting and surprising findings was the significant reduction of TYR and TRP 
levels only in HPC region, at 1-week time point following estrogen deprivation in both of the 
menopausal models. Given the critical roles that amino acids play in brain functions (e.g.  used for 
neurotransmitter, neurotransmitter precursor, or protein synthesis), the significant reductions in 
amino acid levels in the brain are likely to contribute in part to the effects of surgical and 
transitional menopause on brain function and cognitive performance.  
Nevertheless, to the best of our knowledge, previous studies investigating the effects of 
estrogen loss on brain amino acid levels are extremely limited. It is still unknown whether the loss 
of estrogen would have similar or different effects on brain amino acids other than TYR and TRP. 
This prompted us to further our investigation by evaluating six additional nonessential amino acids 
(alanine (ALA), serine (SER), glycine (GLY), aspartate (ASP), glutamate (GLU) and glutamine 
(GLN)) using similar experimental design but with a different analytical method in current study. 
These amino acids are chosen based on their chemical characteristics and unique roles in 
neurotransmission to represent a variety of amino acid classes. For example, based on the 
propensity of the side chain to be in contact with water, ALA and GLY are classified as 
hydrophobic, SER and GLN as polar and ASP and GLU as charged. GLU and ASP are major 
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excitatory amino acids (EAA) while GLY is considered an inhibitory amino acid (IAA). Results 
showed that similar to the effects seen in aromatic amino acids TYR and TRP, significant reduction 
of each amino acid level was detected only in HPC region and only at 1-week time point following 






















3.3 MATERIALS AND METHODS 
 
3.3.1 Amino Acids Analysis by GC-FID 
Multiple amino acid contents in rat brain homogenates were analyzed using a commercially 
available “EZ:faast GC–FID amino acid testing kit” by Phenomenex [136]. The modified assay 
procedure involves sample purification, extraction, derivatization of extracted amino acids, and 
GC analysis.  
Sample Preparation by SPE and Derivatization: 50 μl of the brain homogenate and 50 μl of 
internal standard (the norvaline) were pipetted into each sample preparation vial. A sorbent tip was 
attached to a 1.5 mL syringe. Then the tip was immersed in the solution. The solution in the sample 
preparation vial was forced to pass through the sorbent tip by slowly pulling back the syringe 
piston. Following that, 100 μl of the wash solution was pipetted into the same sample preparation 
vial and let the solution pass slowly through the sorbent tip and into the syringe barrel. The liquid 
from the sorbent bed was drained by pulling air through the sorbent tip. Then the tip was detached 
and left in the sample preparation vial. After that, 100 μl of the freshly prepared elution medium 
was pipetted in the same sample preparation vial. Then the sorbent tip was attached to the 0.6 ml 
syringe with the piston pulled back halfway up the barrel. The sorbent in the tip was wet with the 
eluting medium and let the liquid rise through the sorbent particles and stop when the liquid reaches 
the filter plug in the sorbent tip. Then, the liquid and sorbent particles were ejected out of the tip 
and into the sample preparation vial. Repeat the ejection step until all of the sorbent particles in 
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the tip were expelled into the sample preparation vial. 25 μl of organic solution 1 was transferred 
using the adjustable microdispenser into the sample preparation vial. The liquid in the vial was 
emulsified by repeated vortexing. The emulsion would gradually separate into two layers after 
letting the reaction to proceed for at least 1 min. The liquid in the vial was re-emulsified and 
allowed to react for another minute. 50 μl of Reagent 5 was then transferred with the 
microdispenser and the liquid was med to react for additional 1 minute. Lastly, 50 μl of reagent 6 
was pipetted into the vial. The emulsion was separated into two layers after quick vortexing. After 
sample cleanup procedure, the amino acids were quickly derivatized at room temperature with the 
addition of two reagents, which modify both the carboxyl and amino groups of the amino acids 
forming stable derivatives (Figure 11). The upper layer contains the derivatized AA to be analyzed 
by GC. 
Gas Chromatography: A 10m× 0.25mm ZB-PAAC column from Phenomenex (Torrance, CA, 
USA) was used. Pressure of the carrier gas Heilium was kept constant during the run at 4psi. 
Nitrogen (30 mL/min), hydrogen (35 mL/min) and air (300 mL/min) were used as auxiliary gases. 
The oven temperature program was as follows: initial temperature is 110 ºC. Stage 1: a 30ºC /min 
ramp from 110 ºC to 200 ºC; Stage 2: 35 ºC /min ramp from 200 ºC to 305 ºC; Stage 3: a 25 ºC 
/min ramp from 305 ºC to 330 ºC, held for 2 min. The temperature of the injection port and detector 
was 250 ºC and 330 ºC. A 2 μL sample was injected in split mode with a split ratio of 5:1. The 
limit of quantification for this assay is 1.0 nmole/ml. Coefficients of Variation for amino acids 
were 1.5–6.2% (intra-assay) and 3.8–9.7% (interassay). Concentrations of amino acids in the 




     
           Figure 11. Simplified diagram illustrating EZ:faast derivatization reactions. 
 

















3.4.1 Amino acids levels 
3.4.1.1 Comparison of proestrus vs. diestrus 
Similar to monoamines and metabolites, few differences in levels of amino acids were detected 
in all of the brain tissues collected from gonadally intact cycling rats.   
3.4.1.2 Effects of OVX and VCD treatments 
Significant effects of OVX and VCD treatments on amino acid levels were detected only in 
HPC, not in FCX or STR.   
 
HPC 
One-way ANOVAs consistently revealed significant effects of OVX and VCD treatments on 
all of the amino acids measured: ALA (F[5,35]=18.1, p<0.0001), SER (F[5,35]=8.2, p<0.0001), 
GLY (F[5,35]=10.6, p<0.0001) , ASP(F[5,35]=18.0, p<0.0001), GLU (F[5,35]=16.5 , p<0.0001) 
and GLN (F[5,35]=6.0, p<0.0001).  Similar to changes in neurochemical endpoints reported in 
Chapter 2, effects were observed primarily at 1 week following OVX and VCD treatment (Figure 
13).  Specifically, 1 week following OVX and VCD treatments, levels of each amino acid were 
reduced relative to both diestrus (p<0.05) and proestrus (p<0.05). In contrast, these effects were 
not observed 6 weeks after OVX or 6 weeks following the completion of VCD treatments. Similar 
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to previously studied aromatic amino acids TYR and TRP, by 6 weeks the levels of these amino 
acids had returned to levels comparable to normal cycling rats.  
One-way or two-way ANOVAs did not reveal significant differences between the two 
menopausal models on any of the amino acid endpoints measured in the hippocampus. Results of 
the two-way ANOVAs on each of the measures revealed a significant overall effect (F[3,23]>19.4, 
p<0.0001), a significant effect of time-point (p<0.0001 in each case), no main effect of model, and 
no interaction between model x time-point.  
 
FCX and STR 
In contrast to HPC, one-way ANOVAs did not detect any significant effects of OVX and VCD 
treatments on amino acid levels in FCX and STR. Similarly, results of two-way ANOVAs did not 
reveal any significant overall effect, main effect of menopausal model, time-point as well as 










Figure 12. Profile of amino acid levels by brain region. (A) Rats at P/D ;(B) Rats at 1W; (C) 
Rats at 6W. Since not many model differences on these endpoints were detected, data from OVX 













   
                                                                                               
 
                                                                                                                                                              








Figure 13. Amino acid levels by treatment groups in HPC.  Rats at P (proestrous) and D 
(diestrous) are used as controls. Bars indicate Mean ± SEM. One-way ANOVA (followed by post-
hoc Tukey’s test if p<0.05): *p<0.05, **p<0.01, ***p<0.001 relative to VCD/OVX-1w; #p<0.05, 
##p<0.01, ###p<0.001 relative to P; §p<0.05,§§p<0.01, §§§p<0.001 relative to D;  0.05<p&<0.01 











Table 5. Nonessential Amino Acid Endpoints in HPC of Female Rats Killed at Proestrus or 







































































































































































































































































































































































































































Table 6. Nonessential Amino Acid Endpoints in FCX of Female Rats Killed at Proestrus or 










































































































































































































































































Table 7. Nonessential Amino Acid Endpoints in STR of Female Rats Killed at Proestrus or 






































































































































































































































































3.5.1 Amino acid endpoints remained unchanged in gonadally intact rats 
Similar to TYR and TRP reported in previous study, our results showed that no significant 
changes of amino acid levels were detected in all of the three brain regions associated with cycle 
stage. This is in agreement with the study reported by Löscher et.al, where concentrations of 11 
amino acids (including all of the six amino acids investigated in current study) were determined in 
12 brain regions (including 3 brain regions investigated in current study) of female rats during four 
different stages of the estrous cycle. Similarly, regional amino acid levels were found to remain 
unchanged during estrous cycle [137]. Proestrous and diestrous were chosen in our study with 
respect to their high and low estrogen levels in order to determine the effects of estrogen 
fluctuations in estrous cycle on brain amino acid levels. Our results suggested that brain amino 
acid levels are relatively stable and not sensitive to the estrogen fluctuations naturally. It may be 
due to the change of estrogen level in estrous cycle is transient and not persistent, so that the 
magnitude of effect is not big enough to incur alterations in amino acid levels.  
3.5.2  Effects of OVX and VCD treatments on amino acid endpoints  
Multiple effects were detected, and most effects were both region-specific and time-dependent. 
Interestingly, the effect pattern is quite similar among all of the six amino acids. Similar to 
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monoamine and metabolites, our analysis shows no significant differences in the effects of the two 
models on these amino acid endpoints, given the different sex hormone levels between the two 
models. This indicates that surgical and transitional menopause produce similar effects on these 
endpoints and further suggests that any differences in cognitive performance between OVX and 
VCD-treated rats are not due to differential effects on these nonessential amino acids.  
One of the key findings is that alterations in amino acid levels were only detected in the HPC, 
suggesting that this region of the brain is particularly sensitive to loss of ovarian function. It also 
suggests that whatever mechanisms are responsible for the decreases in AA levels in the HPC do 
not appear to be at play in the FCX and STR. The results were also in agreement with our previous 
findings with aromatic amino acids TYR and TRP [138]. Similar to our previous study, effects of 
both surgical and VCD-induced loss of ovarian function in the HPC were detected only at 1 week, 
but not at 6 weeks, suggesting either the effects are transient or there may be some unknown self-
compensatory processes in the brain that restored the levels of affected amino acids back to normal. 
This needs to be further investigated.  
3.5.3 Potential mechanism of amino acid reduction  
This study is also the first to analyze levels of major excitatory amino acids (GLU and ASP), 
inhibitory amino acid (GLY) as well as other amino acids (ALA, SER, GLN) following loss of 
ovarian function in the same tissues in which multiple amino acid endpoints were measured.  The 
most surprising result was the reduction in levels of each amino acid in the HPC at 1 week 
following OVX or VCD treatments. This further confirms our previous finding that loss of ovarian 
function has substantial acute effects on amino acid homeostasis in this region of the brain [138]. 
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The underlying mechanisms are not fully understood yet. Possible explanations may include 
decreased amino acid synthesis, increased amino acid degradation or decreased amino acid passage 
from blood to the brain following loss of ovarian function.  
Firstly, all of these six amino acids are non-essential amino acids, which means that they can 
be synthesized in the body. These amino acids’ synthesis requires carbon skeletons, which mainly 
come from intermediates of the glycolytic pathway and from intermediates in the Tricarboxylic 
Acid (TCA) cycle, where multiple transaminations, catalyszed by transaminases, take place to 
transfer alpha-amino groups to preexisting amino acids to form new ones. For example, SER and 
GLY can be formed from glycerate-3-phosphate; ALA can be formed from pyruvate; ASP can be 
formed from oxaloacetate and GLU, GLN can be formed from α-ketoglutarate. Therefore, it is 
necessary to conduct future studies to evaluate the levels of the above-mentioned intermediates as 
well as the expression and activities of related enzymes in HPC following loss of ovarian function.  
Secondly, due to the important role that estrogen plays in energy balance and glucose 
homeostasis in the brain [139], it also is possible that increased amino acids have been degraded 
to products that can enter the TCA cycle and then be converted to intermediates or glucose, which 
can be utilized for energy production. For example, the six amino acids are all glucogenic amino 
acids, which can be converted into glucose and ketogenic amino acids through gluconeogenesis. 
Then they could be used for direct energy production or ketone body formation (acetoacetate, β-
hydroxybutyrate, and acetone). Previous studies have reported a substantial reduction in plasma 
glucose level at 10 days after ovariectomy [5]. Further study is required to investigate if the 
degradation of amino acids for energy production has increased in HPC after loss of ovarian 
function. In addition, it is also necessary to evaluate the expression and activities of enzymes 
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involved in the TCA cycle, such as the pyruvate dehydrogenase complex, citrate synthase, 
aconitase, fumarase and malate dehydrogenase etc.  
Lastly, the amino acids in the brain can either come from local synthesis in the brain or from 
plasma amino acids that pass the blood brain barrier. Since its major source is not fully understood, 
a decrease in plasma amino acid levels following loss of estrogen could potentially contribute to a 
decrease in their levels in the brain. Previous studies have reported reductions in amino acids (e.g. 
ALA, GLN) in rat serum following OVX [130]. Therefore, it is likely that in our study OVX and 
VCD treatments resulted in reduction of these non-essential amino acid levels in plasma, followed 
by reduced transportation to the brain through the BBB. Future study is warranted to evaluate the 
impact of estrogen deprivation on levels of these amino acids in plasma as well as the expression 













Collectively, the results of our analysis, for the first time, described significant, region-specific 
and time-dependent changes in local levels of six non-essential amino acid endpoints, using 
validated models of surgical and transitional menopause. Results showed that amino acids in all 
of the three brain regions were surprisingly stable throughout the estrous cycle in female rats. In 
addition, the FCX and STR exhibited the least vulnerability in terms of amino acid concentrations 
to loss of estrogen. With respect to the possible functional meaning of the significant reductions 
in amino acid levels observed in the HPC shortly after loss of ovarian function, the most interesting 
alterations are certainly those of amino acids which act as excitatory or inhibitory 
neurotransmitters in the brain. In this regard, the drastic reductions in levels of GLU, ASP and 
GLY are of particular interest and are likely contributing to changes in synaptic neurotransmission, 












4.0  ESTRADIOL AND SELECTIVE ESTROGEN RECEPTOR AGONISTS 
DIFFERENTIALLY AFFECT BRAIN MONOAMINES AND AMINO ACIDS LEVELS IN 
TRANSITIONAL AND SURGICAL MENOPAUSAL RAT MODELS 
4.1 ABSTRACT 
 
Estrogens have many beneficial effects in the brain. Previously, we compared the effects of 
two models of menopause (surgical vs. transitional) on multiple monoaminergic endpoints in 
different regions of the adult rat brain. Although estrogen replacement has been shown to affect 
neurotransmitter (NT) production and release with corresponding effects on cognitive 
performance, to date there has been little direct comparison of the effects of estrogens and selective 
estrogen receptor (ER) agonist on brain NT pathways between surgical and transitional 
menopause. The objective of current study was to evaluate the effects of ER agonist treatments. 
Neurochemical endpoints were evaluated in the hippocampus (HPC), frontal cortex (FCX), and 
striatum (STR) of adult ovariectomized (OVX) rats and in rats that underwent selective and 
gradual ovarian follicle depletion by daily injection of 4-vinylcyclohexene-diepoxide (VCD), after 
1- and 6-weeks treatment with 17β -estradiol (E2), or with selective ERα (PPT), ERß (DPN), or 
GPR30 (G-1) agonists. Endpoints included serotonin (5-HT) and 5-Hydroxyindoleacetic acid, 
dopamine (DA), 3,4-Dihydroxyphenylacetic acid and homovanillic acid, norepinephrine (NE) and 
epinephrine, as well as the amino acids tryptophan (TRP) and tyrosine (TYR). Significant 
differences between the models were detected. OVX rats were much more sensitive to ER agonist 
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treatments than VCD-treated rats. Significant differences between brain regions also were 
detected. Within OVX rats, more agonist effects were detected in the HPC than in any other region. 
One interesting finding was the substantial decrease in TRP and TYR detected in the HPC and 
FCX in response to agonist treatments, particularly in OVX rats. Other interesting findings 
included increases in the levels of 5-HT, DA, and NE in the HPC of OVX rats treated with DPN, 
increases in DA detected in the FCX of OVX rats treated with any of the ER agonists, and increases 
in 5-HT and DA detected in the STR of OVX rats treated with E2. Many effects that were observed 
at 1-week were no longer observed at 6-weeks, demonstrating that effects were temporary despite 
continued agonist treatment. Collectively, the results demonstrate significant differences in the 
effects of ER agonist treatments on monoaminergic endpoints in OVX vs. VCD-treated rats that 
also were brain region-specific and time-dependent. These results are the first to systematically 
and simultaneously evaluate the effects of ER agonist treatments on multiple monoaminergic 
endpoints in multiple regions of the brain in two models of menopause. The fact that agonist 
treatments had lesser effects in VCD-treated rats than in OVX rats may help to explain reports of 
lesser effects of estrogen replacement on cognitive performance in women that have undergone 
transitional vs. surgical menopause.   
 
Keywords: Estrogen; Selective Estrogen Receptor Agonists; Menopause; VCD; 









   Loss of ovarian function has been associated with increased risk for a variety of 
neuropsychiatric and neurodegenerative diseases, including anxiety and depressive disorders as 
well as Alzheimer’s and Parkinson’s disease [76, 82]. Some women experience loss of ovarian 
function relatively early in adult life, due either to premature ovarian failure or to surgical removal 
of the ovaries for prevention of cancer or other medical conditions. Studies suggest that these 
women have significantly increased long-term risk of cognitive impairment and dementia, as well 
as depressive and anxiety symptoms, compared to women with normal ovarian function [140-144].  
Most women, however, undergo a natural menopause due to accelerated loss of ovarian follicles 
occurring at approximately 51 years of age [145]. Studies suggest that loss of ovarian function due 
to natural menopause also is associated with increased risks for cognitive impairments and 
neurodegenerative disease in women [146, 147]. This includes evidence of frontal lobe 
dysfunction [148], as well as evidence of impaired performance on verbal learning, verbal 
memory, and working memory tasks [83, 149, 150]. The mechanisms responsible for the effects 
of surgical and natural menopause on cognitive performance are still largely unclear.   
    It is well known that estrogens can significantly affect neuronal connectivity and function 
in the brain, with corresponding effects on cognitive performance.  Examples include increased 
neuronal connectivity and synaptic function in areas of the brain critical for learning and memory 
[145, 151, 152], improved performance on specific cognitive tasks, including spatial learning tasks 
in rodents [56, 153], and verbal learning and memory tasks in humans [154], and reductions in risk 
of age-related cognitive decline [143, 146, 147]. Consequently, it is assumed that loss of estrogens 
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contributes significantly to the cognitive impairments that have been associated with surgical and 
natural menopause. Estrogens exert their effects by binding to specific estrogen receptors (ERs) 
located throughout the brain. Three receptors have been identified. ERα and ERβ are ligand-
dependent transcription factors acting in the nucleus to enhance nuclear transcription [22]. There 
is evidence that these receptors also can exist in membrane compartments and can participate in 
rapid effects of estrogens on specific transduction pathways [155]. Recently, a novel membrane 
bound G protein-coupled receptor, GPR30, was identified which is genetically and structurally 
unrelated to ERa and ERß, and can initiate estrogen responses at cellular membranes.  [156].  All 
three receptors are expressed in many tissues, and within the brain that are well known to affect 
neuronal function, plasticity, and cognitive performance [25, 157].  
    Estrogens also have been shown to significantly affect monoaminergic neurotransmitter 
(NT) pathways in the brain, which are well known to be critically involved in neuropsychiatric 
and neurodegenerative diseases. The alteration of NT levels by estrogens and selective ER agonists 
is complicated and dependent on multiple factors such as brain region, dose, duration of treatment, 
type of treatment, as well as age and species of the animal.  Many studies have been conducted by 
different laboratories demonstrating effects on specific NT pathways, however data are not always 
consistent [66, 70-73]. A comprehensive analysis of simultaneous changes that occur both within 
and across pathways in multiple brain regions has not yet been conducted. Also it is not clear what 
role the individual estrogen receptors play, or what effects selective estrogen receptor modulators 
have on these NT pathways. 
     Recently we compared the effects of two models of menopause on monoaminergic 
endpoints in different regions of the adult rat brain [158].  Ovariectomy, a model of surgical 
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menopause, was compared with the effects of daily injections of 4-vinylcyclohexene diepoxide 
(VCD), which has been well studied and validated for use as a model of natural menopause in 
women [92, 95, 101]. In contrast to surgical menopause which produces a rapid and complete loss 
of ovarian hormones, the VCD model produces a gradual loss of ovarian follicles, leading to a 
corresponding reduction in estrogen production but with continued production of androgens by the 
remaining ovarian cells [77].  Hence the VCD model more accurately reflects the shift in the ratio 
of estrogens to androgens that occurs with natural menopause. The study measured multiple 
endpoints in three different brain regions from each rat at two time points, thus enabling a 
comprehensive characterization of simultaneous effects on different NT pathways [158].  Results 
showed significant effects on serotoninergic, dopaminergic, and noradrenergic endpoints that were 
both model and brain region specific, and that varied by time following loss of ovarian function.  
In the current paper we used similar methods to investigate the effects of treating rats with selective 
ER agonists after undergoing either ovariectomy or VCD-induced follicular atresia. Results show 
that ER agonists produce effects on serotoninergic, dopaminergic, and noradrenergic endpoints 
that are agonist dependent, and that also vary by model, brain region, and duration of treatment. 
This is the first study to directly and systematically compare the effects of ER agonists on NT 





4.3 MATERIALS AND METHODS 
 
4.3.1 Animals 
Female Sprague–Dawley rats (~11 weeks of age) were purchased from Hilltop Laboratories, 
Inc.  All rats were individually-housed and maintained on a 12/12 h light–dark cycle (lights on at 
7:00 AM) with free access to food and water. Rats were allowed to acclimate to the housing 
environment for two weeks prior to use. All experiments were conducted in accordance with the 
NIH Guide for Care and Use of Animals and were approved by the Institutional Animal Care and 
Use Committee of the University of Pittsburgh. 
 
4.3.2 Menopausal Models 
Rats were randomly assigned either to the VCD or OVX group. Rats in the VCD group 
received 4-vinylcyclohexene diepoxide (VCD；Sigma Chemicals; St Louis, MO) at a dose of 80 
mg/kg i.p. daily for a period of 30 days as previously described [101]. During this time, rats in the 
OVX group received daily injections of sesame oil (1ml/kg i.p.). At the end of 30 days, rats that 
had received sesame oil underwent bilateral ovariectomy, and rats that received VCD received 
sham surgery. Rats were anesthetized with ketamine (100 mg/kg) and xylazine (7 mg/kg) (0.1 
cc/100 g.b.w.). Ovariectomy was performed using a lateral approach. The apical tips of the uterus 
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were ligated, and the ovaries were removed. The peritoneal muscle was closed with 6.0 suture silk, 
and the overlying skin was closed with metal wound clips. Sham surgery consisted of skin and 
muscle incisions and wound closure only. Antibiotic cream was applied on the wound to reduce 
chance of infection. Rats received Ketofen (3 mg/kg, i.p.）every day for 3 days to reduce post-
surgical pain. One week of time was allocated for the rats to recover from surgeries before 
beginning agonist or vehicle treatment. 
 
4.3.3 Estrogen receptor agonist treatments 
 
Rats received continuous administration of E2 (Sigma Chemicals; St Louis, MO), 
propylpyrazole triol (PPT; Tocris Cookson; Ellisville, MO), diarylpropiolnitrile (DPN; Tocris 
Cookson; Ellisville, MO), G-1 (1-[4-(6-bromobenzo[1,3] dioxol-5yl)-3a,4,5,9b-tetrahydro-3H-
cyclopenta[c] quinolin-8-yl]-ethanone; Cayman; Ann Arbor, MI), or vehicle (10% DMSO and 
20% hydroxypropyl-β-cyclodextrin (HPβCD; Sigma Chemicals; St Louis, MO), beginning one 
week following ovariectomy or sham surgery.  PPT is an ERα-selective agonist that is 
approximately 410-fold more selective for ERα than ERβ [39, 40]. DPN is an ERβ-selective 
agonist with 70-fold higher binding affinity and 170-fold higher potency for ERβ than ERα [41]. 
G-1 is non-steroidal, high-affinity selective GPR30 agonist, with no binding to the classic ERα or 
ERβ [47]. All drugs were administered by miniosmotic pump (Alzet model 2006; Durect Corp., 
Inc.) implanted subcutaneously in the dorsal neck region. These pumps deliver at a constant rate 
of 0.15 µl/hr for up to 6 weeks. E2 was administered at a rate of 3 μg/day (0.125 µg/hr). PPT, DPN 
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and G-1 treatments each were administered at a rate of 5 μg/day (0.208 µg/hr). This dose and route 
of administration was selected based on previous published data from our lab showing that these 
treatments significantly enhance acquisition of a spatial learning task [54], as well as studies 
showing that E2 and G-1 significantly enhance potassium-stimulated ACh release in the 
hippocampus [53].  Treatments continued for either 1 week or 6 weeks.   
 
4.3.4 Tissue collection 
After 1 week or 6 weeks of treatment rats were anesthetized with an overdose of ketamine (3 
mg) and xylazine (0.6 mg) and killed by decapitation. Trunk blood was collected for determination 
of serum levels of estradiol, testosterone, and androstenedione.  Dissections were performed 
according to plate designations in Paxinos & Watson (1998) [102] and were as follows: 
hippocampus (HPC; plates 21-41), frontal cortex (FCX; plates 11-21), and striatum (STR; plates 
11-21). These regions were selected because of the large body of work showing that each region 
plays an important role in learning and memory processes as well as important roles in 
extrapyramidal motor function (e.g., the STR) [159]. In addition, each of these regions have been 
shown to be influenced by ovariectomy and estrogen treatment [56, 160]. Tissues were stored 




Figure 14. Schematic diagram showing the timeline of the experimental protocol 2. 
 
4.3.5 Brain sample preparation 
500 µl 10 mM sodium acetate buffer (pH 6.5) was added to 50 mg tissue in a 1.5 ml microfuge 
tube. Tissues were sonicated at 4 ̊ C until completely dissolved. After sonication, tissues were spun 
at 14,000 g at 4˚C for 10 min. Supernatant was collected and placed at 4 ̊ C. This step was repeated 
three times and the three supernatants were combined. The cell free supernatants were spun at 
15,000g for an additional 40 minutes. A 200 µl aliquot was taken for the determination of protein 
concentration using the Bradford method [103]. The remaining volume of each supernatant was 
filtered through a disposable membrane (0.22μm pore size) micropartition device (Millipore 
Ultrafree-MC) under centrifugation at 14,000g for 30 min at 4 °C to remove any compounds above 




4.3.6 Hormone assays 
Serum levels of E2, T, and AD were quantified as recently described [104, 105, 158, 161]. For 
E2, samples were spiked with internal standard 25µl 2,4,16,16,17-d5-17 beta-estradiol (1 ng/ml in 
methanol) and extracted with 3-4 ml n-Butyl chloride. Samples were then centrifuged, and the 
organic layer was transferred to salinized culture tubes and dried under a steam of nitrogen. 
Residues were derivatized with dansyl chloride. Samples were centrifuged, and the supernatant 
was transferred into glass vials for LC-MS/MS analysis.  E2 was eluted using a Waters Acquity 
UPLC BEH C18, 1.7 µm, 2.1 X 150 mm reversed-phase column, with an acetonitrile: water (0.1% 
formic acid) gradient.   
T and AD levels in serum were quantified using methods similar to the detection of E2.   
Briefly, samples were spiked with 0.25 ng/ml D3-testosterone or D7-androstenedione as the 
internal standard and then extracted with n-butyl chloride. After centrifugation and evaporation, 
the residue was reconstituted in methanol and water (80 μl: 20 μl), centrifuged again and the 
supernatant transferred into glass vials for UPLC-MS/MS analysis. T and AD were eluted from 
the same column as E2, with a methanol: water (0.1% formic acid and 2 mM ammonium acetate) 
gradient from 50 to 85% methanol.  
MS detection and quantification of all hormones was achieved in the positive mode.  
Transitions used for the analysis of estradiol were 506 → 171 for E2, and 511 →171 for the 
deuterated internal standard. Transitions used for T analysis were 289 →97 for T and 292 →97 for 
the deuterated T. Transitions used for AD analysis were 287→100 for AD and 294→ 100 for the 
deuterated AD. Area under the peak was quantified and used to determine absolute levels of E2, 
T, or AD per ml by comparison with corresponding standards. The limit of detectability for the E2 
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assay is 2.5 pg/ml. The limit of detectability for the T and AD assays is 25 pg/ml.  Intra-assay 
statistics show relative standard errors below 8.1% and relative standard deviations below 10.4%. 
Inter-assay statistics show relative standard errors below 5.0% with relative standard deviations 
below 7.4%.  
 
4.3.7 Monoamine analysis by HPLC-CMEAS： 
Monoamines and metabolites were measured with a modified version of a HPLC-ECD method 
and as described in our recent paper [158]. The goal was to characterize levels of targets associated 
with dopaminergic, noradrenergic, and serotoninergic pathways. Targets that were quantified 
included the amino acids tryptophan (TRP) and tyrosine (TYR); dopamine (DA) and its 
metabolites, 3-4-dihydroxyphenylalanine (DOPAC) and homovanillic acid (HVA); 
norepinephrine (NE) and epinephrine (EPI); and serotonin (5-HT) and its metabolite 5-
hydroxyindole acetic acid (5-HIAA). These endpoints were selected because these monoaminergic 
pathways are known to be affected by ovariectomy and estrogen treatment with corresponding 
effects on cognitive and motor performance [73, 162].  
The HPLC methods have recently been described in detail [158].  Briefly, 100 μl of sample 
was injected into an ESA CoulArray Model 5600 HPLC system, consisting of two Model 582 
pumps, one dynamic gradient mixer, two PEEK pulse dampers, a Model 542 refrigerated 
autosampler injector, a CoulArray organizer module, and a serial array of 16 coulometric 
electrodes. Mobile Phase A consisted of 1.1% (w/v) of 1-pentane-sulfonic acid (Specrum, Inc.) at 
87 
 
pH 3.0. Mobile Phase B consisted of 0.1 M lithium acetate (Sigma-Aldrich, Inc.) in a solvent 
mixture of methanol (Avantor Performance Materials, Inc.), acetonitrile (Honeywell, Inc.) and 
isopropanol (Mallinckrodt Baker,Inc.) at the ratio of 80/10/10 (v/v/v) at pH 6.5. Each sample was 
run on a single column (ESA Meta-250, 5 μm ODS, 250 x 4.6 mm ID) under a 68-minute gradient 
elution that ranged from 0% to 100% Mobile Phase B and delivered at a fixed flow rate of 0.6 
ml/min. The retention time and area of the peaks in tissue homogenates were measured and 
compared to an external calibrating standard solution containing TYR, TRP, DA, DOPAC, HVA, 
NE, EPI, 5-HT, and 5-HIAA (Sigma, St. Louis, MO, USA). Concentrations of these substances in 
the samples were calculated and expressed as ng/mg protein. Turnover ratios 












4.4 STATISTICAL ANALYSIS 
 
Results are presented as means ± standard error of the mean (SEM). Statistical analysis was 
conducted in several stages.  An omnibus 3-way ANOVA was performed for each brain region 
with Model, Time, and Agonist as independent variables to investigate their main effects and 
interactions on NT endpoints. A 2-way ANOVA was conducted to explore the main effects and 
interactions between Model and Time in hormonal analysis.  Specific effects of agonist treatments 
for a given Model and Time Point were further explored by 1-way ANOVA. Differences between 
groups were analyzed by Tukey’s test and also by Dunnett’s test comparing agonist treatments 
with corresponding controls. To efficiently present the data, Cohen’s d index was calculated and 
plotted to demonstrate the effect size of agonist treatments on NT in each of the brain region. 
Concentrations below limit of detection was marked as ND (not detectable) and value of limit of 








4.5.1 Serum levels of hormones 
Levels of E2, T, and AD in each of the treatment groups are summarized in Table 8-9. 3-way 
ANOVAs revealed a significant overall effect for E2 (F[19,72]=8.0, p<0.0001), T F[19,68]=3.3, 
p<0.001), and AD F[19,70]=4.8, p<0.0001) levels. For E2 levels, significant main effects of Time 
(F[1,72]=8.1, p<0.01) and Agonist Treatment (F[4,72]=28.4, p<0.0001) were detected, as well as 
a significant Time x Agonist interaction (F[4,72]=5.7, p<0.001).  In OVX rats, levels of E2, as 
well as AD and T were undetectable or extremely low in rats treated with vehicle, PPT, DPN, or 
G-1 regardless of Time-Point.  As expected, levels of E2 were significantly higher in E2-treated 
rats compared with all other groups (p<0.05).  In addition, levels of E2 detected after 6 weeks of 
continuous treatment were significantly higher than levels detected after 1 week of treatment. In 
VCD-treated rats, levels of E2 were significantly higher in E2-treated rats than in all other groups. 
A 2-way ANOVA of Time and Agonist Treatment on E2 levels in VCD-treated rats revealed a 
significant main effect of Agonist (F[4, 37]=11.7, p<0.0001), a significant effect of Time (F[1, 
37]=5.2, p<0.05) and a significant Time x Agonist interaction (F[4,37]=3.0, p<0.05). Post-hoc 
analyses revealed that E2 levels were higher in E2-treated rats relative to non-E2-treated rats 
(irrespective of time-point), and that rats treated with E2 for 6 weeks had significantly higher E2 
levels than all other groups (p<0.05).    
For AD levels, significant main effects of Model (F[1,70]=45.4, p<0.0001), Time 
(F[1,70]=6.9, p<0.05), and Agonist Treatment (F[4,70]=3.5, p<0.05) were detected, as well as 
significant Model x Agonist (F[4,70]=3.1, p<0.05) and Model x Time (F[1,70]=6.0, p<0.05) 
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interactions.  Specifically, AD levels were much higher in VCD-treated than in OVX rats, were 
higher after 1 week than after 6 weeks of treatment, and were substantially lower in E2-treated rats 
than in all other groups when collapsed across Model and Time Point. Levels of AD in VCD-
treated rats were quite variable.  There was some indication that E2 treatment produced a decrease 
and DPN an increase in AD.  A 2-way ANOVA of Time and Agonist Treatment on AD levels in 
VCD-treated rats revealed a significant main effect of Agonist (F[4, 35]=3.4, p<0.05), main effect 
of Time (F[1, 35]=6.4, p<0.05) but no Time x Agonist interaction (F[4,35]=0.7, p=0.60).  Post-
hoc analysis revealed that AD levels in DPN-treated rats were significantly higher than in E2-
treated rats (irrespective of time-point), although neither group differed significantly from controls. 
This is likely due to high variability, and to the fact that AD levels in the controls were much lower 
at 6 weeks than at 1 week. 1-way ANOVA of AD levels in VCD-1W rats show that AD levels 
were significantly lower in E2-treated rats than in controls or DPN-treated rats. 1-way ANOVA of 
VCD levels in VCD-6W rats shows that AD levels were significantly higher in DPN-treated rats 
than in E2-treated rats or controls. 
For T levels, a significant main effect of Model (F[1,68]=34.1, p<0.0001) was detected as well 
as a significant main effect of Agonist (F[4,68]=2.7, p<0.05) interaction. Like AD, levels of T 
were significantly higher in VCD-treated than in OVX rats. Among the VCD-treated rats, levels 
also were significantly higher in DPN-treated than in E2-treated rats when collapsed across Time.  
Like AD, levels of T in VCD-treated rats were quite variable. A 2-way ANOVA of Time and 
Agonist Treatment on T levels in VCD-treated rats produced a nearly significant effect of Agonist 
(F[4,33]=2.5, p=0.06), no significant effect of Time (F[1,33]=0.4, p=0.54), and no Time x Agonist 
interaction (F[4,33]=1.3, p=0.3). 1-way ANOVA of T levels in VCD-6W rats showed that T levels 
were significantly higher in DPN-treated rats than in controls by Dunnett test. No other significant 
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differences in T-levels were detected, again likely due to the very high variance in these values in 
the VCD-treated rats. 
4.5.2 Effects of ER agonists on monoamine, monoamine metabolite and monoamine 
precursor levels in OVX-and VCD-treated rats 
 
Detailed analysis consistently revealed significant effects of E2 as well as ER subtype-selective 
agonists on endpoints associated with noradrenergic, dopaminergic and serotoninergic pathways, 
in both VCD- and OVX-treated rats (refer to Table 10-15). Effects were model- and region-specific 





3-way ANOVAs detected significant overall effects on 5-HT (F[19,74]=6.0, p<0.0001), 5-
HIAA (F[19,74]=12.1, p<0.0001), the ratio of 5-HIAA/5-HT (F[19,74]=8.1, p<0.0001), and the 
amino acid TRP (F[19,74]=61.5, p<0.0001). Main effects of Model (F[1,74]=6.8, p<0.05) and 
Agonist (F[1,74]=4.8, p<0.005) were detected for the ratio of 5-HIAA/5-HT. Specifically, the ratio 
was higher in OVX than in VCD-treated rats when collapsed across Agonist and Time, and was 
greater in controls than in E2, DPN, or G-1 treated rats when collapsed across Model and Time.  
A main effect of Time was detected for the ratio of 5-HIAA/5-HT (F[1,74]=73.9, p<0.0001), as 
well as for 5-HT (F[1,74]=89.8, p<0.0001), 5-HIAA (F[1,74]=207.1, p<0.0001), and TRP 
(F[1,74]=1144.8, p<0.0001). Specifically, the levels of 5-HT, 5-HIAA, and TRP were significantly 
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lower, and the ratio of 5-HIAA/5-HT was significantly greater, at 1 week than at 6 weeks when 
collapsed across Model and Agonist Treatment.  A Model x Agonist interaction was detected for 
the ratio of 5-HIAA/5-HT (F[4,74]=3.0, p<0.05) and for TRP (F[1,74]=3.4, p<0.05). Post-hoc 
analysis showed that the ratio of 5-HIAA/5-HT in OVX controls was significantly higher than in 
all E2, DPN, and G-1-treated rats and in VCD-treated rats treated with PPT, when collapsed across 
Time. Similar analysis showed that levels of TRP were significantly higher in OVX controls than 
in OVX rats treated with E or PPT, when collapsed across Time.  A Model x Time interaction was 
detected for the ratio of 5-HIAA/5-HT (F[1,74]=7.1, p<0.001).  Post-hoc analysis showed that the 
ratio of 5-HIAA/5-HT was significantly greater in OVX-1W rats than in all other groups when 
collapsed across Agonist Treatment, followed by VCD-1W rats, and then by both OVX-6W and 
VCD-6W rats. An interaction between Time x Agonist (F[4,74]=4.2, p<0.005) as well as a full 3-
way interaction (F[4,74]=4.1, p<0.005)  was detected for the ratio of 5-HIAA/5-HT. Post-hoc 
analyses showed that the ratio of 5-HIAA/5-HT was greatest in 1W controls compared to all other 
groups when collapsed across Model.  This was followed by PPT-1W and G-1-1W, both of which 
differed significantly from E2-6W, PPT-6W, and G-1-6W when collapsed across Model.   
1-way ANOVAs on serotoninergic endpoints in the HPC of OVX rats produced significant 
overall effects on 5-HIAA, TRP, and the ratio of 5-HIAA/5-HT at 1 week. Post-hoc analyses 
showed that levels of 5-HIAA were significantly lower in G-1-treated rats than in controls.  Levels 
of TRP were significantly lower in E2-, PPT-, DPN-, and G-1-treated rats than in controls, and the 
ratios of 5-HIAA/5-HT were significantly lower in E2-, DPN-, and G-1-treated rats than in 
controls. No significant effects on levels of 5-HT, 5-HIAA, TRP, or the ratio of 5-HIAA/5-HT 
were detected in OVX rats after 6 weeks of treatment. 
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1-way ANOVAs on serotoninergic endpoints in the HPC of VCD-treated rats showed no 
significant overall effects after 1 week of agonist treatment.  After 6 weeks of treatment a strong 
trend was observed for the ratio of 5-HIAA/5-HT (F[4,19]=, p=0.06). Slight reductions in E2- and 
G-1-treated rats relative to controls were detected using Dunnett’s test.   
 
Dopaminergic Pathway: 
3-way ANOVAs detected significant overall effects on DA (F[19,74]=40.4, p<0.0001) and 
TYR (F[19,74]=50.0, p<0.0001).  Levels of DOPAC and HVA were below the limit of detection 
in the HPC.  Significant main effects of Model, Agonist Treatment, and Time Point were detected 
for both DA and TYR (DA: Model F[1,74]=12.5, p<0.001; Agonist F[4,74]=2.7, p<0.05; Time 
F[1,74]=689.7, p<0.0001; TYR: Model F[1,74]=6.8, p<0.02; Agonist F[4,74]=9.1, p<0.0001; 
Time F[1,74]=909.9, p<0.0001). Significant interactions also were detected. For DA these 
included interactions of Model x Time (F[1,74]=12.6, p<0.001), and Agonist Treatment x Time 
F[4,74]=3.4, p<0.02).  Post-hoc analyses revealed that levels of DA were significantly higher in 
VCD-treated than in OVX rats when collapsed across Agonist and Time, that levels were 
significantly higher at 1W than at 6W when collapsed across Model and Agonist, and  that levels 
of DA were significantly lower in OVX-PPT-treated rats than in VCD-E2, VCD-PPT, VCD-DPN, 
VCD-G-1 or OVX-DPN-treated rats, when collapsed across time.  Analysis also revealed that 
levels in 1W-DPN treated rats were higher than in 1W-controls, 1W-PPT, and 1W-G-1-treated 
rats, when collapsed across time.   
Interaction effects for levels of TYR included Model x Agonist Treatment (F[4,74]=3.5, 
p<0.02) and a 3-way interaction of Model x Agonist Treatment x Time (F[4,74]=3.3, p<0.02). 
Post-hoc analysis revealed that levels of TYR were significantly higher in OVX than in VCD-
94 
 
treated rats when collapsed across Agonist Treatment and Time, were much higher at 6 weeks than 
at 1 week when collapsed across Model and Agonist Treatment, and were significantly lower in 
all treatment groups compared with OVX-controls with the exception of OVX-DPN-treated rats, 
when collapsed across time. 
1-way ANOVAs on levels of DA and TYR in the HPC of OVX rats produced significant 
overall effects after both 1 week and 6 weeks of treatment.  Post-hoc analyses showed that levels 
of DA were significantly higher in DPN-treated rats than in controls and PPT-treated rats after 1 
week of treatment, and were significantly lower in E2-, PPT- and G-1-treated rats than in controls 
after 6 weeks of treatment.  In contrast, levels of TYR were significantly lower in all agonist-
treated rats relative to controls after 1 week of treatment and remained lower than controls in E2- 
and PPT-treated rats after 6 weeks of treatment.  
1-way ANOVAs on levels of DA and TYR in the HPC of VCD-treated rats showed no 
significant overall effects after 1 week of agonist treatment and no effect on DA levels after 6 
weeks of treatment.  An effect on TYR levels was detected after 6 weeks of treatment at which 
point levels in E2-treated rats were significantly lower than in controls.   
 
Noradrenergic Pathway: 
3-way ANOVA detected a significant overall effect on NE (F[19,74]=3.1, p<0.0005).  Levels 
of EPI were below the limit of detection in the HPC.  A significant main effects Time Point was 
detected (F[1,74]=21.7, p<0.0001) as well as a Model x Time interaction (F[1,74]=12.0, p<0.001).  
No significant main effects of Model or Agonist Treatment on NE levels were detected.  Post-hoc 
analyses showed that NE levels were significantly higher at 6 weeks than at 1 week when collapsed 
across Model and Agonist Treatment, and that NE levels in OVX-1W rats were significantly lower 
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than in VCD-1W rats, which in turn were significantly lower than in OVX-6W rats, when 
collapsed across Agonist Treatment. 
1-way ANOVAs on levels of NE in the HPC of OVX and VCD-treated rats revealed no 
significant effects of treatment when compared at each of the 2 time points.  
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Figure 15. Levels of TYR, TRP, NE, DA, 5HT,5-HIAA in HPC changed following E2 and 
ER agonists treatments at 1-W in OVX model. Bars indicate Mean ± SEM. *p<0.05, **p<0.01, 
***p<0.001, relative to control. 1-way ANOVA followed by Dunnett’s test. Data of NT levels that 





    
 
Figure 16. Levels of DA and TYR in HPC changed following E2 and ER agonists treatments 
at 6-W in OVX model. Bars indicate Mean ± SEM. *p<0.05, **p<0.01, relative to control. 1-way 







3-way ANOVAs detected significant overall effects on 5-HT (F[19,72]=3.8, p<0.0001), 5-
HIAA (F[19,72]=5.3, p<0.0001) and the amino acid TRP (F[19,72]=7.2, p<0.0001). Main effects 
of Model were detected for 5-HIAA (F[1,72]=13.1, p<0.001) and TRP (F[1,72]=8.6, p<0.01). 
Specifically, levels of both 5-HIAA and TRP was higher in OVX than in VCD-treated rats when 
collapsed across Agonist and Time.  A main effect of Time was detected for ratio of 5-HIAA/5-
HT (F[1,72]=16.6, p<0.0001) as well as 5-HT (F[1,72]=61.5, p<0.0001) , 5-HIAA (F[1,72]=69.3, 
p<0.0001), and TRP (F[1,72]=100.6, p<0.0001).  Specifically, ratio of 5-HIAA/5-HT as well as 
the levels of 5-HT, 5-HIAA, and TRP were significantly lower at 1 week than at 6 weeks when 
collapsed across Model and Agonist Treatment.  No interaction was detected for the endpoints in 
the serotoninergic pathway. 
1-way ANOVAs on serotoninergic endpoints in the FCX of OVX rats produced significant 
overall effects only on TRP at 1 week.  Post-hoc analyses showed that levels of TRP were 
significantly lower in E2-, PPT-, DPN-, and G-1-treated rats than in controls. No significant effects 
on levels of 5-HT, 5-HIAA, TRP, or the ratio of 5-HIAA/5-HT were detected in OVX rats after 6 
weeks of treatment. 
1-way ANOVAs on serotoninergic endpoints in the FCX of VCD-treated rats showed no 
significant overall effects after 1 week or 6 weeks of agonist treatment.   
 
Dopaminergic Pathway: 
3-way ANOVAs detected significant overall effects on DA (F[19,72]=13.3, p<0.0001) and 
TYR (F[19,72]=5.6, p<0.0001).  Levels of DOPAC and HVA were below the limit of detection in 
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the FCX.  Significant main effects of Model, Agonist Treatment, and Time Point were detected 
for TYR (Model F[1,72]=11.5, p<0.01; Agonist F[4,72]=3.3, p<0.05; Time F[1,72]=62.3, 
p<0.0001) while significant main effect of Time Point was detected for DA (F[1,72]=210.1, 
p<0.0001).  Significant interactions were detected for DA, which included interactions of Model 
x Agonist Treatment (F[4,72]=2.6, p<0.05), Agonist Treatment x Time (F[4,72]=2.8, p<0.05) as 
well as a full 3-way interaction (F[4,72]=2.5, p<0.05).   
Post-hoc analysis revealed that levels of TYR were significantly higher in OVX than in VCD-
treated rats when collapsed across Agonist Treatment and Time; levels of TYR were much higher 
at 6 weeks than at 1 week while levels of DA were much higher at 1 week than at 6 weeks when 
collapsed across Model and Agonist Treatment. 
1-way ANOVAs on levels of DA and TYR in the FCX of OVX rats produced significant 
overall effects after 1 week of treatment.  Post-hoc analyses showed that levels of DA were 
significantly higher in all agonist-treated rats relative to controls after 1 week of treatment.  In 
contrast, levels of TYR were significantly lower in all agonist-treated rats relative to controls after 
1 week of treatment.  
1-way ANOVAs on levels of DA and TYR in the FCX of VCD-treated rats showed no 
significant overall effects after 1 week or 6 weeks of agonist treatment. 
 
Noradrenergic Pathway: 
No significant effect on NE was detected through 3-way ANOVA or 1-way ANOVA. Levels 









Figure 17. Levels of DA, TYR and TRP in FCX changed following E2 and ER agonists 
treatments at 1-W in OVX model. Bars indicate Mean ± SEM. *p<0.05, **p<0.01, relative to 
control. 1-way ANOVA followed by Dunnett’s test. Data of NT levels that remained unchanged 









3-way ANOVAs detected significant overall effects on 5-HT (F[19,72]=9.4, p<0.0001), 5-
HIAA (F[19,72]=3.5, p<0.0001) and ratio of 5-HT/5-HIAA (F[19,72]=6.7, p<0.0001) . Main 
effects of Time Point were detected for 5-HT (F[1,72]=9.4, p<0.0001), 5-HIAA (F[1,72]=36.4, 
p<0.0001) , ratio of 5-HT/5-HIAA (F[1,72]=106.3, p<0.0001) and TRP (F[1,72]=20.8, p<0.0001). 
Specifically, ratio of 5-HIAA/5-HT was significantly lower at 6 weeks than at 1 week while the 
levels of 5-HT, 5-HIAA, and TRP were significantly higher at 6 weeks than at a week when 
collapsed across Model and Agonist Treatment.  The only interaction detected in the serotoninergic 
pathway was a full 3-way interaction for 5-HIAA (F[4,72] =3.7,p<0.01). 
    1-way ANOVAs on serotoninergic endpoints in the STR of OVX rats produced significant 
overall effects only on 5-HT and 5-HIAA at 1 week.  Post-hoc analyses showed that level of 
5-HT was significantly higher in E2-treated rats than in controls while level of 5-HIAA was 
significantly higher in DPN-treated rats than in controls. No significant effects on levels of 5-HT, 
5-HIAA, TRP, or the ratio of 5-HIAA/5-HT were detected in OVX rats after 6 weeks of treatment. 
1-way ANOVAs on serotoninergic endpoints in the STR of VCD-treated rats showed 
significant higher level of 5-HIAA in PPT-treated rats in relative to controls after 6 weeks of 
agonist treatment.   
 
Dopaminergic Pathway: 
3-way ANOVAs detected significant overall effects on DA (F[19,72]=11.8, p<0.0001) , HVA 
(F[19,72]=8.7, p<0.0001) and ratio of DOPAC/DA (F[19,72]=8.1, p<0.0001). Main effects of 
Time Point were detected for all of the endpoints in the dopaminergic pathway: DA 
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(F[1,72]=199.1, p<0.0001), DOPAC (F[1,72]=13.7, p<0.0001) , HVA (F[1,72]=115, p<0.0001) 
ratio of DOPAC/DA (F[1,72]=128.1, p<0.0001) and TYR (F[1,72]=4.1, p<0.05). Specifically, 
ratio of DOPAC/DA and level of DOPAC was significantly lower at 6 weeks than at 1 week while 
the levels of DA, HVA, and TYR were significantly higher at 6 weeks than at a week when 
collapsed across Model and Agonist Treatment. Interaction of Time x Agonist Treatment (F[4,72] 
=2.7,p<0.05) was detected for DA and interaction of Model x Time(F[1,72]=9,9,p<0.01), Model 
x Agonist Treatment (F[4,72]=3.3,p<0.05) and Time x Agonist Treatment (F[4,72]=3.5,p<0.05) 
were detected for HVA. 
       1-way ANOVAs on levels of DA and HVA in the STR of OVX rats produced significant 
overall effects after 1 week of treatment. Post-hoc analyses showed that level of DA was 
significantly higher in E2-treated rats relative to controls after 1 week of treatment.  Levels of 
HVA were significantly lower in E2-, PPT-, DPN-treated rats relative to controls after 6 weeks of 
treatment.  
1-way ANOVAs on levels of HVA in the STR of VCD-treated rats showed significant higher 
levels of HVA in all agonists-treated rats than controls only after 1 week of agonist treatment. 
 
Noradrenergic Pathway: 
3-way ANOVAs detected significant overall effects on NE (F[19,72]=1.9, p<0.05), EPI 
(F[19,72]=7.8, p<0.0001) and ratio of EPI/NE (F[19,72]=2.0, p<0.05) . Main effects of Time Point 
were also detected for NE (F[1,72]=19.6, p<0.0001), EPI (F[1,72]=137, p<0.0001) and  ratio of 
EPI/NE (F[1,72]=21.7, p<0.0001) . Specifically, levels of NE, EPI as well as ratio of EPI/NE was 
significantly higher at 6 weeks than at 1 week when collapsed across Model and Agonist 
Treatment.  No interaction detected in the noradrenergic pathway in STR. 
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1-way ANOVAs followed by post-hoc test in the STR of OVX rats revealed significant lower 
ratio of EPI/NE in PPT-treated rats relative to controls after 1 week of treatment while for the 
VCD-treated rats, higher level of EPI was detected in G-1-treated rats compared with controls after 
1 week of treatment. 
 
     
Figure 18. Levels of DA ,5-HT and 5-HIAA in STR changed following E2 and ER agonists 
treatments at 1-W in OVX model. Bars indicate Mean ± SEM. *p<0.05, **p<0.01, relative to 
control. 1-way ANOVA followed by Dunnett’s test. Data of NT levels that remained unchanged 








Figure 20. Levels of HVA and EPI in STR changed following E2 and ER agonists treatments 
at 1-W in VCD model. Bars indicate Mean ± SEM. *p<0.05, **p<0.01, relative to control. 1-way 
ANOVA followed by Dunnett’s test. Data of NT levels that remained unchanged were not shown. 
 
 
Figure 19. Levels of HVA in STR 
changed following E2 and ER 
agonists treatments at 6-W in 
OVX model. Bars indicate Mean ± 
SEM. *p<0.05, relative to control. 
1-way ANOVA followed by 
Dunnett’s test. Data of NT levels 



















Figure 21. Levels of 5-HIAA in STR changed following E2 and ER agonists treatments at 6-
W in VCD model. Bars indicate Mean ± SEM. *p<0.05, relative to control. 1-way ANOVA 















































































































































































































































































































































































































































































































































































































































































































































































































C E2 PPT DPN G-1
F test P value
HPC/N 5 4 4 4 4
5HT (ng/mg) F(4,16)=2.3 p>0.05 0.12 ± 0.03 0.34 ± 0.14 0.22 ± 0.08 0.45 ± 0.10
§
0.24 ± 0.05
5HIAA (ng/mg) F(4,16)=2.9 p=0.054 9.2 ± 0.73 7.6 ± 0.78 8.9 ± 0.81 9.2 ± 0.63 6.6 ± 0.35
§
DA (ng/mg) F(4,16)=3.5 p<0.05 6.8 ± 0.87 7.4 ± 0.98 6.0 ± 0.37 9.5 ± 0.49
†§
7.8 ± 0.26
NE (ng/mg) F(4,16)=6.7 p<0.01 3.2 ± 0.14 3.4 ± 0.28 3.7 ± 0.30 5.2 ± 0.34
#§§§
3.6 ± 0.42




85.5 ± 5.94 65.1 ± 8.15
*§§








5HIAA/5HT F(4,16)=4.5 p<0.05 91.4 ± 17.08 32.1 ± 7.72
*§






C E2 PPT DPN G-1
F test P value
HPC/N   5 4 5 5 5
5HT (ng/mg) F(4,19)=1.4 p>0.05 2.5 ± 0.87 1.3 ± 0.17 1.5 ± 0.31 1.2 ± 0.09 1.7 ± 0.22
5HIAA (ng/mg) F(4,19)=1.6 p>0.05 15.8 ± 1.42 13.1 ± 0.78 14.4 ± 0.55 13.1 ± 0.79 14.1 ± 0.44




2.3 ± 0.17 1.9 ± 0.14
*§
NE (ng/mg) F(4,19)=1.2 p>0.05 5.5 ± 0.51 5.8 ± 0.61 5.0 ± 0.21 5.2 ± 0.46 6.2 ± 0.41
TRP (ng/mg) F(4,19)=0.9 p>0.05 260.4 ± 10.13 239.2 ± 7.69 232.6 ± 3.00 240.2 ± 14.14 247.3 ± 16.05




557.0 ± 34.39 550.6 ± 22.31
























C E2 PPT DPN G-1
F test P value
FCX/N 5 4 4 4 4
5HT (ng/mg) F(4,16)=0.1 p>0.05 1.4 ± 0.30 1.6 ± 0.34 1.3 ± 0.34 1.3 ± 0.43 1.5 ± 0.35
5HIAA (ng/mg) F(4,16)=2.2 p>0.05 6.9 ± 0.48 6.5 ± 0.66 5.6 ± 0.43 5.8 ± 0.95 4.7 ± 0.30








NE (ng/mg) F(4,16)=0.6 p>0.05 5.1 ± 0.50 5.3 ± 0.34 4.3 ± 0.66 5.1 ± 0.68 4.8 ± 0.32
















5HIAA/5HT F(4,16)=0.6 p>0.05 5.8 ± 1.23 4.6 ± 0.83 5.1 ± 0.99 6.7 ± 2.8 3.7 ± 0.74
One-WAY ANOVA
OVX-6W
C E2 PPT DPN G-1
F test P value
FCX/N 5 4 5 5 5
5HT (ng/mg) F(4,19)=0.2 p>0.05 2.9 ± 0.18 3.2 ± 0.39 2.8 ± 0.27 2.8 ± 0.15 2.9 ± 0.40
5HIAA (ng/mg) F(4,19)=1.2 p>0.05 8.8 ± 0.48 8.8 ± 0.54 7.6 ± 0.53 8.2 ± 0.63 9.2 ± 0.62
DA (ng/mg) F(4,19)=0.6 p>0.05 2.7 ± 0.16 2.3 ± 0.51 2.4 ± 0.11 2.7 ± 0.19 2.4 ± 0.30
NE (ng/mg) F(4,19)=0.5 p>0.05 4.8 ± 0.17 4.8 ± 0.39 4.7 ± 0.41 4.8 ± 0.43 5.5 ± 0.86
TRP (ng/mg) F(4,19)=1.0 p>0.05 196.4 ± 14.28 174.3 ± 19.09 162.6 ± 19.48 176.1 ± 24.10 211.6 ± 18.23
TYR (ng/mg) F(4,19)=1.8 p>0.05 422.2 ± 32.29 335.3 ± 49.34 320.5 ± 66.91 378.2 ± 54.52 495.1 ± 51.04




















C E2 PPT DPN G-1
F test P value
STR/N 5 4 4 4 4
5HT (ng/mg) F(4,16)=2.9 p=0.055 1.5 ± 0.36 3.3 ± 0.7
§
2.4 ± 0.48 2.3 ± 0.47 1.2 ± 0.22
5HIAA (ng/mg) F(4,16)=3.0 p=0.052 13.6 ± 2.04 18.3 ± 4.14 19.3 ± 2.11 22.8 ± 1.18
§
13.5 ± 0.65
DA (ng/mg) F(4,16)=3.5 p<0.05 29.0 ± 6.98 57.3 ± 10.12
§
47.1 ± 5.71 46.9 ± 6.51 25.4 ± 5.24
@
DOPAC (ng/mg) F(4,16)=0.9 p>0.05 51.1 ± 13.85 72.3 ± 18.85 58 ± 9.75 60.3 ± 13.16 37.5 ± 3.91
HVA (ng/mg) F(4,16)=1.3 p>0.05 14.5 ± 2.54 15.9 ± 3.36 13.6 ± 1.69 13.6 ± 0.68 9.1 ± 1.19
NE (ng/mg) F(4,16)=0.7 p>0.05 3.7 ± 0.47 6.0 ± 2.47 6.1 ± 0.40 5.3 ± 0.99 4.7 ± 0.74
EPI (ng/mg) F(4,16)=2.2 p>0.05 23.7 ± 6.04 16.8 ± 4.25 6.8 ± 1.67 12.1 ± 3.44 16 ± 3.53
TRP (ng/mg) F(4,16)=0.5 p>0.05 121.3 ± 27.29 112.5 ± 26.19 107.4 ± 10.8 119.4 ± 22.45 84.1 ± 5.90
TYR (ng/mg) F(4,16)=0.5 p>0.05 254.3 ± 51.12 223.3 ± 54.33 231.4 ± 20.76 233.5 ± 34.54 178.3 ± 20.54
5HIAA/5HT F(4,16)=3.3 p<0.05 9.5 ± 0.72 5.6 ± 0.3 8.7 ± 1.17 10.9 ± 1.55 12 ± 2.28
@
DOPAC/DA F(4,16)=0.9 p>0.05 1.7 ± 0.23 1.2 ± 0.17 1.2 ± 0.13 1.3 ± 0.26 1.8 ± 0.5
HVA/DA F(4,16)=2.4 p=0.094 0.6 ± 0.08 0.3 ± 0.03 0.3 ± 0.06 0.3 ± 0.06 0.4 ± 0.13
EPI/NE F(4,16)=2.9 p=0.057 6.6 ± 1.62 3.8 ± 1.55 1.2 ± 0.29
§
2.6 ± 0.83 3.7 ± 0.92
One-WAY ANOVA
C E2 PPT DPN G-1
F test P value
STR/N 5 4 5 5 5
5HT (ng/mg) F(4,19)=0.5 p>0.05 7.4 ± 0.47 6.9 ± 1.24 7.1 ± 0.73 7.4 ± 0.44 8.2 ± 0.66
5HIAA (ng/mg) F(4,19)=0.3 p>0.05 23.3 ± 1.34 22.7 ± 2.52 21.2 ± 1.85 20.9 ± 1.9 22.2 ± 2.16
DA (ng/mg) F(4,19)=2.1 p>0.05 134.1 ± 8.89 106.6 ± 17.63 117.4 ± 9.85 134.6 ± 10.22 154.4 ± 15.71
DOPAC (ng/mg) F(4,19)=1.5 p>0.05 44.3 ± 2.64 35.6 ± 7.59 29.9 ± 3.16 35.5 ± 4.08 40.1 ± 5.36







NE (ng/mg) F(4,19)=0.8 p>0.05 7.7 ± 1.36 8.7 ± 1.15 6.6 ± 1.17 9.4 ± 0.52 7.9 ± 1.42
EPI (ng/mg) F(4,19)=1.0 p>0.05 50.6 ± 3.97 44.4 ± 8.88 37.3 ± 3.03 44.3 ± 6.06 51.6 ± 6.53
TRP (ng/mg) F(4,19)=0.3 p>0.05 179.0 ± 29.66 175.7 ± 47.15 136.4 ± 32.73 146.8 ± 18.68 162.5 ± 42.21
TYR (ng/mg) F(4,19)=0.3 p>0.05 278.4 ± 44.98 242.6 ± 74.03 212.2 ± 67.03 223.8 ± 28.96 284.3 ± 68.88
5HIAA/5HT F(4,19)=0.7 p>0.05 3.2 ± 0.14 3.6 ± 0.72 3.0 ± 0.28 2.8 ± 0.16 2.8 ± 0.41
DOPAC/DA F(4,19)=1.0 p>0.05 0.3 ± 0.01 0.4 ± 0.13 0.3 ± 0.03 0.3 ± 0.03 0.3 ± 0.03


























C E2 PPT DPN G-1
F test P value
HPC/N 5 5 5 5 5
5HT (ng/mg) F(4,20)=0.9 p>0.05 0.2 ± 0.03 0.4 ± 0.09 0.7 ± 0.20 0.7 ± 0.27 0.3 ± 0.12
5HIAA (ng/mg) F(4,20)=0.5 p>0.05 8.0 ± 0.56 8.5 ± 0.72 8.8 ± 0.76 8.9 ± 0.39 9.2 ± 0.52
DA (ng/mg) F(4,20)=1.1 p>0.05 8.5 ± 0.72 9.3 ± 0.61 9.5 ± 0.61 10.3 ± 1.22 8.3 ± 0.44
NE (ng/mg) F(4,20)=0.8 p>0.05 4.0 ± 0.19 5.1 ± 0.61 5.3 ± 0.80 4.9 ± 0.68 4.5 ± 0.38
TRP (ng/mg) F(4,20)=0.1 p>0.05 77.9 ± 7.52 84.2 ± 9.10 74.1 ± 4.52 78.2 ± 7.84 82.9 ± 6.97
TYR (ng/mg) F(4,20)=0.1 p>0.05 193.6 ± 30.55 175.6 ± 24.07 156.4 ± 8.99 165.2 ± 19.08 197.8 ± 17.15
5HIAA/5HT F(4,20)=0.9 p>0.05 39.2 ± 5.35 25.8 ± 6.18 17.0 ± 4.40 28.8 ± 13.39 39.4 ± 7.69
One-WAY ANOVA
VCD-6W
C E2 PPT DPN G-1
F test P value
HPC/N 5 5 4 5 5
5HT (ng/mg) F(4,19)=1.1 p>0.05 1.17 ± 0.33 1.7 ± 0.29 1.66 ± 0.13 1.29 ± 0.23 1.77 ± 0.23
5HIAA (ng/mg) F(4,19)=0.4 p>0.05 13.6 ± 0.79 12.6 ± 0.87 13.9 ± 1.30 13.3 ± 0.47 12.6 ± 1.2
DA (ng/mg) F(4,19)=1.8 p>0.05 1.9 ± 0.26 2.3 ± 0.28 2.1 ± 0.08 1.8 ± 0.14 2.5 ± 0.23
NE (ng/mg) F(4,19)=1.6 p>0.05 4.4 ± 0.58 5.8 ± 0.36 5.6 ± 0.32 4.8 ± 0.58 4.7 ± 0.46
TRP (ng/mg) F(4,19)=0.4 p>0.05 239.0 ± 14.31 249.1 ± 13.77 259.4 ± 21.59 240.6 ± 8.04 242.3 ± 7.38
TYR (ng/mg) F(4,19)=3.8 p<0.05 533.4 ± 19.67 452.6 ± 17.89
†
555.7 ± 33.27 510.3 ± 12.07 460.8 ± 28.74




















C E2 PPT DPN G-1
F test P value
FCX/N 4 5 5 5 5
5HT (ng/mg) F(4,19)=1.1 p>0.05 2.3 ± 0.59 1.8 ± 0.39 1.4 ± 0.34 1.6 ± 0.42 1.3 ± 0.27
5HIAA (ng/mg) F(4,19)=0.4 p>0.05 5.5 ± 0.39 4.8 ± 0.55 5.4 ± 0.56 5.2 ± 0.47 5.0 ± 0.41
DA (ng/mg) F(4,19)=0.2 p<0.01 8.7 ± 0.78 8.2 ± 1.02 9.0 ± 0.78 9.4 ± 1.40 8.2 ± 1.52
NE (ng/mg) F(4,19)=1.8 p>0.05 3.9 ± 0.17 5.8 ± 0.51 5.2 ± 0.43 5.2 ± 0.30 4.9 ± 0.73
TRP (ng/mg) F(4,19)=0.4 p>0.05 77.9 ± 11.05 82.8 ± 10.87 77.1 ± 6.66 80.8 ± 6.13 75.4 ± 7.37
TYR (ng/mg) F(4,19)=3.8 p<0.05 180.8 ± 28.13 163.7 ± 24.04 168.0 ± 13.79 174.3 ± 14.88 172.0 ± 12.52
5HIAA/5HT F(4,19)=2.7 p>0.05 2.7 ± 0.40 3.3 ± 0.74 5.4 ± 1.59 4.7 ± 1.49 4.4 ± 0.74
One-WAY ANOVA
VCD-6W
C E2 PPT DPN G-1
F test P value
FCX/N 5 5 4 5 4
5HT (ng/mg) F(4,18)=0.5 p>0.05 2.8 ± 0.22 2.4 ± 0.25 2.6 ± 0.47 3.1 ± 0.56 2.9 ± 0.48
5HIAA (ng/mg) F(4,18)=0.3 p>0.05 7.1 ± 0.79 7.7 ± 0.66 6.7 ± 0.50 7.6 ± 1.04 7.0 ± 0.75
DA (ng/mg) F(4,18)=0.7 p>0.05 2.5 ± 0.25 2.1 ± 0.31 1.9 ± 0.27 2.5 ± 0.34 2.2 ± 0.46
NE (ng/mg) F(4,18)=2.3 p=0.097 4.1 ± 0.44 4.0 ± 0.37 3.1 ± 0.46 5.1 ± 0.63 4.8 ± 0.43
TRP (ng/mg) F(4,18)=1.1 p>0.05 157.9 ± 23.14 131.6 ± 20.79 115.5 ± 17.11 166.7 ± 38.87 186.1 ± 12.90
TYR (ng/mg) F(4,18)=1.3 p>0.05 334.7 ± 66.46 241.6 ± 44.29 234.5 ± 33.53 354.8 ± 70.73 369.8 ± 35.96












      
VCD-1W
C E2 PPT DPN G-1
F test P value
STR/N 4 4 5 5 5
5HT (ng/mg) F(4,18)=0.8 p>0.05 2.7 ± 0.47 4.3 ± 2.84 2 ± 0.35 1.9 ± 0.46 1.8 ± 0.39
5HIAA (ng/mg) F(4,18)=0.4 p>0.05 16.9 ± 1.98 17 ± 4.01 15.3 ± 1.15 15.1 ± 0.91 14.1 ± 0.77
DA (ng/mg) F(4,18)=0.2 p>0.05 38.1 ± 9.76 50.5 ± 17.05 40.3 ± 8.3 42 ± 8.8 42.4 ± 11.72
DOPAC (ng/mg) F(4,18)=0.9 p>0.05 37.6 ± 6.1 42.1 ± 5.67 44.9 ± 3.42 56.5 ± 12.05 51.9 ± 8.12








NE (ng/mg) F(4,18)=0.7 p>0.05 7.3 ± 1.68 4.5 ± 1.28 5.2 ± 1.08 5.0 ± 0.62 5.2 ± 1.47
EPI (ng/mg) F(4,18)=3.2 p<0.05 6.9 ± 0.67 10.4 ± 4.75 10.4 ± 1.92 13.7 ± 3.03 19.7 ± 2.02
*§
TRP (ng/mg) F(4,18)=0.8 p>0.05 113.3 ± 18.6 116.6 ± 34.73 89.8 ± 7.97 97.5 ± 9.95 82.1 ± 7.06
TYR (ng/mg) F(4,18)=0.1 p>0.05 180.8 ± 41.04 207.6 ± 57 184.1 ± 12.54 192.3 ± 21.82 177.9 ± 14.94
5HIAA/5HT F(4,18)=0.3 p>0.05 7.3 ± 2.22 8.5 ± 2.92 8.4 ± 1.15 10.3 ± 2.57 9.3 ± 1.63
DOPAC/DA F(4,18)=0.3 p>0.05 1.1 ± 0.12 1.3 ± 0.45 1.3 ± 0.26 1.5 ± 0.29 1.5 ± 0.3
HVA/DA F(4,18)=0.6 p>0.05 0.2 ± 0.04 0.3 ± 0.11 0.3 ± 0.06 0.3 ± 0.07 0.4 ± 0.08
EPI/NE F(4,18)=1.2 p>0.05 1.1 ± 0.19 4.4 ± 3.27 2.4 ± 0.71 2.7 ± 0.37 5.5 ± 1.79
One-WAY ANOVA
VCD-6W
C E2 PPT DPN G-1
F test P value
STR/N 5 5 4 5 5
5HT (ng/mg) F(4,19)=1.0 p>0.05 7.2 ± 0.95 6.5 ± 0.6 7.3 ± 0.78 8.5 ± 1.16 6.1 ± 1.02
5HIAA (ng/mg) F(4,19)=2.4 p=0.083 19.1 ± 1.84 21.4 ± 1.39 26.2 ± 2.41
§
22.5 ± 1.42 19.8 ± 1.66
DA (ng/mg) F(4,19)=0.5 p>0.05 132.8 ± 17.93 111 ± 25.06 115.4 ± 16.88 106.2 ± 8.05 129.1 ± 13.93
DOPAC (ng/mg) F(4,19)=0.8 p>0.05 34.4 ± 3.91 33.4 ± 5.79 43.3 ± 7.42 35.9 ± 6.04 44.7 ± 5.98
HVA (ng/mg) F(4,19)=0.4 p>0.05 22.9 ± 2.94 20.8 ± 1.1 21.9 ± 2.84 24.9 ± 3.25 24.7 ± 2.81
NE (ng/mg) F(4,19)=1.4 p>0.05 6.3 ± 1.16 8.4 ± 0.97 6.7 ± 1.63 8.8 ± 1.14 5.9 ± 0.62
EPI (ng/mg) F(4,19)=0.3 p>0.05 42.8 ± 8.02 45.4 ± 8.6 55.8 ± 9.79 54.7 ± 12.87 49.2 ± 9.01
TRP (ng/mg) F(4,19)=1.2 p>0.05 175.5 ± 36 109.8 ± 13.77 210.1 ± 48.00 152.8 ± 6.23 167.5 ± 42.83
TYR (ng/mg) F(4,19)=1.4 p>0.05 261.9 ± 49.73 160.4 ± 33.93 340.5 ± 85.32 227.4 ± 17.3 267.0 ± 69.43
5HIAA/5HT F(4,19)=0.8 p>0.05 2.7 ± 0.3 3.5 ± 0.54 3.8 ± 0.66 2.8 ± 0.36 3.6 ± 0.64
DOPAC/DA F(4,19)=0.4 p>0.05 0.3 ± 0.06 0.3 ± 0.04 0.4 ± 0.08 0.3 ± 0.08 0.4 ± 0.05
HVA/DA F(4,19)=0.4 p>0.05 0.2 ± 0.03 0.3 ± 0.09 0.2 ± 0.03 0.2 ± 0.05 0.2 ± 0.03
EPI/NE F(4,19)=0.6 p>0.05 7.9 ± 2.03 5.5 ± 0.90 11.3 ± 5.14 7.5 ± 2.61 9.1 ± 2.59
One-WAY ANOVA
Values are mean ± sem.  
Symbol Alpha Test
§ p<0.05 Dunnetts Differs from Controls
§§ p<0.01 Dunnetts Differs from Controls
§§§ p<0.001 Dunnetts Differs from Controls
* p<0.05 Tukey Differs from Controls
** p<0.01 Tukey Differs from Controls
† p<0.05 Tukey Differs from PPT
# p<0.05 Tukey Differs from all other groups
## p<0.01 Tukey Differs from all other groups





Figure 22. Main effects of Model and Time on monoamines, metabolites, amino acids and 
metabolite/monoamine ratios in (A) HPC and (B) FCX. Bars indicate Cohen’s d value. p value 







Figure 23. Main effects of Model and Time on monoamines, metabolites, amino acids and 










Figure 24. Main effects of Agonist on monoamines, metabolites, amino acids and 
metabolite/monoamine ratios in (A) HPC and (B) FCX. Bars indicate Cohen’s d: value. p value 






Figure 25. Main effects of Agonist on monoamines, metabolites, amino acids and 









4.6.1 Serum hormone measurements 
The goal of current study was to characterize changes in relevant neurochemical endpoints in 
the brain associated with surgical and transitional menopause, in response to chronic treatments of 
estradiol and selective ER agonists. Circulating levels of E2, T and AD confirm that representation 
of the two menopausal models was successfully achieved. AD and T were readily detectable in 
most rats receiving VCD treatments. This is in agreement with prior studies [81, 158] and is due 
to the preservation of androgen-producing ovarian tissues. In contrast, levels of T, AD, and E2 
were all below detectability in OVX controls.  
Results show that 6 weeks of DPN treatments led to significant elevations in T and a strong 
trend for elevation of AD in VCD-treated rats. The exact mechanism of this is currently unknown. 
ERβ is expressed by both thecal and granulosa cells [163]. It may be that activation of ERβ by 
DPN stimulates thecal cells to increase biosynthesis of androgens, or alternatively inhibits the 
transformation of androgens to estrogens in the granulosa cells via an effect on aromatase. This 
needs to be investigated. As expected, rats receiving E2 demonstrated significantly higher plasma 
E2 levels relative to other groups. It is interesting that continuous administration of E2 at a dose 
of 3 μg/day resulted in physiological levels after 1 week of treatment and supra-physiological 
levels after 6 weeks of treatment. This indicates that long-term chronic treatment with even modest 
doses of E2 can exceed the capacity for clearance and result in accumulation beyond the 
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physiological range. This highlights the importance of verifying plasma hormone levels in any 
studies involving chronic E2 treatments.  In this study we were concerned primarily with effects 
in the brain. The relationship between serum and brain levels of E2 in OVX rats treated with 
different doses of estradiol was recently characterized by our laboratory [164]. Results of this study 
showed that levels in the brain increase in accordance with levels in the serum when serum levels 
are in the physiological range, but that levels in several brain regions plateau when serum levels 
are well beyond the physiological range. This suggests that even at supra-physiological levels in 
serum, brain levels of E2 can remain within physiological limits.   
 
4.6.2 Main effects of Model, Time-Point and Agonist Treatment 
The current data demonstrate significant effects of Model and Time-Point on multiple 
measures of serotoninergic, dopaminergic and noradrenergic endpoints. These effects were region 
specific. For example, main effects of Model were detected in the HPC and FCX, but not in the 
STR. In the HPC levels of TYR were higher and levels of DA were lower in OVX vs VCD-treated 
rats. In the FCX levels of 5-HIAA, TRP and TYR were higher in OVX vs VCD-treated rats. These 
effects, while statistically significant, were relatively small. Indeed, many of the effects of ‘Model’ 
were not detected in our previous study which used fewer rats and had less statistical power [158]. 
Several effects were more striking, however, when separated by Time-Point. For example, the 
ratio of 5-HIAA/5-HT in the HPC was much higher in OVX vs VCD-treated rats at 1W, but not 
at 6W. This could indicate a strong effect of OVX on 5-HT turnover in this region at early time-
points.  In contrast, levels of DA in the HPC were much lower in OVX vs. VCD-treated rats at 
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1W, but not at 6W. This corresponds with significantly reduced levels of TYR in the HPC at the 
1W time-point, and may indicate a significant reduction in DA activity in this region at early time-
points following OVX. In the FCX, levels of 5-HIAA, TRP and TYR all were significantly higher 
in OVX vs. VCD-treated rats at 6W, but not at 1W. This may indicate significant compensatory 
responses resulting in superior normalization of amino acid levels and 5-HT turnover over time in 
the FCX following OVX than occur following VCD-induced loss of ovarian function. Collectively 
these findings demonstrate significant differences in the effects of OVX vs. VCD models of 
menopause on NT endpoints, and that the effects vary depending on brain region and time.   
Main effects of ‘Time-Point’ (i.e., collapsed across model and agonist treatment) were much 
more robust than the main effects of ‘Model’ for all regions examined.  In many cases endpoints 
were greater after 6W vs. 1W of treatment. Effects on several endpoints were consistent across 
brain regions. For example, levels of 5-HT, 5-HIAA, TRP and the ratio of 5-HIAA/5-HT were 
higher in each brain region at 6W vs 1W. This suggests significant recovery of endpoints 
associated with serotonin production and signaling over a period of weeks following OVX or VCD 
treatment. This is consistent with our prior report showing significant increases in TRP, TYR, 5-
HIAA and the ratio of 5-HIAA/5-HT in the HPC at 6W vs 1W following OVX or VCD treatment. 
This also suggests that these effects reflect increases over time independent of ER agonist 
treatment. Effects of Time-Point on other endpoints differed across brain regions. In the HPC, 
levels of DA were lower, whereas levels of NE and TYR were higher, at 6W vs 1W.  In the FCX 
levels of DA were lower, levels of TYR were higher, and levels of NE were unaffected at 6W vs 
1W. In the STR levels of DA and NE were higher and levels of TYR were unaffected at 6W vs 
1W. These findings indicate time- and region-specific effects on dopaminergic and noradrenergic 
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endpoints. Notably these effects were not observed in our prior study which did not include agonist 
treatments. 
In addition to the main effects of Model and Time-Point, the data also show significant main 
effects of agonist treatment on multiple NT endpoints that differed by brain region.  For example, 
in the HPC, E2, PPT, DPN and G-1 each were associated with decreases in the ratio of 5-HIAA/5-
HT and in levels of TYR compared with untreated controls. This suggests that in the HPC these 
effects can be achieved by activation of any of the three ER subtypes.  In contrast DPN, an ERβ 
selective agonist, was associated with an increase in DA whereas PPT and G-1 had no effect.  In 
the FCX, E2 was associated with a decrease in TYR. PPT was associated with decreases in TRP 
and TYR, and DPN was associated with an increase in DA. This suggests that in the FCX 
activation of ER is associated with decreases in TRP and TYR whereas activation of ERß is 
associated with increases in DA. No significant main effects of agonist treatment were detected in 
the STR. Collectively, these data indicate that estrogens can influence NT endpoints following loss 
of ovarian function, that endpoints are differentially affected by activation of specific ER subtypes, 
and that these effects are brain region-dependent. 
   
4.6.3 Specific effects of Agonist Treatment as a Function of Model and Time-Point 
This study is the first to analyze levels of TRP and TYR following ER agonist treatments in 
the same tissues in which multiple monoaminergic endpoints also were measured. Results indicate 
that the effects of agonist treatments are model- and time-point-dependent. This is clear from the 
interaction effects detected in the 3-way ANOVAs, and from the data presented in Table 10-15. 
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One general observation is that the majority of ER agonist effects were detected in OVX rats as 
opposed to VCD-treated rats and were detected after 1W vs. 6W of agonist treatment. This 
suggests that these NT endpoints are particularly sensitive to ER agonist treatments beginning soon 
following the complete and sudden loss of ovarian function, and that differences between treated 
rats vs. controls decline over time. In addition, the majority of ER agonist effects were detected in 
the HPC, suggesting that this region of the brain is particularly sensitive to ER agonist treatments. 
For clarity, the discussion of specific effects is organized below by brain region.  
 
HPC 
One surprising result was the low levels of TRP and TYR detected in the hippocampus of OVX 
rats after 1W of agonist treatment. Previously we reported that levels of TRP and TYR are 
significantly reduced in the HPC 1W after OVX or VCD treatment and that levels recover by 6W 
[158].  We predicted that agonist treatment would help to restore the amino acid levels. In contrast, 
OVX rats treated for 1W with E2 had much lower levels of TRP and TYR than vehicle-treated 
controls. This was also the case for rats treated with PPT and G-1, and to a lesser extent with DPN, 
suggesting that activation of any of the three ERs suppresses the amino acid levels even further at 
this early time point.  Rats treated for 1W with E2 also had a significantly lower ratio of 5-HIAA/5-
HT than controls, suggesting a reduction in 5-HT turnover.  This also was the case for rats treated 
with DPN and G-1, but not PPT, suggesting that activation of ERß and GPR30 are sufficient to 
produce this effect. Rats treated for 1W with G1 resulted only in reductions in 5-HIAA, suggesting 
that activation of GPR30 is sufficient to reduce 5-HT metabolism. After 6 weeks of treatment the 
effects on TRP, 5-HIAA and on the ratio of 5-HIAA/5-HT were no longer evident.  The effects on 
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TYR were still evident but were reduced in magnitude, corresponding to the reduction in DA. This 
indicates that the effects mitigate with time, even with continued ER agonist treatment.   
Another interesting finding was that only activation of ERβ by DPN treatment at 1W increased 
levels of all three major neurotransmitters DA, 5-HT and NE simultaneously in HPC. Furthermore, 
DPN treatment reinstated the significant reduction in NE levels observed following ovariectomy 
in our previous study [158]. The differential effects between activation of ERα and ERβ on levels 
of DA, 5-HT and NE may possibly due to their relative expression in HPC after estrogen 
deprivation. This, however, would not account for the reductions in TRP and TYR observed in the 
HPC. Note that none of these effects of agonist treatment were observed in VCD-treated rats 
despite the fact that levels of TRP and TYR also are significantly reduced at 1W and recover by 
6W following treatment with VCD [158]. This demonstrates that the HPC of VCD-treated rats is 
much less responsive to ER agonist treatment with respect to these endpoints than the HPC of 
OVX rats. This suggests a fundamental difference in the responsiveness of the HPC to estrogen 
therapy following transitional vs surgical menopause. 
 
FCX 
Agonist treatments produced fewer effects on neurochemical endpoints in FCX relative to 
HPC. As in the HPC, OVX rats treated for 1W with E2 had significantly lower levels of TRP and 
TYR than vehicle-treated controls.  This also was the case for rats treated with PPT, DPN, and G-
1.  This suggests that, as in the HPC, activation of either ERα, ERβ, or GPR30, is sufficient to 
suppress these amino acid levels during the first week after OVX. The reduced levels of TYR may 
be due to its increased utilization to synthesize DA in the dopaminergic pathway, which may be 
caused by increased tryptophan hydrolase expression or activity following estrogen receptor 
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activation.  Effects were no longer observed after 6 weeks of treatment, demonstrating that, as in 
the HPC, the effects mitigate with time even with continued treatment.  Despite the reduced levels 
of TYR, no effect on NE levels were detected suggesting no adverse effect on NE signaling.  
Likewise, despite the reductions in TRP, no significant effects on 5-HT, 5-HIAA or the ratio of 5-
HIAA/5-HT were detected, suggesting no significant adverse effects on 5-HT signaling.  Elevated 
levels of DA were detected in OVX rats treated for 1W with E2, PPT, DPN, and G-1, suggesting 
either an increase in DA production or a reduction in DA release and degradation at this time point.  
As in the HPC, the effects of agonist treatments detected at 1W in OVX rats were not detected in 
VCD-treated rats, suggesting a fundamental difference in the responsiveness of the FCX to 
estrogen therapy following transitional vs. surgical menopause.   
 
STR 
Effects of agonist treatments on NT endpoints in the striatum were different in several ways 
from effects detected in the HPC and FCX.  First, no effects of E2 or the other ER agonists on the 
levels of TRP or TYR were detected.  Following OVX, rats treated for 1 week with E2 had 
significantly higher levels of 5-HT and DA than vehicle-treated controls.  This was not observed 
in rats treated with any of the selective ER agonists. Since E2 will act at all three ERs this suggests 
that activation of two or more ER receptors is necessary to produce these effects. These results are 
consistent with either an increase in 5-HT and DA production, or with decreases in 5-HT and DA 
release and degradation in response to E2.  
Treatment with PPT was associated with a significant increase in 5-HIAA relative to vehicle-
treated controls, which would be consistent with an increase in 5-HT release. This effect was not 
observed at 6W despite continuous treatment. In contrast, OVX rats treated for 6W with E2 showed 
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a significant reduction in levels of HVA relative to vehicle-treated controls.  Similar effects were 
observed in rats treated with PPT or DPN but not G-1. This suggests that activation of ER or 
ERß, but not GPR30, is sufficient to elicit this effect and that the reductions in HVA manifest after 
longer-term continuous treatment. In contrast with the reductions in HVA detected in OVX rats 
after 6 weeks of treatment, significant increases in HVA were detected in VCD-treated rats after 
1W of treatment with E2, PPT, DPN, or G-1. This is consistent with an increase in DA turnover, 
but notably was not accompanied by any increases in DOPAC or the DOPAC/DA or HVA/DA 
ratios. An increase in the level of EPI also was detected after 1W treatment with G-1, but not with 
any other agonist.  This suggests that activation of GPR30 may have an effect on the NE pathway 
associated with increased NE turnover. The fact that a similar effect was not observed in rats 
treated with E2 suggests that this effect is unique to GPR30 activation and may be negated by 
activation of the other ERs. The effects on HVA and EPI levels in VCD-treated rats were not 
detected after 6W of treatment despite continuous treatment. These data again demonstrate a 
fundamental difference in the responsiveness to estrogen therapy following transitional vs. surgical 
menopause. 
In summary, in contrast with surgical menopause, the VCD model of transitional menopause 
was associated with far less responsiveness to ER agonists treatment as reflected by fewer effects 




4.6.4 Comparisons with existing literature 
To our knowledge, this report is the first to provide a comprehensive description of changes in 
NT endpoints for dopaminergic, serotonergic and noradrenergic pathways in two models of 
menopause and following E2 and selective ER agonist treatments. Most prior studies have focused 
on OVX rats and mice and on the effects of ER agonists on small numbers of NT endpoints. 
Several of our current findings are consistent with previous results. For example, previous studies 
found no change in NE and 5-HIAA levels in HPC following 4-6 weeks of chronic E2 treatment 
in OVX mice [66] and rats [71]. This is consistent with the lack of effect of E2 treatment on these 
NT endpoints in HPC detected in our study. Inagaki et.al [70] reported that a single s.c. injection 
of E2 in OVX rats significantly increased levels of DA but had no effect on NE, DOPAC or 5-
HIAA in STR. This is consistent with our results in OVX rats treated for 1W with E2. Lubbers et 
al. [72] reported that 4 days s.c. treatment with E2 but not PPT increased levels of 5-HIAA in the 
STR of OVX rats. This is consistent with our results suggesting that increased levels of 5-HIAA 
may be mediated by ERβ activation.  
Several inconsistencies with our current findings also have been reported. For example, 4-6 
weeks of chronic E2 treatment was reported to decrease levels of 5-HT, but not DA, in HPC of 
OVX mice [66] and rats [71].  In addition, it has been reported that E2 and PPT treatments 
increased NE levels [72] while E2 treatment reduced 5-HT levels in the FCX of OVX rats [71]. In 
another study, 4 days s.c. treatment of E2 was shown not to alter levels of DA and 5-HT in the 
STR of OVX rats [72]. Jacome et al. [73] reported no effects on monoaminergic endpoints in OVX 
rat STR 2 days after a single s.c. injection of DPN. Some of these differences with our current 
results likely are due to differences in dose, timing and duration of treatments. 
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Note that all of the above studies used OVX rats or mice when studying effects on NT 
endpoints. Pestana-Olivera et al. [75] recently evaluated the effects of estrogen therapy on 
serotonin in VCD-treated rats. They reported measurements of 5-HT, as well as mRNA levels of 
ERβ and progesterone receptor in several brain regions following continuous subcutaneous 
administration of E2. Specifically, 3W of E2 treatment significantly increased 5-HT levels in 
dorsal HPC of VCD-treated rats. This differs from our current finding in which no effect on 5-HT 
level in HPC was reported after 1W or 6W of E2 treatment in VCD-treated rats. Differences in E2 
treatment duration (3W vs 1W/6W), circulating E2 levels after E2 supplementation (~40 vs 
~70/210 pg/ml), specific brain region analyzed (dorsal HPC vs HPC), VCD dosing regimen (160 
mg/kg daily for 15 days vs 80 mg/kg daily for 30 days) could potentially account for the differences 
in results. This suggests that effects of chronic ER agonist treatment after transitional menopause 
may vary considerably as a function of dose and time of treatment, as well as how quickly ovarian 
function is lost.  This requires further study. 
 
4.6.5  Potential mechanism of model differences in responsiveness to ER agonist 
treatments 
One of the interesting findings was that OVX rats were much more responsive to ER agonist 
treatments than VCD-treated rats. The underlying mechanism remains largely unknown. One 
possibility could be due to the differences in terms of estrogen receptor expressions and functions 
following estrogen deprivation and treatments in the two menopausal models. It has been widely 
demonstrated that differential ER expressions could affect the sensitivity to steroid hormones and 
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consequently alter the effects of estrogens on the brain. In rodent brain, both up- and down-
regulation of ER mRNA and protein levels by E2 has been reported. The effects are often brain 
region- and age-specific and are not always consistent, in part due to various treatment regimens 
and physiological state of the animals. Previous studies have reported that treatment of the 
hypothalamic neurons with E2 caused a rapid and transient increase of the ERα proteins in the 
plasma membrane. Furthermore, exposure of the neurons to E2 was found to significantly increase 
internalization of ERα membrane proteins, which is considered as a measure of receptor activation 
[165].                                                                                                                                                                                                                                                                                                                                                                                                                             
For OVX surgical menopausal model, previous study has demonstrated that following long-
term OVX, the levels of ERα mRNA were significantly increased in the cerebral cortex but were 
not changed in the cerebellum and brainstem. It was also shown that ERα mRNA levels remained 
unchanged in all of the three brain regions following 12-week of E2 treatments [166]. Additionally, 
Scott et al. showed long-term estrogen deprivation caused tissue-specific reduction in ERα levels 
in the HPC, altering hippocampal sensitivity to E2, similar to the ERα reduction occurring 
naturally during the aging process [167]. Study has also shown that the expression of ERα and 
ERβ protein was differentially influenced by age and gonadal steroids in the mouse cerebral cortex. 
Specifically, it was shown that E2 supplementation increased ERα protein level in old OVX female 
mice and increased ERβ protein level in adult OVX female mice [168]. Additionally , OVX rats 
and mice receiving either an acute [169] or chronic [170] treatment of estradiol benzoate were 
found to have decreased levels of ERα mRNA in the hypothalamus. Since the VCD-induced 
transitional menopausal model is relatively new, studies on the effects of estrogens on ERs are 
quite limited. Previous study by Pestana-Oliveira et al.[75] demonstrated that the dorsal raphe 
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nucleus (DRN) of transitional menopausal rats exhibited lower expression of ERβ mRNA. In 
addition, they also showed that chronic E2 treatment restored the ERβ mRNA levels and number 
of serotonergic cells in the DRN caudal subregion and increased ERβ expression in HPC. 
Androgens could also affect ER expression in females. Specifically, ER expressions were 
found to be downregulated by circulating androgens such as T.  Previous study has shown that T 
treatment attenuates ERα mRNA expression in the hypothalamus[171]. Another study 
demonstrated that T supplementation decreased ERα protein level in old OVX female mice and 
decreased ERβ protein level in adult OVX female mice [168] in the cerebral cortex. 
One important but understudied area of research is that whether systemic circulating hormones 
or locally synthesized hormones in the brain play a more significant role affecting brain NT levels. 
One mechanism for controlling local estrogen synthesis is regulation of the aromatase enzyme, 
which is a member of the cytochrome P450 superfamily and is widely expressed in the brain. For 
example, E2 and estrone (E1, predominant circulating estrogen after menopause) can be 
synthesized from T and AD through aromatase while E2 and T can be synthesized from E1 and 
AD through 17β-Hydroxysteroid dehydrogenase (17β-HSD) in the brain. Therefore, the levels of 
steroid hormones in the brain are determined by both systemic and local production and are usually 
region-specific. Previously, our lab conducted a detailed analysis of brain region-specific E2 
concentrations in OVX, E2-, and T-treated rats and demonstrate the degree to which these 
concentrations are aromatase–dependent [164]. Similar studies in the future using VCD model 
could provide additional important information regarding how the two models would differ in 
terms of local hormonal synthesis.  
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In summary, both estrogens and androgens could affect ER expressions and functions in the 
brain. Two potential explanations to the model differences in responsiveness to ER agonist 
treatments are: 1) it is possible that 30 days of VCD treatment impaired ERs responsivity to agonist 
treatments; and 2) the residual androgens in VCD model may diminish agonist effects due to 
downregulation of ER expressions in specific brain region. Due to the massive degree of 
complexity of CNS, further investigations that simultaneously evaluate the ER expressions and 
steroid hormone synthesis enzymes (e.g. aromatase and 17β-HSD) in the same set of brain tissues 
are warranted. 
 
4.6.6 Cognitive significance of NT changes after ER agonist treatments 
Many of the effects on NT endpoints could have important implications for effects on cognitive 
performance. The HPC is critical to memory consolidation, which is adversely affected by 
Alzheimer’s disease as well as by normal aging. Studies show that gene expression in the HPC is 
significantly altered following OVX [172]. E2 as well as specific ER agonists have been shown to 
affect hippocampal structure and function in several important ways, including effects on spine 
density in CA1 [13], synaptic formation and plasticity [173], and activation of PI3K/AKT and 
ERK/MARK neuronal signaling pathways [174]. 
The FCX also plays an important role in learning and memory, in addition to effects of sensory 
stimuli on mood and emotion. Effects on mesocortical dopaminergic pathways have been 
associated with cognitive processes such as short-term memory, anxiety and impulsivity. Previous 
studies have shown that increasing DA levels in FCX reduces impulsivity in humans [175]. In our 
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current study, DA is the only monoamine affected in the FCX and upregulation of DA levels were 
reported following E2 and all of the ER agonists treatments. Although 5-HT levels remained 
unchanged, estrogens also have been shown to affect serotoninergic endpoints through other 
mechanisms. For example, in the FCX of OVX rats, estrogens can produce rapid receptor-
mediated decreases in 5-HT1A receptor function [176]. Chronic exposure to E2 also induces a 
significant increase in the density of 5-HT2A receptors [177]. Further study is required to provide 
a better understanding of the potential effects of estrogen replacement on cognitive and emotional 
functions in menopausal women. 
The STR is part of the extrapyramidal motor system. In addition to modulating motor control, 
it also plays a critical role in motor (i.e., procedural) learning and memory [178]. Studies in rats 
show that OVX rats have a predisposition for using a response (i.e., procedure) strategy when 
solving a spatial task whereas E2-treated rats preferentially use an allocentric strategy [179-181]. 
This is consistent with our data showing effects of E2 on 5-HT, DA and metabolites in the STR of 
OVX rats, and suggests that E2 treatment can significantly affect extrapyrmidal function.  
However, the finding that effects differed in VCD-treated rats and varied as a function of time and 
ER agonist indicate that the effects are complex and may not be readily observed in women who 
undergo transitional menopause. Further study is needed to better understand the potential effects 
of ER agonists on extrapyramidal function and motor learning in women.   
In the current study the HPC was more responsive to ER agonist treatments than other regions. 
In addition, OVX rats were much more responsive to ER agonist treatments than VCD-treated rats. 
Similar effects in humans would be consistent with observations that estrogen treatments have less 
of a positive effect in older women that have undergone transitional menopause than in younger 
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women that have experienced oophorectomy [76]. This may help account for the fewer benefits of 
estrogen replacement that have been reported in postmenopausal women [182].  
Age also is a factor, and previous research suggests a window of opportunity for realizing 
beneficial effects of estrogen on cognitive performance in women [160, 183]. Note that in such 
studies it is sometimes difficult to distinguish effects of age from effects of menopause. In female 
rodents aging results in reproductive senescence which is characterized by a loss of cyclicity and 
an extended period of estrus. The current study used young adult rats to avoid confounding factors 
associated with reproductive senescence. The fact that ER agonists had less effect in VCD-treated 
rats than in OVX rats suggests a fundamental difference between surgical vs. transitional 
menopause in the responsiveness to ER agonist treatment independent of age. This could 
contribute to the significant differences that have been reported in the effects of estrogen treatments 
on cognitive performance in older women that have experienced transitional menopause vs. 
younger women that experience rapid and sudden loss of ovarian function due to oophorectomy 
[143, 184]. 
Different estrogen receptors also may contribute to different effects on cognitive performance.  
Both ERα and ERβ have been implicated in mediating effects on different types of learning and 
memory [185], as well as on anxiety [186]. In our study, the ERβ agonist DPN simultaneously 
upregulated levels of all three major NTs (DA, 5-HT and NE) in HPC of OVX rats following 1W 
of treatment. Jacome et al. [73] previously reported that ERβ mediates effects of estrogens on 
recognition memory and that memory enhancements by DPN may occur through alterations in 
multiple monoaminergic systems primarily in HPC. Walf and Frye [35] showed that administration 
of an ERβ selective agonist to the HPC decreased anxiety and depressive behavior in OVX rats. If 
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true in humans, this would provide support for selectively targeting ERβ in estrogen therapy to 




















Collectively, our study is the first to directly and systematically compare the effects of ER 
agonists on NT pathways in the brain in these two models of menopause. The results of our analysis 
described significant changes in local levels of serotoninergic, dopaminergic, and noradrenergic 
endpoints in association with validated models of surgical and transitional menopause following 
E2 and selective agonist treatments. Notably, effects were brain-region specific and agonist-
dependent. The alternations in neurotransmitter levels following estrogen deprivation are likely 
relevant to changes in neural function and cognitive performance, which are partially reversed by 
either estrogen or selective agonists treatments. Furthermore, the transitional menopausal animals 
seem to be much less sensitive to ER agonist treatments than the OVX model with minimal effects 
on NT endpoints observed in striatum. This could contribute to the significant differences that have 
been reported in the effects of estrogen treatments on cognitive performance in older women that 
have experienced transitional menopause vs. younger women that experience rapid and sudden 
loss of ovarian function due to oophorectomy. Future studies that focus specifically on the anabolic 
and catabolic enzymes involved in monoamine regulation, regional expression and activity of 
monoamine transporters, ER receptors as well as relevant behavioral tests will further add to our 
understanding of the way that hormonal replacement and selective estrogen receptor activation 







5.0  CHAPTER 5: ESTRADIOL AND SELECTIVE ESTROGEN RECEPTOR AGONISTS 
DIFFERENTIALLY AFFECT BRAIN NONESSENTIAL AMINO ACIDS LEVELS IN 
TRANSITIONAL AND SURGICAL MENOPAUSAL RAT MODELS 
 
 
5.1  ABSTRACT 
 
Estrogens have many beneficial effects on the brain that extend beyond their role in the control 
of the reproductive function. Previously, we conducted a comprehensive analysis of the effects of 
estrogens and selective ER agonists on brain monoamines and metabolites between surgical and 
transitional menopause. Although amino acids TYR and TRP were included in previous 
investigation as neurotransmitter precursors, the information of ER agonist effects on brain amino 
acid levels following loss of ovarian function is still scanty. Using similar experimental design, 
the objective of current study was to further evaluate the effects of ER agonist treatments on 
additional amino acid endpoints in the brain. Endpoints included ALA, GLY, SER, ASP, GLU 
and GLN. Our results showed that most of the amino acids in the brain remained surprisingly 
stable and were not significantly affected by E2 and selective agonist treatments. However, limited 
but significant changes were detected in local levels of amino acids e.g. ASP and GLU following 
agonist treatments. These effects were region- and model- specific as well as time-and agonist-
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dependent. The reductions in excitatory amino acid levels following either E2 or selective agonist 
treatments are of great interest and may contribute in part to the balance of brain excitability and 
amino acid homeostasis. 
 























Amino acids are critically important for proper neurodevelopment. In addition to their basic 
role as protein building blocks, they also function as the precursors for a variety of 
neurotransmitters, nucleotides, sphingolipids, polyamines, or as the donors for nitric oxide. Some 
of them can also work as potent antioxidants, regulators of endocrine function, and signaling 
modulators [187, 188]. In addition, as amino acids (e.g. glutamate, aspartate, proline, GABA, 
glycine, serine,β-alanine, and taurine etc.) comprise the most abundant neurotransmitters in the 
CNS, a large body of work has been conducted to investigate the important roles that amino acids 
play in neurotransmission, especially for the amino acids that are excitatory (ASP and GLU) and 
inhibitory (gamma-aminobutyric acid (GABA) and glycine) [189][190]. 
GLU, for example, is the most abundant amino acid and also one of the major EAAs in the 
CNS. It is stored in synaptic vesicles and is released from presynaptic terminals by depolarization 
in a Ca2+ dependent manner. Once released into the synaptic cleft, GLU binds to specific 
postsynaptic neuronal receptors (e.g. N-methyl-n-aspartate (NMDA) receptor) and excite the 
postsynaptic neuron. NMDA activation requires the binding of two molecules of GLU or ASP as 
well as GLY as co-agonist [191]. Previous studies have shown that alterations in the concentration 
of GLY can dramatically alter NMDA-receptor-mediated responses [192-194]. After the receptor 
is activated, it directly leads to the opening of a group of ion channels that are typified by their 
different permeabilities to Na+, K+, and Ca2+. The receptor activation results in rapid glutamate-
mediated excitatory synaptic transmission in the CNS and are critically involved in long-term 
potentiation (LTP) and synaptic plasticity underlying learning and memory storage. [195, 196].   
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    A growing body of studies have suggested estrogens can affect EAA-induced neuronal 
activity, possibly due to activation of ERs [197, 198]. In Chapter 4, we compared the effects of E2 
and selective ER agonist treatments on monoaminergic endpoints in different regions of the adult 
rat brain, using two models of menopause. Results showed significant effects on serotoninergic, 
dopaminergic, and noradrenergic endpoints that were both model and brain region specific, and 
that varied by time following loss of ovarian function. Although we also included evaluation of 
TYR and TRP levels in our previous study, only two amino acids (aromatic amino acids) were 
investigated in this respect. Despite that comprehensive metabolomics study on effects of estrogen 
treatments on neurochemical endpoints, there is still a paucity of information regarding whether 
significant changes in other amino acid levels in the brain would be induced by similar estrogen 
treatment regimen. Therefore, in the current paper we used similar methods to investigate the 
effects of treating rats with selective ER agonists after undergoing either ovariectomy or VCD-
induced follicular atresia on brain amino acid levels, especially those which play important roles 
in neurotransmission. Like the previous study, we still chose to focus on three brain regions, 
hippocampus, frontal cortex and striatum, which are thought to be critically involved in the 
regulation of cognitive functions, motor functions and excitability. Results show that most of the 
amino acids in the brain remained stable and were not significantly altered following E2 and 
selective agonist treatments. A few but significant changes were detected in local levels of amino 
acids following agonist treatments. Notably, these effects were region- and model- specific as well 
as time-and agonist-dependent. This is the first study to directly and systematically compare the 
effects of ER agonists on multiple amino acid endpoints in the brain in these two clinically relevant 




5.3 MATERIALS AND METHODS 




5.4.1 Effects of ER agonists on amino acid levels in OVX-and VCD-treated rats 
Detailed analysis revealed significant effects of E2 as well as ER subtype-selective agonists 
on amino acid endpoints associated, in both VCD- and OVX-treated rats (refer to Figure 26, Table 
16-21). Effects were also model- and region-specific as well as time-dependent. Results show that 
most of the effects of agonist treatments resulted in reductions in levels of amino acids. However, 
most of the amino acids seem to be quite stable and remained unchanged following E2 and 
selective agonist treatments. The most significant change in amino acid levels were seen between 
two time-points, as demonstrated in the main effect of time point analysis (shown in Figure 27-
28). For clarity, results are organized by brain region. 
 
HPC 
3-way ANOVAs detected significant overall effects on each of the amino acids: ALA 
(F[19,69]=4.36, p<0.0001); GLY (F[19,69]=3.84, p<0.0001); SER (F[19,69]=3.26, p<0.0001); 
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ASP (F[19,69]=2.69, p<0.01); GLU (F[19,69]=7.04, p<0.0001) and GLN (F[19,69]=2.54, 
p<0.01). Also, a main effect of Time was detected for each of the amino acids: ALA 
(F[1,69]=71.71, p<0.0001); GLY (F[1,69]=60.66, p<0.0001); SER (F[1,69]=47.38, p<0.0001); 
ASP (F[1,69]=37.86, p<0.0001); GLU (F[1,69]=122.65, p<0.0001) as well as GLN 
(F[1,69]=30.05, p<0.0001). Specifically, the levels of each amino acid were significantly lower at 
1 week than at 6 weeks when collapsed across Model and Agonist Treatment. No main effect of 
Model or Agonist Treatment was detected. No significant interaction effects of Model x Time 
Point, Agonist Treatment x Time Point, Model x Agonist Treatment or Model x Time Point x 
Agonist Treatment were detected in the HPC. 
1-way ANOVAs on levels of amino acids in the HPC of OVX and VCD-treated rats revealed 
no significant effects of treatments when compared at the 1-week time point. Also, no significant 
effects of treatments were seen in OVX rats at 6 weeks. After 6 weeks of treatment in VCD-treated 
rats, a strong trend of reduction was observed for levels of GLY and SER in PPT-treated rats while 
trend of reduction for level of ASP was also detected in E2-treated rats. Furthermore, significant 
reduction in ASP level was detected following 6-week PPT treatment using Dunnett’s test (Figure 
26 A).   
 
FCX 
3-way ANOVAs detected significant overall effects on ALA (F[19,73]=2.6, p<0.01), SER 
(F[19,73]=3.1, p<0.001) , ASP (F[19,73]=2.2, p<0.01) and GLU (F[19,73]=5.5, p<0.0001).  Main 
effects of Model were detected for ALA (F [1,73] =10.6, p<0.01), GLY (F[1,73]=9.7, p<0.01), 
SER (F[1,73]=8.1, p<0.01) and  ASP (F[1,73]=6.3, p<0.05). Specifically, these amino acid levels 
were higher in OVX than in VCD-treated rats when collapsed across Agonist and Time.  Also, a 
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main effect of Time was detected for these amino acids except GLY: ALA (F[1,73]=11.9, 
p<0.001); SER (F[1,73]=20.3, p<0.0001); ASP (F[1,73]=14.4, p<0.001); GLU (F[1,73]=78.6, 
p<0.0001) as well as GLN (F[1,73]=14.8, p<0.001). Specifically, ALA, ASP, GLU and GLN were 
significantly lower at 1 week than at 6 weeks when collapsed across Model and Agonist Treatment. 
On the contrary, SER was significantly higher at 1 week than at 6 weeks. Main effect of Agonist 
Treatment was not detected in FCX. 
A few interactions were also detected in FCX. For example, interactions of Model x Time 
Point were detected on ALA (F [1,73] =7.1, p<0.01), ASP(F[1,73]=5.7, p<0.05) and GLU 
(F[1,73]=8.0, p<0.01). Interactions of Time Point x Agonist Treatment were detected on ALA 
(F[4,73]=2.9, p<0.05) and GLY (F[4,73]=2.7, p<0.05). Interaction of Model x Agonist Treatment 
was detected on SER (F[4,73]=3.6, p<0.01). In addition, interaction of Model x Time Point x 
Agonist Treatment was detected on SER (F[4,73]=2.9, p<0.05). 
1-way ANOVAs on levels of amino acids in the FCX of OVX and VCD-treated rats revealed 
no significant effects of treatments when compared at 6-week time point. In addition, no significant 
effects of treatments were seen in VCD-treated rats at 1 week.  Furthermore, 1-way ANOVAs on 
amino acids in the FCX of OVX rats produced significant overall effects only on SER at 1 week.  
Post-hoc analyses showed that levels of SER were significantly lower in G-1-treated rats than in 
controls by Dunnett’s test. Post-hoc Tukey’s test also suggested that SER level in G-1 treated rats 
were significantly lower than E2-treated rats as well as than controls (Figure 26 B). 
 
STR 
3-way ANOVAs detected significant overall effects on ALA (F[19,73]=3.7, p<0.0001), GLU 
(F[19,73]=36.5, p<0.0001) and GLN (F[19,73]=2.5, p<0.01). Main effects of Time Point were 
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detected for ALA (F[1,73]=26.3, p<0.0001), GLY (F[1,73]=11.2, p<0.01) and GLU 
(F[1,73]=650.3, p<0.0001). Specifically, ALA and GLY were significantly lower at 6 weeks than 
at 1 week while the levels of GLU were significantly higher at 6 weeks than at a week when 
collapsed across Model and Agonist Treatment. Main effect of Agonist Treatment was found in 
ALA (F [4,73] =3.4, p<0.05). Main effect of Model was not detected in STR. Additionally, only 
two interactions were detected in STR:  one was the interaction of Model x Treatment Agonist for 
GLU (F [4,73]=3.02, p<0.05) and the other was a full 3-way interaction for ALA (F[4,73]=4.1, 
p<0.01). 
1-way ANOVAs followed by post-hoc test in the STR of OVX and VCD-treated rats revealed 
no significant change in amino acid levels following 6 weeks of agonist treatments. However, 
significant or strong trend of changes in several amino acids were detected in both of the models 
when compared at the 1-week time point. Specifically, in VCD model, significant reductions in 
levels of GLU were observed in PPT, DPN, G-1-treated rats as shown by post-hoc Dunnett’s or 
Tukey’s test (Figure 26 C). Also, a strong trend of reductions in levels of GLU and ASP compared 
with controls were observed after 1 week of E2 and G-1 treatments, respectively.  In OVX model, 
post-hoc Tukey’s test revealed that levels of ALA were significantly higher in PPT- than E2-
treated rats. Dunnett’s also showed higher levels of GLN were detected in PPT-treated rats in 
relative to controls. Most of the ALA and GLY levels were below the limit of detection (ND) in 












     
  
Figure 26. Nonessential amino acids levels in (A) VCD-6W (HPC), (B) OVX-1W (FCX) , (C) 
VCD-1W (STR) and (D) OVX-1W (STR) by treatment groups. Rats at vehicle treatment are 
used as controls. Bars indicate Mean±SEM. One-way ANOVA: *p<0.05 (post-hoc Tukey’s test), 
relative to control; †p<0.05 (post-hoc Tukey’s test), relative to G-1; ^p<0.05 (post-hoc Tukey’s 
test), relative to E2. §p<0.05 (post-hoc Dunett’s test) relative to control; & 0.05<p<0.01 (post-hoc 






















C E2 PPT DPN G-1
F test P value
HPC/N 5 4 4 4 4
ALA F(4,16)=0.58 p>0.05 6.44±0.25 4.93±0.8 5.38±1.69 5.73±0.63 4.74±0.86
GLY F(4,16)=1.02 p>0.05 16.63±1.13 12.23±1.18 13.67±3.49 13.07±1.44 12.16±1.64
SER F(4,16)=0.39 p>0.05 44.97±2.15 34.9±4.48 42.22±13.51 36.82±5.59 44.01±7.12
ASP F(4,16)=0.57 p>0.05 44.72±3.24 34.92±3.42 41.57±8.56 41.72±6.19 36.76±4.55
GLU F(4,16)=0.13 p>0.05 47.32±3.28 43.54±3.74 50.19±10.46 46.71±5.97 45.17±3.89
GLN F(4,16)=1.24 p>0.05 27.16±2.97 17.26±0.8 26.16±6.8 27.15±3.87 20.8±3.51
One-WAY ANOVA
OVX-6W
C E2 PPT DPN G-1
F test P value
HPC/N 5 4 5 5 5
ALA F(4,19)=0.30 p>0.05 15.76±3.22 19.25±7.8 23.12±4.47 21.66±3.68 20.25±6.51
GLY F(4,19)=0.14 p>0.05 30.65±4.87 36.41±15.66 38.69±6.49 38.97±5.51 36.66±11.64
SER F(4,19)=0.42 p>0.05 98.46±23.19 123.1±68.91 171.75±40.11 161.05±37.31 143.61±57.09
ASP F(4,19)=0.07 p>0.05 79.58±16.05 75.18±25.06 85.35±15.14 82.1±11.21 74±23.16
GLU F(4,19)=0.15 p>0.05 187.19±41.94 162.79±53.04 206.4±34.8 190.62±31.59 182.02±38.91




















C E2 PPT DPN G-1
F test P value
FCX/N 5 4 4 4 4
ALA F(4,16)=1.29 p>0.05 1.12±0.25 1.49±0.64 1.11±0.5 1.39±0.36 0.29±0.13
GLY F(4,16)=1.30 p>0.05 3.02±0.99 4.29±1.4 3.64±1.3 4.95±1.1 1.53±0.74






ASP F(4,16)=2.05 p>0.05 53.89±3.33 59.03±8.09 55.69±7.39 63.15±7.72 38.17±6.17
GLU F(4,16)=1.92 p>0.05 65.85±5.7 71.58±8.01 57.3±8.6 61.46±9.83 43.6±5.21
GLN F(4,16)=0.58 p>0.05 11.89±1.02 13.26±1.49 12.04±2.49 11.69±2.03 9.17±2.52
One-WAY ANOVA
OVX-6W
C E2 PPT DPN G-1
F test P value
FCX/N 5 4 5 5 5
ALA F(4,19)=1.89 p>0.05 2.07±0.45 2.57±0.52 1.68±0.38 1.94±0.57 3.71±0.88
GLY F(4,19)=1.18 p>0.05 4.6±0.7 3.9±1.15 3.16±0.74 2.37±1.12 5.94±2.12
SER F(4,19)=0.70 p>0.05 23.5±3.33 22.07±6.51 16.98±2.19 14.37±4.62 22.61±6.69
ASP F(4,19)=0.88 p>0.05 82.27±5.21 85.98±5.1 70.46±4.83 78.69±5.63 76.68±8.54
GLU F(4,19)=0.75 p>0.05 107.89±4.01 117.63±9.74 103.44±4.64 106.88±6.22 115.94±9.27
GLN F(4,19)=0.45 p>0.05 19.3±4.52 17.54±4.21 27.72±10.68 18.82±3.8 17.36±5.75
One-WAY ANOVA
Values are mean ± sem.  
Symbol Alpha Test
§ p<0.05 Dunnetts Differs from Controls



















C E2 PPT DPN G-1
F test P value
STR/N 5 4 4 4 4
ALA F(4,16)=2.61 p=0.07 0.55±0.41 0.05±0.05 1.8±0.61^ 0.58±0.34 0.79±0.28
GLY F(4,16)=0.71 p>0.05 3.78±1.65 1.15±0.84 2.24±0.81 5.23±3.29 4.79±2.37
SER F(4,16)=0.37 p>0.05 42.99±13.38 53.59±13.52 60.37±18.56 67.17±24.26 64.1±10.72
ASP F(4,16)=0.95 p>0.05 17.24±7.15 9.27±4.17 12.48±4.23 29.07±14.83 24.01±5.8
GLU F(4,16)=1.37 p>0.05 22.82±1.63 23.66±3.26 26.16±1.48 29.22±3.97 21.83±1.54





C E2 PPT DPN G-1
F test P value
STR/N 5 4 5 5 5
ALA NA NA 0.04±0.04 ND ND ND ND
GLY F(4,19)=0.22 p>0.05 1.09±1.09 0.8±0.61 0.89±0.89 0.98±0.98 1.95±1.2
SER F(4,19)=2.19 p>0.05 51.77±9.98 71.8±15.67 59.3±11.54 69.63±11.75 30.57±7.6
ASP F(4,19)=0.16 p>0.05 15.64±6.56 15.83±3.77 14.35±3.01 16.7±2.76 12.08±5.37
GLU F(4,19)=0.90 p>0.05 86.23±4.98 90.93±4.16 93.71±8.9 99.93±4.93 87.89±3.85
GLN F(4,19)=1.88 p>0.05 14.53±2.15 10.93±2.29 14.13±1.67 18.21±1.65 12.97±1.8
One-WAY ANOVA
Values are mean ± sem.  
Symbol Alpha Test
& 0.05<p<0.1 Dunnetts Differs from Controls (trend)
^ p<0.05 Tukey Differs from E2



















C E2 PPT DPN G-1
F test P value
HPC/N 3 5 5 4 5
ALA F(4,17)=0.63 p>0.05 4.86±1.01 5.13±1.31 3.55±0.74 5.67±1.05 5.05±0.83
GLY F(4,17)=0.41 p>0.05 11.84±1.98 13.1±1.9 9.98±1.02 11.1±4.03 13.18±1.84
SER F(4,17)=0.18 p>0.05 39.88±6.62 43.02±9.8 37.56±3.59 47.01±14.9 38.97±6.33
ASP F(4,17)=0.22 p>0.05 44.57±7.33 44.79±5.86 41.95±2.21 47.05±6.64 41.14±4.25
GLU F(4,17)=1.5 p>0.05 42.51±6.23 55.71±5.33 62.88±7.12 73.57±13.99 53.69±7.99
GLN F(4,17)=0.54 p>0.05 26.12±4.96 25.15±5.3 19.28±2.31 26.83±5.28 22.35±3.22
One-WAY ANOVA
VCD-6W
C E2 PPT DPN G-1
F test P value
HPC/N 5 4 4 4 4
ALA F(4,17)=0.58 p>0.05 23.8±6 16.79±4.93 11.59±1.44 21.65±1.87 17.88±5.27
GLY F(4,17)=0.59 p>0.05 48.3±12.47 27.74±7.29 22.24±2.05
&
40.1±2.65 30.75±7.54
SER F(4,17)=0.60 p>0.05 202.77±51.95 111.57±23.08 68.43±8.1
&
164.63±9.03 136.21±51.56





GLU F(4,17)=0.62 p>0.05 199.14±30.31 160.23±17.74 129.64±12.45 179.86±11 186.8±34.74
GLN F(4,17)=0.63 p>0.05 53.36±13.14 40.32±13.34 33.79±3 63.86±9.94 51.68±21.24
One-WAY ANOVA
Values are mean ± sem.  
Symbol Alpha Test
§ p<0.05 Dunnetts Differs from Controls
& 0.05<p<0.1 Dunnetts Differs from Controls (trend)





















C E2 PPT DPN G-1
F test P value
FCX/N 4 5 5 5 5
ALA F(4,19)=0.54 p>0.05 0.61±0.23 1.4±0.65 1.14±0.52 0.84±0.24 0.77±0.17
GLY F(4,19)=0.63 p>0.05 1.61±0.94 3.04±1.43 3.8±1.66 1.8±0.73 1.98±0.69
SER F(4,19)=1.06 p>0.05 10.59±5.1 24.94±10.64 32.09±8.15 24.35±5.34 29.57±6.46
ASP F(4,19)=1.15 p>0.05 38.69±12.18 58.95±11.98 64.42±9.53 57.26±4.44 48.29±5.76
GLU F(4,19)=1.33 p>0.05 55.57±4.43 70.76±10.83 74.69±6.49 63±6.66 57.81±3.36
GLN F(4,19)=0.83 p>0.05 10.82±2.24 15.74±4.3 9.73±1.19 10.48±2.94 11.29±0.82
One-WAY ANOVA
VCD-6W
C E2 PPT DPN G-1
F test P value
FCX/N 5 5 4 5 5
ALA F(4,19)=0.88 p>0.05 1.6±0.64 0.97±0.36 0.49±0.16 1.11±0.5 1.44±0.32
GLY F(4,19)=1.01 p>0.05 2.85±1.23 0.83±0.37 0.74±0.39 2.15±1.44 2.56±0.67
SER F(4,19)=1.63 p>0.05 10.65±3.25 6.23±1.83 12.28±4.18 19.82±6.24 9.79±3.21
ASP F(4,19)=0.79 p>0.05 65.14±6.26 52.72±6.15 49.29±2.88 75.25±21.36 53.62±11.17
GLU F(4,19)=0.77 p>0.05 83.64±3.09 81.72±9.44 82.33±6.36 110.85±21.46 93.68±18.47






















C E2 PPT DPN G-1
F test P value
STR/N 5 5 4 5 5
ALA F(4,19)=1.23 p>0.05 0.06±0.06 ND 0.53±0.53 ND ND
GLY F(4,19)=0.70 p>0.05 ND 1.28±1.28 0.69±0.66 1.11±0.74 ND
SER F(4,19)=0.27 p>0.05 58.16±3.78 58.8±12.8 61.83±11.61 73.11±17 56.69±15.37
ASP F(4,19)=0.23 p>0.05 14.94±3.94 14.96±6.29 16.82±5.23 21.44±5.6 21.63±11.34
GLU F(4,19)=2.03 p>0.05 93.88±4.4 75.61±2.94 95.32±13.64 88.68±4.33 101.23±7.63
GLN F(4,19)=1.42 p>0.05 19.57±3.43 11.3±1.27 18.75±2.23 19.39±3.22 16.48±3.61
One-WAY ANOVA
Values are mean ± sem.  
Symbol Alpha Test
§ p<0.05 Dunnetts Differs from Controls
& 0.05<p<0.1 Dunnetts Differs from Controls (trend)
* p<0.05 Tukey Differs from Controls
0.05<p<0.1 Tukey Not Shown
Unit: nmole/mg
VCD-1W
C E2 PPT DPN G-1
F test P value
STR/N 4 5 5 5 5
ALA F(4,19)=3.09 p<0.05 1.28±0.46 0.06±0.04 0.41±0.28 1.42±0.64 0.08±0.08
GLY F(4,19)=0.95 p>0.05 7.26±5.6 1.17±1.01 2.53±1.37 4.8±2.34 1.5±1.31
SER F(4,19)=1.04 p>0.05 71.7±28.49 42.55±13.34 60.18±8.97 76.84±13.32 45.19±10.94
ASP F(4,19)=1.96 p>0.05 37.46±13.92 12.45±4.95 16.49±7.54 24.11±7.62 9.65±2.85
&














Figure 27. Main effects of Model and Time on nonessential amino acids in (A) HPC and (B) 









Figure 28. Main effects of Model and Time on nonessential amino acids in STR. Bars indicate 







Figure 29. Main effects of Agonist on nonessential amino acids in (A) HPC and (B) FCX. Bars 









Figure 30. Main effects of Agonist on nonessential amino acids in STR. Bars indicate Cohen’s 










5.5.1 Main effects of Model, Time-Point and Agonist Treatment 
The results of this analysis demonstrate significant effects of Model, Time-Point and Agonist 
Treatment on multiple amino acid endpoints. These effects were region specific. For example, 
main effects of Model were detected only in the FCX, but not in the HPC and STR. In the FCX, 
levels of ALA, GLY, SER and ASP were all higher in OVX vs VCD-treated rats. This is consistent 
with our previous analysis with TRP and TYR, where higher levels were detected in OVX vs. 
VCD-treated rats in FCX. Noted these effects, while statistically significant, were relatively small. 
Main effects of Time-Point (i.e., collapsed across model and agonist treatment) were the most 
robust main effects for all regions examined.  In many cases endpoints were greater after 6W vs. 
1W of agonist treatments. Effects on several endpoints were consistent across two or three brain 
regions. For example, levels of ASP and GLN were higher in HPC and FCX at 6W vs. 1W. Levels 
of GLU were higher in HPC and STR at 6W vs 1W. This is in agreement with the prior reports for 
main effects of Time Point for TYR and TRP in Chapter 4, where higher amino acids levels were 
observed at 6W vs. 1W. This suggests significant increases in certain amino acids including major 
excitatory amino acids GLU and ASP over a period of weeks following OVX or VCD treatment. 
Effects on ALA were not entirely consistent across brain regions. Specifically, levels of ALA were 
higher in HPC and FCX while were lower in STR at 6W vs. 1W. On the other hand, effects on two 
endpoints differed between brain regions. Levels of GLY were higher in HPC but were lower in 
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STR at 6W vs. 1W. Similarly, levels of SER were higher in the HPC, but were lower in the FCX 
at 6W vs.1W. These findings indicate time- and region-specific effects on amino acid endpoints.  
In addition to the main effects of Model and Time-Point, the data also showed significant main 
effects of Agonist Treatment but only on ALA and only in the STR. This may be due to relatively 
limited effects of Agonist Treatment on these endpoints especially analyzed with 3-way ANOVA 
with Model and Time Point collapsed. It suggests that the levels of these amino acids may not be 
as sensitive as the levels of monoamine/metabolites measured in Chapter 4 in response to estrogen 
and selective agonist treatments. Nevertheless, specific effects of agonist treatments were detected 
in all of the three brain regions. These effects were statistically significant and are discussed in 
further detail below 
5.5.2 Specific effects of Agonist Treatment as a function of Model and Time-Point 
This study is the first to analyze levels of excitatory amino acids GLU and ASP, inhibitory 
amino acid GLY as well as other amino acids following ER agonist treatments. Results indicated 
that, although not many, the effects of agonist treatments were model- and time-point-dependent. 
Two general observations were made from the results.  One is that the majority of ER agonist 
treatments resulted in reductions in amino acid levels relative to controls, which included 
reductions in ASP in HPC and GLU in STR. This may indicate ER agonist treatments can affect 
neurotransmission or brain excitability through down-regulation of excitatory amino acid levels. 
Notably, it is consistent with the findings in Chapter 4 that ER agonist treatments significantly 
reduced levels of two aromatic amino acids TYR and TRP in both HPC and FCX. The other 
observation is that most of the effects were detected after 1W vs. 6W of agonist treatments. This 
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is also in agreement with our previous findings for monoamines, metabolites, TYR and TRP. This 
suggests that similar to NT endpoints reported in Chapter 4, the amino acid endpoints are also 
responsive to ER agonist treatments at an early stage following loss of ovarian function.  
In our current study, VCD-treated rats treated with PPT for 6W had significantly lower ASP 
levels in the HPC than controls. Similarly, VCD-treated rats receiving E2 treatment for 6W also 
showed a strong trend for reductions in ASP levels relative to controls. This suggests that in the 
HPC the reduction of ASP can be achieved by activation of ER. In FCX, OVX rats treated with 
G-1 for 1W had a significantly lower SER level relative to controls, suggesting that this effect may 
be mediated through activation of GPR30. Multiple effects of agonist treatments were detected in 
STR. Treatment with E2, PPT, DPN and G-1 for 1W all significantly reduced GLU levels compare 
with controls in VCD-treated rats, suggesting these effects can be achieved by activation of any of 
the three ER subtypes. Previous studies have reported that in regions with high GABA levels, such 
as the hypothalamus and substantia nigra, a significant percentage of GLU is used as a precursor 
for GABA synthesis [199]. In addition, studies also have reported that a large number of neurons 
and terminals in STR contain GABA and GABAergic inhibition has been thought to play a major 
role in regulating neuronal activity in the STR [200]. Thus, it is possible that a reduction in GLU 
levels in STR reflect increased synthesis of GABA, via decarboxylation in response to ER 
activation. Future investigation into changes in GABA levels and glutamic acid decarboxylase 
expression in STR following ER agonist treatments is warranted. A strong trend of ASP reduction 
also was detected following 1W of G-1 treatment. These findings further support that activation 
of ERs may decrease levels of excitatory amino acids in specific brain region. Collectively, these 
data indicated that estrogens can influence amino acid endpoints after loss of ovarian function. 
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Similar to monoamine and metabolites reported in previous study, amino acids are differentially 
affected by activation of specific estrogen receptors and the effects are brain region-dependent.   
Another interesting finding was that the treatment effects seen in one model were not observed 
in the other model at same time point and at the same brain region. This clearly suggests a 
fundamental difference in the responsiveness to estrogen therapy between transitional vs surgical 
menopause. One of the possible explanations may be the different hormonal profiles inherent in 
the two models. 
 
5.5.3 Potential mechanisms of estrogen induced neuroprotection 
Although estrogen has well-described neuroprotective effects, the exact mechanism of 
estrogen induced neuroprotection has yet to be fully determined. One theory is that estrogens may 
mediate their neuroprotection via excitatory neurotransmitter systems. As major EAAs, GLU and 
ASP cause depolarization and excitation of neurons in the mammalian CNS [201]. Since excessive 
concentrations of GLU and ASP have been found to exert neurotoxic properties, the significant 
reductions in such amino acids following E2 and agonist treatments in discrete brain regions 
further supports this theory. Additionally, previous literatures have demonstrated multiple effects 
of estrogen on EAA-related neurotransmission. The effects appear to be region-specific and were 
not always consistent. For example, estrogens have been shown to attenuate glutamatergic receptor 
activation [202] . It has also been shown that the size of a glutamate-induced lesion was 
significantly reduced in rats given pretreatment with E2 prior to local glutamate application [203]. 
In contrast, potentiating actions of E2 on glutamate-induced excitation has also been previously 
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reported [204]. Also, it has been demonstrated that E2 plus progesterone causes a significant 
enhancement of veratridine-induced release of glutamate from preoptic-area synaptosomes of 
OVX rats [205]. In a recent study, it was shown that in the arcuate nucleus, E2 significantly 
increased protein levels of the two enzymes in the glutamate-glutamine cycle, glutamine 
synthetase and glutaminase, which underly functional changes in neurotransmitter availability 
[206]. 
In summary, this additional analysis provides a detailed description of changes in amino acid 
endpoints including excitatory and inhibitory amino acids in two models of menopause after E2 
and selective ER agonist treatments. To the best of our knowledge, no similar study has been 
conducted before. However, cautions should be exercised when interpreting current data as the 
steady state amino acid concentrations observed in the present experiments may not correctly 
reflect the dynamic changes (e.g. release, turnover) for these endpoints. For example, no change 
observed among the endpoints could either mean no effects of ER agonist treatment or that a new 
dynamic balance of synthesis and catabolism is reached. Future studies on synthesizing and 
degrading enzymes of these amino acids and the corresponding behavioral testing are warranted 








Collectively, our study is the first to provide a detailed and in-depth comparison of the effects 
of ER agonists on the levels of six nonessential amino acids in three brain regions, at two-time 
points following loss of ovarian function. The results of our analysis showed that most of the amino 
acids in the brain remained relatively stable and were not significantly altered following E2 and 
selective agonist treatments in models of surgical and transitional menopause. Despite that, we 
also demonstrated limited but significant changes in local levels of amino acids (including 
excitatory and inhibitory amino acids) following agonist treatments. Notably, these effects were 
region- and model- specific as well as time-and agonist-dependent. The reductions in excitatory 
amino acid levels following either estrogen or selective agonist treatments are of great interest and 




6.0  SUMMARY AND PERSPECTIVES 
 
6.1 SUMMARY OF KEY RESEARCH FINDINGS 
 
Estrogens have many beneficial effects in the brain. One of the mechanisms for estrogens to 
deliver the effects is through the regulation of multiple neurotransmitter levels involved in a variety 
of cognitive functions, in specific regions of the brain. Previously, different laboratories 
demonstrated changes in individual NT pathways under limited conditions. However, a 
comprehensive analysis of simultaneous changes both within and across pathways has not yet been 
available. Therefore, it is not clear what role the individual estrogen receptors play, or what effects 
selective estrogen receptor modulators have on these NT pathways. Given the fact that these 
complex NT pathways are constantly interacting with each other, results from analysis of 
individual NT pathways would be difficult and insufficient to explain the effects of estrogens. 
Additionally, recent studies suggest that the effects may differ depending on how and when loss 
of ovarian function occurs (e.g., surgical vs. natural menopause).  
To address these issues, in this thesis, we have for the first time comprehensively and 
systematically conducted a metabolomics analysis of monoamines, precursors, metabolites and 
amino acids in three brain regions (hippocampus, frontal cortex and striatum) at two time points 
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(1 week vs. 6 weeks), in two clinically relevant models of menopause (surgical vs. transitional) 
with/without estrogen receptor agonist treatments.  
In Chapters 2 and 3, we utilized both high-pressure liquid chromatography-coulometric multi-
electrode array system (HPLC-CMEAS) and gas chromatography coupled to flame ionization 
detector (GC-FID) to investigate and compare the effects of two models of menopause on NT 
pathways of interest.  Results show that (a) significant effects are detected in the HPC and FCX 
associated with cycle stage and are limited primarily to the serotonin pathway; (b) multiple effects 
were detected following OVX and VCD treatments and most effects were both region-specific and 
time-dependent. Relatively few differences were present in the effects of the two models on 
neurochemical endpoints, despite the fact that the hormonal profiles were quite different. This 
suggests that the two types of menopause produce similar effects on these endpoints, at least during 
the early weeks following menopause. This, in turn, suggests that any differences in cognitive 
performance between OVX and VCD-treated rats are not due to differential effects on 
monoaminergic pathways and amino acid signalings; (c) the greatest number of effects were 
detected in the HPC, suggesting that this region of the brain is particularly sensitive to loss of 
ovarian function; (d) significant reduction in the levels of amino acids detected in the HPC, but 
not in the FCX or STR, at 1 week following OVX or VCD treatments, suggesting loss of ovarian 
function has substantial acute effects on amino acid homeostasis in this region of the brain.  
In Chapters 4 and 5, using similar analytical methods, we further evaluated the ability to 
modify the deficits on the NT pathways induced by OVX and VCD treatment by treating with 
different estrogen receptor agonists. Results show that (a) significant region-specific effects of 
“Model” and “Time-Point” were detected on multiple measures of serotoninergic, dopaminergic, 
noradrenergic and amino acid endpoints; (b) main effects of ‘Time-Point’ were much more robust 
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than the main effects of ‘Model’ for all regions examined.  In many cases endpoints were higher 
at 6W vs. 1W after loss of estrogens. For example,  effects on several serotoninergic endpoints 
were consistently higher across brain regions at 6W vs. 1W, suggesting significant recovery of 
endpoints associated with serotonin production and signaling over a period of weeks following 
OVX or VCD treatment; (c) significant main effects of “Agonist Treatment” were detected on 
multiple NT endpoints that differed by brain region; (d) specific effects of “Agonist Treatments” 
are model- and time-point-dependent. For monoamines, the majority of ER agonist effects were 
detected in OVX rats as opposed to VCD-treated rats and were detected after 1W vs. 6W of agonist 
treatments. In addition, the majority of ER agonist effects were detected in the HPC, suggesting 
that this region of the brain is particularly sensitive to ER agonist treatments. For amino acids, the 
majority of ER agonist treatments resulted in reduction of AA levels in relative to controls. In 
addition, most of the effects were detected after 1W vs. 6W of agonist treatments; (e) many of the 
effects on NT endpoints could have important implications for effects on cognitive performance. 
Collectively, this dissertation has provided novel and rich information :1) describing and 
comparing neurochemical changes associated with two different and clinically relevant models of 
menopause in three regions of the brain; 2) describing and comparing neurochemical changes 
produced by selective ER agonists in each of the menopausal models; 3) first comprehensively 
evaluating the effects of a selective GPR30 agonist (G-1) on brain neurochemistry. These data will 
be extremely useful for understanding the effects of menopause and hormone treatment on 
cognitive processes, and for developing and designing better hormone replacement strategies for 




6.2 LIMITATIONS AND FUTURE DIRECTIONS 
 
The studies presented in this thesis are metabolomics studies. The overall goal was to 
characterize neurochemical changes associated with surgical vs. VCD-induced transitional 
menopause as well as treatments of 17β-estradiol and selective estrogen receptor agonists in the 
rat brain. Like most ‘-omics’ studies, the focus was descriptive, not mechanistic. Therefore, the 
possible mechanisms involved in the effects observed on neurotransmitter levels were not 
investigated in depth in current studies. However, based on our understanding of the topic and 
previous published literatures, serious efforts have been made to discuss the potential mechanisms 
as well as their related cognitive significance in specific sections of the chapters, thus providing 
more mechanistic underpinning of the results reported in our study. The interpretation of our 
findings needs to be carried out with caution, since the levels of these neurochemical endpoints do 
not necessarily represent a dynamic measure of neuronal activities. Utilization of techniques such 
as microdialysis in future studies may add valuable data and information to current understanding 
of this field. Also, since the behavioral studies are not included in the current studies, whether and 
how would such NT levels alternations translate to cognitive function remains unknown. 
The neurochemical changes reported in the studies may be due to multiple factors e.g. regional 
differences in sensitivity to estrogen deprivation as well as estrogen-regulated alterations of 
expression and activities of anabolic and catabolic enzymes, specific estrogen receptors, 
autoreceptors, neurotransmitter reuptake transporters, etc. Furthermore, the mechanisms 
contributing to the differences in responsiveness of ER agonist treatments between surgical and 
transitional menopauses, between different brain regions have yet to be fully characterized. These 
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research areas would be valuable focuses for future mechanistic studies, building on the descriptive 
information reported here. 
More studies are needed to further understand the underlying mechanisms. Future research 
plans are to expand the studies to evaluate (1) mechanisms that underlie the different effects of 
surgical vs. ‘natural’ menopause on the neurotransmitter signatures, such as expression and 
activities of anabolic and catabolic enzymes (e.g. monoamine oxidase, catechol-O-
methyltransferase, dopamine beta-hydroxylase, aromatic L-amino acid decarboxylase, tyrosine 
hydroxylase, tryptophan hydroxylase ,etc.) ; (2) how the effects of surgical vs. natural menopause 
differentially affect cognitive performance by conducting a battery of behavioral tests (e.g. fear 
conditioning test, water maze test, object recognition task etc.) and (3) to determine if the effects 
differ as a function of age as well as the timing of hormone treatment relative to the loss of ovarian 
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